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The interplay of different signaling pathways activated by factors of the cellular environment
and expression the proto-oncogene c-Myc (MYC ) defines B cell fate in the germinal center
(GC). Importantly, the same signaling networks are chronically active in different types of
B-cell lymphoma. While the effects of aberrantly expressed MYC on cell proliferation and
metabolism were intensively studied, less is known about the cross talk of pathways, like
NF-κB and JAK/STAT signaling, in the context of B cell proliferation and metabolic re-
programming. Therefore, the aim of the study was to analyze (i) how chronic active factors
of the GC microenvironment and their interaction networks can reprogram global gene ex-
pression (gGE) and metabolism of resting B cells to support B cell proliferation, (ii) what is
common with MYC overexpression and (iii) whether this is important for lymphoma. Thus
the P493-6 B cell line, carrying a conditional MYC expression construct, was stimulated
with random combinations of GC derived factors as α-IgM, CD40L, IGF1, CpG and IL10
to model different signaling pathway and Myc activation on the same genetic background.
Linear regression analysis of gGE and metabolome changes in stimulated Myc depleted cells
revealed qualitative similar but quantitative different changes on these parameters by the
different stimulations. Thereby, greatest changes where observed after IL10+CpG stimula-
tion due to a strong synergy on gGE and metabolome associated with sustained cell cycle
entry and cell proliferation. Using small molecule inhibitors and RNAi mediated knockdown
a dependency of IL10+CpG induced proliferation on NF-κB and JAK/STAT3 signaling was
revealed. Furthermore, simultaneous binding of STAT3 and p65 to proximal promoter of the
cell cycle regulator CDK4 but also the aspartate amino transaminase GOT2 was detected by
chromatin immunoprecipitation. The increase in gGE mediated by IL10+CpG stimulation
resembled Myc induced gene expression changes accompanied by a comparable cell prolifera-
tion but different glutamine metabolism. Herein, GOT2 was essential for cell proliferation of
both conditions. However, glutamine tracing, respiration analysis and rescue experiments re-
vealed distinct dependencies of proliferation on glutamine derived metabolites: In IL10+CpG
treated cells a strong dependency of cell proliferation on glutamine derived aspartate and
nucleotides was observed, whereas in MYC overexpressing cells α-ketoglutarate was most
important for respiration and proliferation. Using CA-46, OCI-LY3 and L-428 lymphoma
cell lines the important role of GOT2 for Myc and STAT3/NF-κB dependent proliferation
but also the differences in glutamine usage in context of these pathways could be confirmed.
Last of all, a high expression of GOT2 in proliferating centroblasts but also primary B cell
lymphoma could be shown. Thereby, activated B cell like diffuse large B cell lymphoma
(DLBCL) were characterized by higher GOT2 expression as germinal center like DLBCL.
More importantly high GOT2 expression was associated with a worse clinical outcome of R-
CHOP treated DLBCL patients. Overall, a new role for IL10R and TLR9 signaling and the
interaction of STAT3 and NF-kB signaling in gGE, proliferation and metabolism of B cells
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Normal and transformed germinal center (GC) B cells are embedded within a complex net-
work of surrounding cells. The corresponding autocrine and paracrine signals are defining
B cell fate as proliferation, growth, maturation or cell death. The pathways activated by
these signals, when switched from acute or temporary to chronic or aberrant activation, are
an important part in the transformation process from GC B cells to lymphoma cells (Rui
et al., 2011). Thereby cells must undergo gene expression changes to overcome cell cycle
arrest and reprogram metabolism to induce sustained proliferation. These changes are so
far best studied in the case of overexpression of the proto-oncogene c-Myc (MYC ). How-
ever, less is known about gene expression changes mediated by other signaling pathways and
the connections between proliferation and metabolism are not well characterized in B cells.
Studying the effects and underlying mechanisms of signaling pathways and transcription
factors on gene expression, proliferation and metabolism can therefore improve our under-
standing of B cell activation and lymphomagenesis and help to reveal new therapeutic targets
in lymphoma with deregulated signaling. The following chapters will introduce the GC in
context of B cell activation and lymphomagenesis and will focus on the signaling pathways
involved in both processes. Gene expression changes that are needed to induce proliferation
in B cells in general will be given on the example of Myc activation and new aspects of gene
regulation by Myc will be presented.
1.1 Germinal centers: sites of mature B cell activation and
transformation
B cells are immune cells of the adaptive defense that mature inside the bone marrow (LeBien
& Tedder, 2008). After selection for a functional but non-selfreactive B cell receptor (BCR)
they are released to the blood stream and migrate into the peripheral lymphoid organs
like lymph nodes, tonsils, spleen and Peyer’s patches. The function of mature B cells
is to recognize foreign antigens by binding to different receptors, like the BCR or toll-
like receptors (TLR). After activation by these antigens, B cell proliferation and interac-
tion with other immune cells induces formation of a typical structure inside the periph-
eral lymphoid organs called germinal center (GC) (Klein & Dalla-Favera, 2008; Natkunam,
2007).
1.1.1 Germinal centers and mature B cell activation
There are two different antigens that can activate B cells: T cell independent (TI) and
T cell dependent (TD) antigens (Maddaly et al., 2010). TI antigens do not require direct
contact with T cells or activation of the BCR (Fagarasan & Honjo, 2000). Instead pathogen
recognition receptors TLRs directly recognize bacterial antigens. However, in some cases
additional stimulation with cytokines released from T cells are required for full activation
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(Bucala, 1992). In contrast, T cell dependent antigens are soluble proteins that are, after
BCR binding, processed to peptides and presented by the major histocompatibility complex
at the surface of the B cell (Parker, 1993). These peptides are than recognized by the
T cell receptor of the T cell and trigger the expression of further co-receptors. Beside BCR
activation, further stimulation through these co-receptor interactions and additional cytokine
stimulations are required to activate complex signaling pathways inside the cell to induce
B cell proliferation and differentiation. Therefore, the activation of B cells is dependent on
a complex interaction of different factors and their corresponding signaling events.
Activation of B cells by these factors leads to formation of the GC, characterized by a
typical structure: a dark and a light zone (MacLennan, 1994). The dark zone consists of
proliferating B cells known as centroblasts, whereas the light zone is build up by smaller,
non-dividing B cells called centrocytes, interacting with follicular dendritic cells (FDC),
T cells and macrophages. Beside proliferation in centroblasts, the antigen affinity of the
BCR is altered by somatic hypermutation of the immunoglobolin (Ig) locus. B cells then
leave into the light zone, where B cells with high affinity BCR are positively selected by
survival signals from FDC and T cells, while other B cells undergo apoptosis. Positively
selected B cells enter a second round of hypermutation in the light zone or leave the GC as
differentiated plasma or memory B cells.
1.1.2 Germinal centers and B cell transformation
The GC is an important structure in B cell activation and differentiation. However, analysis
of Ig rearrangements and gene expression profiles revealed that GC cells are also precursors
of the majority of mature B cell lymphomas (Küppers, 2005; Klein & Dalla-Favera, 2008).
Typically, these B cell lymphomas are divided into Hodgkin lymphoma (HL) and aggressive
Non-Hodgkin Lymphoma (NHL). In the following only lymphoma subtypes important for
this study are presented.
Pathological alterations of glands and spleen in children were first described by Thomas
Hodgkin in 1832 (Hodgkin, 1832). 30 Years later this disease was called Hodgkin disease
and today it is known that this disorder is a B cell derived lymphoma (Küppers et al., 2012).
In general, HL are associated with a good overall survival (65-90% of patients are disease
free in five years) and the current goal of HL treatment is the reduction of toxicity while
maintaining treatment efficiency (Küppers et al., 2012).
In contrast, aggressive NHL are more common than HL (9.3 per 100.000 people) and char-
acterized by a more aggressive growth and worse clinical outcome (Ferlay et al., 2013). With
about 30% of all NHL Diffuse Large B Cell Lymphoma (DLBCL) are the most common
subtype of NHL (Anderson et al., 1998). However, chromosomal and gene expression anal-
ysis revealed that DLBCLs are not one kind of disease but clinically and morphological
heterogenic (Morin et al., 2013). Beside clinical and histochemical classifications, currently
molecular classifications of DLBCL are in clinical implementation. One subgroup of DL-
BCL, characterized by a gene expression profile resembling in vitro activated B cells, was
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called activated B cell like DLBCL (ABC DLBCL) (Alizadeh et al., 2000). The other shows
an expression profile comparable to GC B cells and was therefore called germinal center
B cell like DLBCL (GCB DLBCL). Interestingly, patients with GCB classified lymphoma
had a significant better overall survival than ABC patients. In general, therapy of DLBCLs
dramatically increased by combining conditional CHOP treatment (cyclophosphamide, dox-
orubicin, vincristine, and prednisone) with the anti-CD20 monoclonal antibody rituximab
(R-CHOP) (Sehn, 2010). Nevertheless, about 40% of DLBCL still evade proper treatment.
Investigating the molecular mechanisms characterizing different subtypes can therefore help
to find new therapy targets and improve therapy of R-CHOP resistant lymphoma.
A third well studied aggressive NHL but different from DLBCL is called Burkitt Lymphoma
(BL), which can be divided into an endemic and a sporadic subtype (Molyneux et al., 2012).
The endemic BL is a common tumor in central Africa and associated with Epstein barr
virus and malaria infections. The sporadic subtype is not associated with any infection and
mostly found in western Europe and the United States. A hallmark of Burkitt lymphoma
is a special t(8;14) translocation, which affects the regulation of the proto-oncogene c-Myc
(section 1.2.4). In contrast to DLBCLs that are mostly found in adult people, BLs only
account for 1-2% of adulthood lymphomas, while 30-40% of childhood NHL are classified as
BL (Mbulaiteye et al., 2009). While the prognosis of BL in young patients was substantially
improved since 1995, the 5 year-survival rate of patients over 60 year is still 50% or less
(Castillo et al., 2013).
All three described lymphoma entities frequently harbor gene mutations, that are possi-
bly mediated by physiologic B cell activation and BCR rearrangement itself (Dunn-Walters
et al., 2001). Depending on the oncogenes or tumor suppressors that are deregulated by
these mechanisms the different B cell lymphoma subtypes can develop (Küppers, 2005).
Importantly, a single mutation does not seem to be sufficient to induce cell transforma-
tion alone, but a combination of mutations affecting different oncogenes and tumor sup-
pressors is often found during DLBCL progression (Morin et al., 2013). However, beside
these classical mutations, it became evident that the microenvironment of the GC itself
might be involved in lymphoma development and progression as well (Burger et al., 2009),
(Lenz et al., 2008).
1.2 Signaling pathways involved in normal and aberrant B cell
activation
Signaling cascades connect extracellular signals with intracellular events like gene regulation,
proliferation and metabolism. Under physiological conditions these pathways are strongly
regulated. However, in cancer cells specific mutations can led to aberrant activation of these
pathways leading to an uncoupling of proliferation from physiological regulation (Hanahan
& Weinberg, 2011). Previous experiments performed in the working group have shown that
stimulation of a B cell line with GC derived factors can be used to mimic these aberrant
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activated signaling pathways in lymphoma (Schrader et al., 2012a). Here, activation of the
NF-κB, JAK/STAT, PI3K and MAPK signaling by stimuli treatment resulted in specific
global gene expression changes. Sorting NHL-patients according to their similarity in the
expression of TOP100 affected genes to the stimulated B cell discriminated individual DL-
BCL subtypes. These experiments show, that in vitro stimulations of cell lines are a suitable
tool to analyze pathway dependency in lymphoma.
In the next chapters the most important signaling cascades in lymphoma, which are im-
portant for the study, are described and how these pathways can be activated by either
extracellular stimuli or corresponding pathway mutations in lymphoma. An overview about
these pathways, stimuli and mutations is given in Figure 1.
1.2.1 Canonical and non-canonical NF-κB signaling
NF-κB signaling plays an important role in normal B cell activation and transformation.
Main activators of the canonical (p65/p50) pathway are B cell receptor and toll-like recep-
tor signaling while CD40 (cluster of differentiation 40) signaling is additionally activating
non-canonical (p52/RelB) signaling in B cells (Figure 1A)(Vallabhapurapu & Karin, 2009).
The BCR complex consists of a membrane bound immunoglobulin (Ig) and the two co-
receptors Igα (CD79a) and Igβ (CD79b) (Kurosaki, 2011). Crosslinking of the BCR by
antigen binding results in tyrosine phosphorylation of the cytosolic regions of Igα/β and
recruitment of different tyrosine kinases. This process triggers the formation of the sig-
nalosome, a complex built up from various kinases, docking proteins and further signaling
enzymes. A complex consisting of MALT1 (mucosa-associated lymphoid tissue lymphoma
translocation protein), CARD11(caspase recruitment domain family, member 11) and TAK1
(transforming growth factor beta-activated kinase 1) is then activated, which in turn acti-
vates the inhibitor of nuclear factor kappa-B kinase (IKK). This leads to the phosphorylation
and proteasomal degradation of the inhibitor of nuclear factor kappa-B (IκBα), releasing the
transcription factor NF-κB (dimer of p50 and p65/RelA in case of canonical signaling), which
further translocates into the nucleus. There NF-κB is binding to a variety of target genes,
including inflammation, survival, angiogenesis or proliferation associated genes, dependent
on further posttranslactonal modifications or interactions with other transcription factors
(Hayden & Ghosh, 2012).
Beside BCR activation, this signaling cascade can be activated by TLRs. Human B cells
were shown to express TLR1, 6, 7, 9 and 10 depending on the maturation and differentiation
status of the cells (Chiron et al., 2008). Inside the GC high expression levels of TLR9 were
found (Månsson et al., 2006). TLR9 is located in the endosome of the B cell, where it is
activated by unmethylated double-stranded deoxyribonucleotides with repeating CpG motifs
(further referred to as CpG). After ligand binding, the signaling adaptor MyD88 (myeloid dif-
ferentiation primary response gene 88) is recruited (Peng, 2005). MyD88 activates IRAK1
(interleukin-1 receptor-associated kinase 1) and IRAK4, which then phosphorylate IKK,
thereby activating canonical NF-κB signaling. Due to the co-activation of other pathways
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Figure 1: Scheme of main signaling nodes activated by a set of microenvironmental factors
observed in activated B cells. (A) Under physiological conditions canonical NF-κB signaling can be
activated via BCR, TLR or CD40 signaling, while non-canonical NF-κB signaling is activated by CD40L.
Mutations in main components of these signaling pathways (indicated by lightnings) chronically activate these
pathways in different mature B cell lymphoma (B) JAK/STAT signaling can be activated via interleukin
binding or mutations affecting JAK/STAT itself or negative feedback loops. (C) PI3K and MAPK are
activated by a variety of signaling pathways. The figure shows an example of PI3K and MAPK activated
by BCR and IGF-1 signaling, that are chronically active in different B cell lymphoma.
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by TLR signaling, the target genes of BCR activated NF-κB signaling can differ from TLR
activated signaling.
Another activator of canonical NF-κB signaling is CD40 signaling. However, also non-
canonical NF-κB signaling is activated by CD40 signaling in B cells (Elgueta et al., 2009).
CD40 is a transmembrane glycoprotein receptor expressed at the surface of B cells that is
activated by interaction with the CD40 ligand (CD40L/CD154) located on T cells. After
receptor-ligand interaction intracellular mediators called TNF-receptor associated factors
(TRAFs) are recruited and activated. While one TRAF is able to activate the canonical
NF-κB pathway via phosphorylation of IKK by TAK1, others activate the non-canonical
NF-κB pathway (p52/RelB). Thereby IKKα is phosphorylated by the NF-κB inducing ki-
nase (NIK). IKKα in turn phosphorylates p100, which is then partially degraded by the
proteasome to its active form p52. This protein dimerizes with RelB (v-Rel avian reticu-
loendotheliosis viral oncogene homolog B), translocates into the nucleus and activates the
gene expression of several cytokines, chemokines and typical B cell activation markers.
Deregulated NF-κB signaling was shown to play an important role in lymphoma patho-
genesis. For example, in DLBCL ABC patients a strong activation of canonical NF-κB
pathway was observed (Davis et al., 2001). This activation was dependent on a chronical
active BCR signaling mediated by either CARD11 or CD79B mutation, amplification of
MALT1 or mutations activating MYD88 connecting TLR signaling with DLBCL develop-
ment (Davis et al., 2010), (Sanchez-izquierdo et al., 2003; Ngo et al., 2011). Further, genomic
amplification of RELA (p65) and NIK as well as mutations in the negative regulator IκBα
were found in HL and proliferation of HL cell lines was shown to be dependent on this NF-κB
activation (Joos et al., 2002; Emmerich et al., 2003; Bargou et al., 1997). Therefore, NF-κB
signaling is not only involved in normal B cell activation, but, when aberrantly activated, a
major player in lymphomagenesis.
1.2.2 JAK/STAT signaling
Main activators of the janus kinase/ signal transducer and activator of transcription (JAK/
STAT) pathway are autocrine or paracrine secreted interleukins (IL) (Rawlings et al., 2004)
(Figure 1B). Beside IL4 and IL6, IL10 and IL21 were shown to be involved in differentiation
processes in the GC (Yoon et al., 2009). Thereby abundancy of IL10 seems to be crucial for
GC formation as it is regulating B cell survival as well as proliferation (Levy & Brouet, 1994;
Rousset et al., 1992). The major pathway activated by IL10 is the JAK1/STAT3 pathway
(Sabat et al., 2010). IL10 binds to the IL10 receptor (IL10R), leading to the dimerization
of the two receptor units IL10R1 and IL10R2. While JAK1 is bound to IL10R1, the ty-
rosine kinase 2 (TYK2) is bound to IL10R2. Dimerization of the subunits leads to close
proximity of JAK1 and TYK2 and concurrent trans-phosphorylation. Thereby, the kinases
are activated and in turn are now able to phosphorylate STATs, mostly STAT3 in case of
IL10 signaling. This phosphorylation triggers dimerization and activation of STAT3 itself,
which translocates into the nucleus and induces target gene expression. Beside proliferation,
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survival and inflammation associated genes, STAT3 regulates the transcription of suppres-
sors of cytokine signaling (SOCS)(Carpenter & Lo, 2014; Yoshimura, 2009). SOCS3 itself
deactivates STAT3 signaling by direct binding to the IL10R and inhibiting further STAT3
phosphorylation buildung a negative feedback loop. Beside STAT3 other STATs like STAT1,
STAT5 or STAT6 can be activated by the different interleukins.
In addition to NF-κB signaling, deregulated JAK/STAT signaling is often found in lym-
phoma. Importantly, STAT3 mutations can be found in DLBCL and STAT3 and IL10
levels themselves are associated with a worth clinical outcome in DLBCL (Wu et al., 2011),
(Lech-Maranda et al., 2006). But also in HL JAK/STAT activation was described. For ex-
ample, mutations in JAK2 and in SOCS1 were found (Weniger et al., 2006),(Joos et al.,
2000). In line with the found mutations, proliferation of HL cell lines was shown to be
dependent on STAT5 as well as STAT3 signaling (Scheeren et al., 2008; Holtick et al.,
2005).
1.2.3 PI3K/MAPK signaling
Phosphoinositide-3-kinase (PI3K) and mitogen activating protein kinase (MAPK) are im-
portant components of B cell activation. They are activated by variety of external stim-
uli and regulate cell cycle as well as metabolism by activating further downstream targets
(Figure 1D).
After B cell activation, these pathways are activated by the signalosome (section 1.2.1)
(Kurosaki, 2011). In brief, PI3K generates the signaling molecule phosphatidylinositol-3,4,5-
trisphosphate and thereby activates the downstream kinase AKT by triggering tyrosine and
serine phosphorylation. Phosphorylated AKT in turn regulates proliferation, growth and
survival via phosphorylation of a variety of proteins. In parallel, activation of phospholipase
C (PLC) leads to the generation of diaglycerol and Ca2+ release, which activate protein
kinase C (PKC) and cooperatively induce MAPK signaling, including extracellular-signal
regulated kinase (Erk) and p38 phosphorylation.
Beside BCR activation different growth factors, including the insulin-like growth factors
(IGFs), play an important role in PI3K and MAPK activation and within the last two decades
an emerging role for IGF1 signaling in B cell development and differentiation was shown
(Adams et al., 2000; Smith, 2010). In general, IGF1 binds to the IGF1 receptor (IGF1R),
thereby inducing auto-phosphorylation of intracellular domains of the IGF1R (O’Connor
et al., 2008). This phosphorylation recruits the insulin receptor substrate (IRS), growth
factor receptor-bound protein 2 (Grb2) and son of sevenless (SOS). IRS activation leads to
increased metabolism and survival via activation of the PI3K/AKT pathway, while Grb2
and SOS activate Erk signaling to induce proliferation.
PI3K and MAPK signaling are important for physiological BCR activation. However, PI3K
signaling was also found in Burkitt cell lines, which was dependent on transcription factor
3 (TCF3) and ID3 (inhibitor of DNA binding 3) activity (Schmitz et al., 2012). Impor-
tantly, these factors are frequently mutated in BL patients indicating an important role for
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PI3K signaling in BL development and progression(Richter et al., 2012; Love et al., 2012).
Another indication for PI3K and MAPK signaling is given from HL, where overexpression
of the IGF-1R is associated with a favored outcome, but the underlying mechanism is still
unclear (Liang et al., 2014).
1.2.4 The proto-oncogene c-Myc
c-Myc (Myc) is a major regulator of proliferation, metabolism and differentiation in different
tissues and cell types and one of the most important oncogenes (Meyer & Penn, 2008). How-
ever, no MYC expression was found in centroblast in the dark zone of the germinal center
although these cells are highly proliferative (Klein et al., 2003). Nevertheless, Myc activity
was shown to be important for the formation and maintenance of the GC (Dominguez-sola
et al., 2012; Calado et al., 2012). Both studies showed that Myc is expressed in the early
stages of B cell activation and then repressed by the transcriptional regulator BCL-6 (B cell
lymphoma 6 protein). In the light zone interaction with follicular and T cells leads to down-
regulation of BCL-6 and therefore reinduction of Myc in centrocytes. Furthermore, Myc was
shown to be essential for BCR and CD40L/IL-4 mediated B cell proliferation (Murn et al.,
2009; de Alboran et al., 2001). Beside downregulation of BCL-6, these stimuli can directly
increase Myc levels by transcriptional and posttranscriptional regulation by NF-κB, STAT3
or Erk/PI3K activation (Basso et al., 2012; La Rosa et al., 1994; Ling & Arlinghaus, 2005;
Sears, 2000).
Importantly, deregulated MYC expression resulting from gene translocations and muta-
tions or chronic active signaling events is associated with the development of aggressive
lymphomas (Slack & Gascoyne, 2011). Effects of MYC overexpression are best studied in
BL. On the molecular level BL are characterized by a high MYC expression and activ-
ity (Hummel et al., 2006). In about 70-80% of BL a t(8;14)(q24;q32) translocation can be
found, which results in translocation of the MYC gene into the IGH region and therefore
deregulation of its expression in B cells (Zech et al., 1976). Notably, also in DLBCL high
expression levels or activity of MYC were found but correlated with worse clinical outcome
than BL (Schrader et al., 2012b; Horn et al., 2013).
1.2.5 Myc as a global gene amplifier
Myc is a basic helix-loop-helix leucine zipper that binds together with its dimerization part-
ner Max to so called E-box motifs (Grandori et al., 2000). These motifs can be found in the
majority of genes at approximately every 1000 base pairs (bp). In 2012 two groups showed
that under physiological conditions Myc is bound to canonical E-boxes of all actively tran-
scribed genes (Lin et al., 2012; Nie et al., 2012). Moreover, under overexpressing conditions
Myc also binds to non-canonical E-box motifs, which can be found mostly in enhancers.
This binding increasing the expression of already activated genes and but not the number
of target genes in total. By this mechanism Myc is thought to increase the expression of for
example cell cycle and metabolism genes over a certain threshold, thereby inducing prolif-
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eration. As an additional effect, MYC overexpression leads to a global increase of all active
genes in the cell which is accompanied by an increase of total RNA in the cell (Lin et al.,
2012), (Nie et al., 2012). Lovén et al. (2012) showed, that this global amplification of RNA
influences gene expression analysis in general and recommended gene normalization on total
cell numbers by using external spike-in controls.
1.2.6 Cooperation of signaling pathways
The previous sections described different signaling pathways activations by the microen-
vironment that are involved in B cell activation. Importantly, these factors do not act
independently but rather cooperative or even synergistic in changing B cell fate (Galibert
et al., 1996; Rousset et al., 1992; Nikitin et al., 2014). This is further supported by the
fact that TD and TI B cell activation dependents on additional coactivating signals from
surrounding cells (sec. 1.1.1). But also in B cell lymphoma evidence about cooperation of
signaling pathways exist. For example, it was shown, that MYC overexpression alone is not
sufficient to induce BL like tumors in mice, but that coactivation of the PI3K pathway is
needed (Sander et al., 2012). Another working group showed, that this PI3K activation in
MYC overexpressing mice activates NF-κB and STAT3 signaling, that are both involved in
lymphoma proliferation and survival (Han et al., 2010). Further evidence for an interaction
of NF-κB and STAT is given by the fact, that both, DLBCL and HL, frequently harbor
mutations affecting both signaling pathways. First evidence about a cooperational role for
STAT3 and NF-κB signaling in DLBCL ABC exist (Lam et al., 2008). Therefore, the inter-
action of different signaling pathways is important for B cell activation as well as lymphoma
pathogenesis.
To date there are hints, that one pathway can influence the activity of the another by reg-
ulating the gene expression of main signaling components. For example, it was shown that
NF-κB can upregulate IL6 gene expression, which activates STAT3 in a feedback loop (Lam
et al., 2008). In the same study, it was supposed that STAT3 and NF-κB can interact
to induce gene expression in B cells as it was shown in solid tumors before (Grivennikov
& Karin, 2010). Moreover, BCR activation can induce gene expression of TLR9 on naive
B cells making them reactive towards CpG stimulation (Bernasconi et al., 2003). However,
it is not known if and how other signaling pathways interact and which of these interac-




1.3 Regulation of cell cycle and metabolism
Regardless of normal B cell activation or transformation, specific gene expression changes
occur to induce proliferation in cells (Whitfield et al., 2006). Important stages are overcoming
the restriction point of the cell cycle and the evasion of further cell cycle check points
by increasing and activating positive cell cycle regulators, while negative regulators must
be shut down (Malumbres & Barbacid, 2001). However, in the last years an important
role for metabolic adaptations for sustained proliferation became evident (Vander Heiden
et al., 2011). So far less is known about how the previously described signaling pathways,
or their combinations, regulate cell cycle or metabolism in B cells. On the other hand,
Myc was shown to be a major regulator of all these steps in other cell entities (Bouchard
et al., 1998; Dang, 2012). Using the example of Myc, important cell cycle and metabolic
adaptations that are needed to induce cell proliferation will be described in the following
chapters.
1.3.1 Cell cycle regulation
The cell cycle is composed of different cell cycle phases (Norbury & Nurse, 1992). The
most important ones are the synthesis (S) phase, where DNA replication takes place, and
the mitosis (M) phase, where cells start to divide. Between these so called gap (G) phases
are defined. In the G1 phase, cells start to prepare for the DNA synthesis, whereas in the
G2 phase, between the S and M phase, cells are checked for DNA damage and prepare for
the progress of division. Naive B cells are stuck in the G0 of the cell cycle. Within this
quiescent stage of the cell cycle they achieve growth signals that activate cell cycle regula-
tors to enter the G1 phase. These regulators are a group of serine/threonine kinases called
cyclin dependent kinases (CDK) that form active heterodimers with so called cyclin proteins
(Johnson & Walker, 1999). The entry into a new cell cycle is controlled by the binding of cy-
clin D’s (gene names CCND1 to CCND3 ) to CDK4 and/or CDK6. In activated B cells, the
gene expression of cyclin D can be induced by activating B cell signaling including transient
MYC expression (Richards et al., 2008). However, in lymphoma cells MYC overexpression
alone is sufficient to increase cyclin D and CDK4 to overcome this threshold (Pajic et al.,
2000). CDK4 and CDK6 phosphorylate the retinoblastoma (Rb) protein, which sequesters
the transcription factor E2F. After phosphorylation Rb dissociates from E2F, which becomes
activated and induces expression of G1 and S phase regulatory genes. Within them cyclin
E (CCNDE) and A (CCNDA) are increased, which bind to CDK2 and CDK1 and promote
S phase progression by phosphorylation of genes involved in DNA replication. Like cyclin D,
the expression of cyclin E and cyclin A can be further increased by Myc thereby promoting
this step (Hanson et al., 1994). Additionally, Myc decreases the expression of the negative
regulators of CDK activity (p16/CDKN2A, p21/CDKN1A and p27/CDKN1B), which in-
hibit CDK activity by direct interactions. By analog sequential gene expression regulation
of the different cyclins, CDKs and their negative regulators, also the transition into the next
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cell cycle stages is regulated. After division, cells can become quiescent again (G0) or in case
of MYC overexpression enter a new round of cell cycle.
1.3.2 Metabolic regulation
Activated and transformed lymphocytes are thought to undergo similar metabolic reprogram-
ming to support proliferation since both highly increase glucose and glutamine metabolism
(Altman & Dang, 2012; Macintyre & Rathmell, 2013). Thereby glucose is metabolized to lac-
tate even if oxygen is present, a process which was first described by Otto Warbug (Warburg,
1956; Greiner et al., 1994). While regulation and fate of glucose metabolism was extensively
described, the role of glutamine in lymphocyte proliferation is not well described (Vander
Heiden et al., 2001; Jacobs et al., 2008).
Glutamine is a major carbon as well as nitrogen source, being involved in the tricarboxylic
acid cycle (TCA), amino acid and nucleotide synthesis but also redox balance (Newsholme,
2001). Thereby glutamine is metabolized via a process called glutaminolysis. The first step
of glutaminolysis is the conversion of glutamine to glutamate catalyzed by the glutaminase
(GLS). Glutamate is than metabolized to α-ketoglutarate (aKG) via deaminases (GLUD)
or aminotransaminases (Glutamic Oxaloacetic Transaminase/ GOT or Glutamic Pyruvate
Transaminase/ GPT). Please note, that through this study official gene names instead of
the protein names are used to facilitate comparison with gene expression data. To enable
differentiation of proteins and genes, gene names are written in italic letters.
Via multiple steps, aKG is oxidized inside the TCA to generate the reduction equivalents
(NADH and FADH2). These molecules can be used for anabolic biosynthesis processes, re-
dox balance or as proton donors in the respiratory chain to produce adenosine triphosphate
(ATP) in order to meet energy demands. Additionally, aspartate transaminases generate
the amino acid aspartate from glutamate which is important for further biosynthesis pro-
cesses like nucleotide synthesis. Importantly, lymphocytes do not proliferate in the absence
of glutamine indicating that at least one of this glutamine dependent processes is essential
for their proliferation (Newsholme et al., 1985; Crawford & Cohen, 1985).
The best described regulator of lymphocyte and cancer metabolism is Myc (Wise et al., 2008;
Wang et al., 2011). Myc was described to increase the expression of GLS (Gao et al., 2009).
A glucose independent role for glutamine in TCA function was further described in Myc
overexpressing cells, but also amino acid and nucleotide synthesis can be regulated by Myc
(Le et al., 2012; Liu et al., 2012). However, whether these metabolic changes are restricted
to aberrant MYC expression still needs to be investigated in more detail. First experiments
in T-cells show that CD28 activation increases GLS expression independent from Myc by a
pathway that involves activation of the Erk MAP kinase (Carr et al., 2010). Thereby, Erk
directly increases GLS expression by a mechanism distinct to Myc activation. These data
imply that glutamine metabolism can be increased by other signaling pathways and that the
mechanism can be different from Myc activity. However, the direct link between glutamine
metabolism and proliferation in B cells is not well characterized.
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Figure 2: Schematic presentation of selected metabolic pathways affected by high MYC expres-
sion. Metabolic changes support proliferation by providing energy (ATP), reducing equivalents (NADH) and
biosynthesis building blocks (as for example nucleotides). Glucose and glutamine (Gln) are main sources for
these processes and the gene expression of key metabolic enzymes (HK2, GLS) for their metabolism is regu-
lated by Myc. Glucose can be metabolized via the pentose phosphate pathway to synthesize ribose molecules
for nucleotide synthesis or degraded via glycolysis to pyruvate, which can be anaerobically converted to lac-
tate or used to fuel the TCA via acetyl-CoA. The TCA can also be fueled by Gln via aminotransferases (GOT
and GPT) or deaminases (GLUD). Reduction equivalents from the TCA are then used in the respiration
complex to build up a membrane potential which is necessary to generate ATP. Beside energy production
amino acids like aspartate are generated from Gln which are important precursors for nucleotide synthesis.
Gene names of important enzymes are shown in grey and italic letters. Gln = glutamine, Glu = glutamate,
Ala = alanine, Asp = aspartate, aKG = α-ketoglutarate, Suc = succinate, Fum = fumarate, Mal = malate,
OAA = oxaloacetate, Cit = citrate, Isocit = Isocitrate, Pyr = pyruvate.
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1.4 Aim of the study
Mutual interacting signaling pathways activated by factors of the cellular environment de-
fine B cell homeostasis and are thought to be involved in transformation processes. While
the effects of the proto-oncogene c-Myc on these processes are increasingly understood less
is known about how aberrant B cell signaling pathway activations and their interactions,
like NF-κB or JAK/STAT signaling, regulate metabolic adaptations for B cell proliferation.
From a previous study of Schrader et al. (2012a) evidence was provided that stimulation of a
B cell line with factors of the cellular environment allows to stratify lymphoma samples and
partially to predict pathways involved. However, pathway cross talks were not taken into
account in this approach, the used cell line was transformed by Myc and the effects of global
gene expression changes on key biological functions as cell proliferation or metabolism were
not defined. This study intents to get further insight into the interaction of signaling path-
ways and their potential to induce proliferation and associated metabolic reprogramming in
resting B cells. Thereby, answering the following questions is aimed:
(i) What is the impact of combination of factors of the B cell environment on global gene
expression and the metabolome?
(ii) Are pathway interaction networks able to reprogram the metabolism of resting B cells
to support B cell proliferation?
(iii) What is common or different in gene expression, proliferation and metabolism of stim-
ulated and Myc transformed cells?
(iv) Are these pathway dependent interactions/mechanisms also important for lymphoma?
To answer these questions, the P493-6 B cell line with a conditional MYC expression is used
to enable the modeling of combinations of stimuli and Myc activation on the same genetic
background. Analysis of global gene expression and metabolic changes in relation to prolifer-
ation of B cells are performed and the following analyses are conducted:
(i) Qualitative and quantitative assessment of the effects of selected single and combined
microenvironmental factors on global gene expression and metabolome in relation to
cell proliferation and in comparison to MYC overexpressing cells.
(ii) Functional assessment of pathway interactions and underlying mechanisms in the con-
text of gene expression, proliferation and related metabolic reprogramming.
(iii) Evaluation of identified regulatory circuits in different lymphoma cells and patients
derived data.
This study design will enable to characterize molecular pathways and new regulatory cir-
cuits for a better understanding of B cell homeostasis but also lymphoma biology and hope-




2 Material and Methods
2.1 Material, recipes and equipment
2.1.1 Biological material
Cell lines according to Table 1 were used in this study.
Table 1: Cell lines
Cell line Source Distributor Reference




CA-46 Homo sapiens DSMZ, (Magrath et al., 1980)
Burkitt Lymphoma Brunswick
OCI-Ly3 Homo sapiens DSMZ, (Tweeddale et al., 1987)
Diffuse Large B Cell Lymphoma
(ABC)
Brunswick
L-428 Homo sapiens DSMZ, (Schaadt et al., 1980)
Hodgkin Lymphoma Brunswick
Schneider Drosophila melanogaster DSMZ, (Schneider, 1972)
(S)-2 late embryo cells Brunswick
2.1.2 Chemicals and consumable supplies




4-Iodophenylboronic acid (4-IPBA) Sigma-Aldrich, Munich GER
5-Bromo-2-deoxyuridin (BrdU) Sigma-Aldrich, Munich GER
Acrylamid/Bisacrylamid 40% BioRad, Munich GER
Agarose Sigma-Aldrich, Munich GER
Ammonium persulphate Sigma-Aldrich, Munich GER
Bovine serum albumin (BSA) Serva, Heidelberg GER
Bradford solution RotiQuant-Roth, Karlsruhe GER
Bromphenol blue Sigma-Aldrich, Munich GER
Cell-Tak Cell and Tissue Adhesive Corning Incorporated, Corning USA
Deoxyribonucleoside triphosphates PrimeTech LTD, Minsk BY
cOmplete protease inhibitor cocktail Roche, Mannheim GER




di-Sodium tetraborate decahydrate Merck, Darmstadt GER
Ethanol (100%) J.T. Baker, Deventer NL
Ethidiumbromid Sigma-Aldrich, Munich GER
Ethylenediaminetetraacetic acid (EDTA) Riedel-de Haen, Seelze GER
FACS Flow Becton Dickinson, Heidelberg GER
Formaldehyde Sigma-Aldrich, Munich GER
Full Range Rainbow Molecular GE Healthcare, Munich GER
Glycerol Roth, Karlsruhe GER
Glycine Roth, Karlsruhe GER
HEPES Sigma-Aldrich, Munich GER
Hot FIREpol DNA polymerase (5 U/µl) PrimeTech LTD, Minsk BY
Hydrochloric acid (37%) Merck, Darmstadt GER
Hydrogen peroxide Sigma-Aldrich, Munich GER
Isopropanol Sigma-Aldrich, Munich GER
Luminol Sigma-Aldrich, Munich GER
Methanol 100% J.T. Baker, Deventer NL
Milk powder Roth, Karlsruhe GER
Nonidet P-40 Sigma-Aldrich, Munich GER
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Munich GER
Phosphatase inhibitor PhosSTOP Roche, Mannheim GER
Propidium iodide Sigma-Aldrich, Munich GER
RPMI-1640 Lonza, Basel CH
RPMI-1640 w/o glucose w/o glutamine PAN-Biotech, Aidenbach GER
Sodium chloride Merck, Darmstadt GER
Sodium deoxycholate Merck, Darmstadt GER
Sodium dodecyl sulfate (SDS) Merck, Darmstadt GER
Sodium hydrogen carbonate Merck, Darmstadt GER
Sodium hydroxide Merck, Darmstadt GER
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Munich GER
Thiolglycerol Sigma-Aldrich, Munich GER
Trisbase Sigma-Aldrich, Munich GER
Triton X-100 Sigma-Aldrich, Munich GER
Trypanblue 0.4% in PBS Life Technologies, Eggenstein GER
Tween-20 Merck, Darmstadt GER





96 well plate, round/flat bottom Sarstedt, Nümbrecht GER
384-Well clear optical reaction plate Applied Biosystems, Foster City USA
Optical adhesive covers Applied Biosystems, Foster City USA
Amicon ultra-4 centrifugal filter units Millipore, Schwalbach/Ts. GER
Cell culture flasks Sarstedt, Nümbrecht GER
Cryo box Nunc, Wiesbaden GER
Cryotubes Nunc, Wiesbaden GER
Diethylaminoethyl-cellulose Whatman, International Ltd UK
Electroporation cuvettes BioRad, Munich GER
FACS tubes Becton Dickinson, Franklin Lakes, USA
Falcon tubes Sarstedt, Nümbrecht GER
Filter tips Starlab, Ahrensburg GER
Micro touch examination gloves Ansell, Munich GER
Pasteur pipettes Sarstedt, Nümbrecht GER
Pipette tips w/o filters Sarstedt, Nümbrecht GER
Reaction tubes Sarstedt, Nümbrecht GER
Serological pipettes Sarstedt, Nümbrecht GER
Tissue culture plates Sarstedt, Nümbrecht GER
XFe96 fluxPak Seahorse Bioscience, Copenhagen, DNK
2.1.3 Buffers, solutions and media
Buffer solutions, recipes and cell culture media used in this study are listed in Table 4 till
Table 6.
Table 4: Ready to use solutions/buffers
Solution Manufacturer
4x loading buffer Roti-Load Roth, Karlsruhe GER
HEPES Buffer Millipore, Schwalbach/Ts. GER
PBS pH 7.4 (cell culture grade) Lonza, Verviers BEL
Ponceau S Sigma-Aldrich, Munich GER
Reblot plus mild antibody stripping solution
(10x)
Millipore, Schwalbach/Ts. GER
Roti-Quant Bradford assay Roth, Karlsruhe GER
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Table 5: Buffer recipes
Buffer Recipe




Running buffer (1x): 25mM Tris-base
192mM Glycin
34.67mM SDS
Transfer buffer (1x) 25mM Tris-base
192mM Glycin
15% (v/v) MeOH
Separation gel mix 250mM Tris-base, pH 8.8
25% (v/v) Acrylamid/Bis solution (40%)
0.0004% (w/v) APS
0.00125% (v/v) TEMED
Stacking gel mix 250mM Tris Base pH 6.8
12.5% (v/v) Acrylamid/bis solution (40%)
0.0004% (w/v) APS
0.00125% (v/v) TEMED
TBS (1x) 20mM Tris-base
137mM Sodium chloride
Adjusted to pH 7.6
TBS-T 1x TBS
0.1% (v/v) Tween-20
Chemiluminescence solution 1 100mM Tris/HCl pH 8.8
2.5mM Luminol
4mM 4-IPBA
Chemiluminescence solution 2 100mM Tris/HCl pH 8.8
5.3mM H2O2











20U/ml Hot FIREpol DNA polymerase
0.25% (v/v) Triton X-100
0.5mM Trehalose in depc water








ChIP sonification buffer 50mM Tris-HCl pH 8.0
1% (w/v) SDS
10mM EDTA





TE buffer 1M Tris-HCl pH 8.0





Drosophila medium Schneiders drosophila medium (Gibco)
10% (v/v) FBS (Gibco)
200U/ml penicillin + 200µg/ml streptomycin
Freezing medium (drosophila ) 45% (v/v) FBS (Gibco)
45% (v/v) conditioned drosophila medium
10% (v/v) DMSO
Cell culture medium I RPMI-1640 with glutamine (Lonza)
10% (v/v) FBS (Gibco)
200U/ml penicillin + 200µg/ml streptomycin
Cell culture medium II RPMI-1640 w/o glucose w/o glutamine (PAN)
10% (v/v) FBS (Gibco)
200U/ml penicillin + 200µg/ml streptomycin
2mM L-glutamine
2 g/l (11mM) glucose
Gln labelling Medium RPMI-1640 w/o glucose w/o glutamine
10% (v/v) FBS (Gibco)
200U/ml penicillin + 200µg/ml streptomycin
2mM 13C5-glutamine
2 g/l (11mM) glucose
Freezing medium (human) 90% (v/v) FBS (Gibco)
10% (v/v) DMSO




Equipment was used as shown in Table 7.
Table 7: Equipment
Instrument Manufacturer
7900HT Fast Real-Time PCR System ThermoFisherScientific, Massachusetts USA
Accu-jet Brand, Hamburg GER
Bioanalyser 2100 Agilent technologies, Santa Clara, USA
Biofuge Pico Heraeus Instruments, Hanau GER
Biofuge Primo R Heraeus Instruments, Hanau GER
CAT RM 5 horizontal roller CAT M Zipperer, Staufen GER
Centrifuge 5451D Eppendorf, Hamburg GER
Consort E734 Power Supply Schütt Labortechnik, Göttingen GER
FACSscan flow cytometer Becton Dickinson, Heidelberg GER
Hera freeze -80◦C freezer Heraeus Instruments, Hanau GER
IKA KS 260 shaker IKA, Staufen GER
IKAMAG RCT magnetic stirrer IKA, Staufen GER
Incubator Cytoperm Heraeus Instruments, Hanau GER
Incudrive incubator Schütt Labortechnik, Göttingen GER
LAS-4000 Image Reader Fujifilm, Düsseldorf GER
Microcoolcentrifuge 1-15k Sigma, Munich GER
Microflow Laminar Downflow Workstation Bioquell, UK
Multifuge 3 L-R Heraeus Instruments, Hanau GER
ND-1000 Spektralphotometer NanoDrop, Wilmington USA
Neubauer Counting Chamber Improved Lo Labor Optik, Friedrichsdorf GER
Power Pac 300 Power Supply Bio-Rad, Munich GER
SunriseTM Microplate Reader Tecan, Crailsheim GER
Thermocycler 60 Biomed, Theres GER
Thermocycler Mastercycler Eppendorf, Hamburg GER
Thermocycler T3000 Biometra, Göttingen GER
Thermomixer Compact Eppendorf, Hamburg GER
Vortex Genie 2 Schütt Labortechnik, Göttingen GER
Water bath Köttermann Labortechnik, Hänigsen GER
XFe96 analyser Seahorse Bioscience, Copenhagen, DNK
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2.1.5 Cell culture supplements, inhibitors and siRNA
Cells were stimulated with soluble stimulation factors shown in Table 8. Table 9 shows
metabolites and their working concentrations used for glutamine rescue experiments. In-
hibitors used in cell culture experiments are shown in Table 10, inhibitors used in respiratory
analysis in Table 11 and siRNA for transient transfection in Table 12.
Table 8: Stimulants
Working concentration
Stimulant Source Full Reduced
goat anti human IgM F(ab)2 Jackson ImmunoResearch,
Hamburg GER
1.3µg/ml 26 ng/ml
ODN2006 (CpG) InvivoGen, Toulouse FR 0.5µM 0.1µM
recombinant human IGF-1 Peprotech, Hamburg GER 100 ng/ml 20 ng/ml
recombinant human IL10 Peprotech, Hamburg GER 25 ng/ml 5 ng/ml
sCD40L Autogen bioclear, Wiltshire
UK
100 ng/ml 20 ng/ml
Table 9: Metabolites
Metabolite Source Working concentration
13C5-Glutamine Campo Scientific, Berlin GER 2mM
Adenine Sigma-Aldrich, Munich GER 100µM
Aspartate Sigma-Aldrich, Munich GER 10mM
Diethyl malate Sigma-Aldrich, Munich GER 1mM
Dimethyl 2-oxoglutarate Sigma-Aldrich, Munich GER 1mM
Glucose Sigma-Aldrich, Munich GER 11mM
Glutamine Biochrom/ Merck, Berlin GER 2mM
Oxaloacetic acid Sigma-Aldrich, Munich GER 1mM
Pyruvate Sigma-Aldrich, Munich GER 1mM
Thymine Sigma-Aldrich, Munich GER 100µM
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Table 10: Inhibitors used in cell culture
Inhibitor Source Working
concentration
10058-F4 Sigma-Aldrich, Munich GER 60µM
Aminooxyacetic acid (AOA) Sigma-Aldrich, Munich GER 500µM
CB-839 Selleckchem, Munich GER 1µM
IKK2 inhibitor VIII (ACHP) Calbiochem/Merck, Darmstadt GER 7µM
JAK inhibitor I (Pyridone 6) Calbiochem/Merck, Darmstadt GER 1µM
MLN120b MedChemExpress, Princeton USA 5µM
PD0332991 Selleckchem, Munich GER 0.5µM
Ruxolitinib Selleckchem, Munich GER 1µM
Table 11: Inhibitors used for respiratory analysis
Inhibitor Source Working
concentration
Oligomycin Sigma-Aldrich, Munich GER 1.5µM
Carbonylcyanide-4-
(trifluoromethoxy)- Sigma-Aldrich, Munich GER 0.5µM
phenylhydrazone (FCCP)
Antimycin Sigma-Aldrich, Munich GER 2µM
Rotenon Sigma-Aldrich, Munich GER 1µM
Table 12: siRNA
siRNA Source
Silencer Select Negative Control No. 1 ThermoFisherScientific, Massachusetts USA
SMARTpool: ON-TARGETplus STAT3 Dharmacon, Lafayette, USA
SMARTpool: ON-TARGETplus RELA Dharmacon, Lafayette, USA
SMARTpool: ON-TARGETplus GOT1 Dharmacon, Lafayette, USA
SMARTpool: ON-TARGETplus GOT2 Dharmacon, Lafayette, USA




Antibodies used for chromatin immunoprecipitation (ChIP, Table 13), Flow Cytometry (Ta-
ble 14) and Immunoblot analysis (Table 15) are listed below.
Table 13: ChIP antibodies
Antibody Order nr. Source Working
concentration
α-IgG sc-2027 Santa Cruz, Heidelberg GER 5µg per IP
α-STAT3 sc-482 Santa Cruz, Heidelberg GER 5µg per IP
α-p65 sc-372 Santa Cruz, Heidelberg GER 5µg per IP
Table 14: Flow cytometry antibodies
Antibody Order nr. Source Working
concentration
NF-κB p65 #8242 Cell Signalling Technology,
Frankfurt a. M. GER
1:400
Alexa 488 mouse α-pSTAT3
(pY705)
#557814 BD Biosciences, Oxford UK 1:5
FITC donkey α-rabbit IgG #406403 Biolegend, San Diego US 1:50
Alexa 488 mouse α-BrdU B35139 Life technologies, Carlsbad US 1:15
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Table 15: Immunoblot antibodies
Antibody Order nr. Source Working
concentration
rabbit α-p-STAT3 (Tyr705) #9131 Cell Signalling Technology,
Frankfurt a. M. GER
1:1 000
rabbit α-STAT3 #9132 Cell Signalling Technology,
Frankfurt a. M. GER
1:1 000
rabbit α-p-p38 #4511 Cell Signalling Technology,
Frankfurt a. M. GER
1:1 000
rabbit α-p-p42/p44 #4377S Cell Signalling Technology,
Frankfurt a. M. GER
1:1 000
rabbit α-p-Akt (Ser473) #4060 Cell Signalling Technology,
Frankfurt a. M. GER
1:1 000
rabbit α-IκBα #4812 Cell Signalling Technology,
Frankfurt a. M. GER
1:1 000
rabbit α-p-p65 (Ser536) #3033 Cell Signalling Technology,
Frankfurt a. M. GER
1:1 000
rabbit α-p65 #4764 Cell Signalling Technology,
Frankfurt a. M. GER
1:1 000
mouse α-tubulin #05-829 Millipore, Schwalbach GER 1:5 000
rabbit α-c-Myc ab32072 Abcam, Cambrige UK 1:10 000
mouse α-GAPDH ab8245 Abcam, Cambrige UK 1:20 000
rabbit α-GOT2 14886 Proteintech, Manchester, UK 1:1 000
rabbit α-GOT1 14800 Proteintech, Manchester, UK 1:1 000
goat α-rabbit IgG-HRP sc-2004 Santa Cruz, Heidelberg GER 1:2 000




Oligonucleotides used for quantitative real time PCR (qRT PCR) and ChIP analysis are
shown in Table 16 and Table 17, respectively.
Table 16: Oligonucleotides used for qRT PCR








Table 17: Oligonucleotides used for ChIP analysis






2.1.8 Ready to use reaction systems
Commercial ready to use reaction systems are shown in Table 18.
Table 18: Reaction Systems
Description Manufacturer
NucleoSpin RNA Isolation Kit Machery-Nagel, Düren GER
SuperscriptII RT Kit Invitrogen, Karlsruhe GER
Nucleofector Kit V Lonza, Basel CH
Nucleofector Kit L Lonza, Basel CH





If not stated elsewhere the following software products were used: the present thesis was
written with LaTeX and BibTeX. Literature-management and bibliography were generated
using Mendeley Desktop Version 1.15.3. Graphs were created using GraphPad PRISM 6 or
’R’ version 3.3.0. Figures were assembled using Adobe Illustrater CS2 and Microsoft Office
PowerPoint 2010. Real time analysis was performed using SDS 2.4 and RQ Manager 1.2.1
(Applied Biosystems). Schemes were drawn with the help of items taken from servier medical
art (www.servier.com).
2.2 Cell biology
2.2.1 Cell culture techniques
Drosophila cell cultivation and spike-in preparation
Schneider-2 (S2) cells were cultured in drosophila medium at room temperature and nor-
mal air pressure. Cells were seeded in tissue flasks at 2·106 cells/ml and maintained below
20·106 cells/ml by splitting 1:2 to 1:5 twice a week.
For spike-in preparation, S2 cells were counted using a hemocytometer and trypan blue
exclusion. Cells were sedimented (centrifugation 300 x g, 7min at RT) and resuspendend
at a density of 1·106 cells/ml in drosophila freezing medium and aliquoted in vials of 1ml.
Isopropanol filled cryo boxes were used to gradually cool down cells to -80 ◦C and cryotubes
were stored at -150 ◦C.
Human B cell cultivation
All human cell lines used in this study were cultured in RPMI-1640 supplemented with
10% FBS, penicillin/streptomycin and stable glutamine (cell culture medium I) at 37 ◦C,
5% CO2. Living cells were counted by using a hemocytometer and trypan blue exclusion.
The human B cell lines P493-6, OCI-Ly3 and L-428 cells were maintained in a density
between 0.5·106 - 1.5·106 cells/ml by splitting two to three times a week. Human BL derived
CA-46 was cultured in a lower density between 0.3·106 - 1.0·106 cells/ml. P493-6 cells were
cultured without the addition of tetracycline or estradiol to generate Myc overexpressing cells
(Mychigh ) or treated with 1 ng/ml doxycycline for at least 16h to decrease MYC expression
(Myclow ). One day prior all experiments, all cell lines were seeded in fresh cell culture
medium II including freshly added glutamine (P493-6=1·106 cells/ml, OCI-Ly3/ L-428=
5·105 cells/ml, CA-46=3·105 cells/ml). For generation of Myclow cells 1 ng/ml doxycycline
was added to P493-6 cells at this step.
For cryopreservation, cells were centrifuged (250 x g, 5min at RT) and resuspended in human
freezing medium. Per aliquot 5·106 cells were frozen using cryoboxes as described above. For
revitalization, cells were thawed in 37 ◦C water bath, transferred to 5ml of warm medium




Activation of P493-6 cells with soluble factors
To stimulate P493-6 cells for transcriptomic and metabolic analysis, cells were counted,
centrifuged and seeded in fresh cell culture medium II at a density of 1·106 cells/ml. As
depicted cells were treated with either anti human IgM F(ab)2 fragment (α-IgM), sCD40L
(CD40), rh IGF-1 (IGF), rh IL-10 (IL10), ODN2006 (CpG) or combinations of those (for
concentrations see Table 8). For all single stimulations a full dosage of stimuli were used
(depicted as 1), while a reduced dosage was included in combinatorial experiments (de-
picted as 0.2). Combinations of stimuli used for linear regression experiments are shown in
Table 19.
To analyze pathway activation (immunoblot) cells were stimulated for 1 h at 37 ◦C 5%
CO2. For gene expression, metabolome and cell cycle analysis cells were stimulated for
24 h at 37 ◦C 5% CO2. Precise harvest procedure is described in corresponding method
sections.
Inhibitor treatment
Cells were seeded in fresh cell culture medium II (P493-6=1·106 cells/ml, other cell lines
0.5·106 cells/ml) and treated with inhibitors listed in Table 10. In case of stimulated P493-
6 Myclow cells, cells were treated with stimuli 3 h after inhibitor treatment. As described
before, cells were harvested after 24 h for transcriptomic or metabolome analysis. Samples
for western analysis were taken 2 h after inhibitor treatment in OCILy-3, L-428 and CA-46,
and 1 h after stimulation in P493-6 Myclow cells. Details for harvesting of cells are described
in corresponding method sections.
Transfection of siRNA
For knockdown experiments, siRNA pools against specific targets (see Table 12) were used.
siRNAs were transfected into cells by electroporation using Amaxa Nucleofector system
according to manual instructions (analog to protocol for Ramos cells). Cell line specific
modifications are shown in Table 20. P493-6 cell line was transfected in Mychigh state and
doxycycline was added 3 h after transfection to generate Myclow cells. All following experi-
ments, including western blot analysis to analyze knockdown efficiency, were performed 24 h
after knockdown.
Table 20: Cell line specific transfection parameters
Shown are values for a single transfection.
Cell line Number of cells siRNA Kit program
P493-6 4·106 4µg V C-009
OCI-Ly3 2·106 2µg V A-020
L-428 2·106 2µg L X-001
CA-46 2·106 2µg V R-013
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Table 19: Matrix of stimuli combinations used for linear regression experiments. P493-6
Myclow (0) and Mychigh (1) cells were each stimulated with combinations of α-IgM, CD40L, CpG, IGF-1
or IL10. 1= full concentration, 0.2= reduced concentration, 0=no stimulus added. Horizontal lines seper-
ate batches.
Sample CD40L BCR IGF CpG IL10 Myc Sample CD40L BCR IGF CpG IL10 Myc
1 1 0 0 0 0 1 51 1 0 0 0 0 1
2 0 1 0 0 0 0 52 0 1 0 0 0 0
3 0 0 0 0 0 0 53 0 0 0 0 0 0
4 0 0 0 0 0 1 54 0 0 0 0 0 1
5 0 1 1 1 1 1 55 0 0 0 0.2 1 1
6 1 1 1 1 1 1 56 0.2 0.2 0.2 1 1 1
7 1 1 0 1 0 1 57 0.2 1 1 0 0 1
8 1 0 0 1 1 0 58 1 1 0 1 1 0
9 0.2 1 1 0 1 0 59 1 1 1 1 1 0
10 0 0 0 1 1 0 60 0.2 0 1 0.2 1 0
11 0 1 0 0 0 1 61 0 1 0 0 0 1
12 0 0 1 0 0 0 62 0 0 1 0 0 0
13 0 0 0 0 0 0 63 0 0 0 0 0 0
14 0 0 0 0 0 1 64 0 0 0 0 0 1
15 0 1 0.2 0.2 0 1 65 0.2 1 1 0 1 1
16 1 0.2 0.2 0 0 1 66 1 0.2 0 0 1 1
17 1 1 1 1 0.2 1 67 1 1 0 1 1 1
18 0.2 0.2 0.2 0.2 0.2 0 68 0 0.2 0 0.2 1 0
19 1 0.2 0 0 1 0 69 1 1 1 1 0.2 0
20 0.2 1 0.2 0 0.2 0 70 1 1 0 1 0 0
21 0 0 1 0 0 1 71 0 0 1 0 0 1
22 0 0 0 1 0 0 72 0 0 0 1 0 0
23 0 0 0 0 0 0 73 0 0 0 0 0 0
24 0 0 0 0 0 1 74 0 0 0 0 0 1
25 0.2 0.2 0.2 0 0 1 75 0 0.2 0 0.2 1 1
26 0.2 1 0 0 1 1 76 0.2 0.2 0.2 0.2 0.2 1
27 1 0 0 1 1 1 77 0.2 1 0.2 0 0.2 1
28 0.2 1 0.2 1 0 0 78 0 1 1 1 1 0
29 0 0 0 0.2 1 0 79 0.2 0.2 0 1 1 0
30 0.2 1 0.2 0.2 0.2 0 80 0.2 0.2 0.2 1 1 0
31 0 0 0 1 0 1 81 0 0 0 1 0 1
32 0 0 0 0 1 0 82 0 0 0 0 1 0
33 0 0 0 0 0 0 83 0 0 0 0 0 0
34 0 0 0 0 0 1 84 0 0 0 0 0 1
35 0.2 1 0.2 0.2 0.2 1 85 0.2 1 1 0.2 0 1
36 1 1 0.2 0.2 0 1 86 0.2 0.2 1 0 0.2 1
37 0.2 0 1 0.2 0 1 87 1 0 1 1 0.2 1
38 1 1 0.2 0.2 0 0 88 0 1 0.2 0.2 0 0
39 0.2 1 1 0.2 0 0 89 0.2 0.2 1 0 0.2 0
40 1 0 1 1 0.2 0 90 1 0 1 0.2 0 0
41 0 0 0 0 1 1 91 0 0 0 0 1 1
42 1 0 0 0 0 0 92 1 0 0 0 0 0
43 0 0 0 0 0 0 93 0 0 0 0 0 0
44 0 0 0 0 0 1 94 0 0 0 0 0 1
45 0 0 0 1 1 1 95 1 0 1 0.2 0 1
46 0.2 0.2 0 1 1 1 96 0.2 1 0.2 1 0 1
47 0.2 0 0.2 1 0 1 97 0.2 0 1 0.2 1 1
48 0.2 0.2 0.2 0 0 0 98 0.2 1 1 0 0 0
49 0.2 1 0 0 1 0 99 0.2 0 1 0.2 0 0




To analyze the proliferation capacity of cell lines under different conditions, cell doubling
was analyzed 48 h after treatment. For this cells were seeded into 100µl of culture medium
II using a 96 round bottom well plate. In case of metabolic depletion experiments, culture
medium II without the addition of either glutamine or glucose was used. Rescue experiments
of glutamine deprivation were performed by adding metabolites listed in Table 9 directly to
the media. After addition of metabolites, pH of cell culture media was adjusted to pH7
by adding 1M NaOH or 1M HCl. To account for different cell doubling times, cells were
seeded at different densities (P493-6/ OCILy-3=5·105 cells/ml, L-428=3·105 cells/ml, CA-
46=2·105 cells/ml). Cells were treated as depicted and incubated at 37 ◦C 5% CO2 for 48 h.
In case of stimulated P493-6 Myclow , cell stimulation was repeated 24 h after first treatment.
After 48 h the total number of viable cells was calculated using hemocytometer and trypan
blue exclusion.
2.2.2 Respiratory analysis
To simultaneously measure oxygen consumption rates (OCR) and extracellular acidification
rates (ECAR) in stimulated P493-6 Myclow cells the Seahorse XFe96 system was used.
Coating of cell culture plates
To measure suspension cells in a XF analyzer, attachment of the cells to the culture plate
was needed. Therefore, a Seahorse 96 cell culture microplate was coated with Cell-Tak
according to manufactures protocol. In brief, 18.8µl Cell Tak were dissolved in sterile 2.5ml
0.1M sodium bicarbonate (pH 8.0) and 9µl of 1M NaOH was added to start adsorption to
the plastic surface. 25µl of this solution was added to each well of a 96 cell culture plate,
incubated for 20min and washed two times with sterile H2O.
Measurement of respiratory parameters
P493-6 Myclow cells were stimulated for 24 h in medium II (supplemented with 11mM glu-
cose and/or 2mM glutamine), counted and 100 000 cells per well were seeded in XF Base
medium (supplemented with 11mM glucose and/or 2mM glutamine) according to manu-
factures protocol for suspension cells. Cells were incubated for 30min at 37 ◦C without the
addition of CO2 to allow cells to attach to the surface. In the meantime inhibitors of mi-
tochondrial respiration complexes were prepared and loaded to hydrated assay cartridge.
Port loading and concentrations are described in Table 21. The assay cartridge was cali-
brated, cell plate loaded into XFe analyzer and cycles were performed as listed in Table 23.
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Figure 3: Calculation of resp. parameters
Picture was taken from manufactures protocol
(www.seahorsebio.com).
Table 23: Mix and measuring cycle times for
XF assay






















Measurement of glutamine dependency
Myclow cells were stimulated for 24 h in medium II without glutamine. Cells were counted
and 100 000 cells per well were seeded in XF Base without glutamine. Cells were allowed
to attached, ports were loaded with inhibitors described in Table 22 and assay was run as





To analyze cell cycle distribution and number of cells in synthesis-phase (S), 5 ·105 P493-6
Myclow cells were labeled with 20µM 5-bromo-2’-deoxyuridine (BrdU) for 1h at 37 ◦C 5%
CO2. Cells were centrifuged (400 x g, 3min, 4 ◦C), resuspended in 300µl PBS and three
times 300µl ice cold 100% EtOH was added stepwise. Cells were fixed at 4 ◦C for at least
3h. Afterwards, cells were centrifuged (400 x g, 3min, RT) and pellet was permeabilized by
incubating in 500µl 2N HCl/ 0.5% Triton-X100. After centrifugation cells were neutralized
by adding 500µl 0.1M sodium tetraborat (pH 8.5) and washed once with 500µl 1% BSA
in TBS. Cells were resuspended in 50µl 1:15 Alexa488 anti-BrdU mouse antibody (diluted
in 1% BSA in TBS-T) and stained over night at 4 ◦C. Next day, cells were washed with
1% BSA in TBS-T, resuspended in 1% BSA in TBS and 1µg/ml propidium iodide (PI)
was added. Fluorescence of cells was analysed in BD FACScan System with gating scheme
shown in Figure 4. Cell doublets were excluded by propidium iodide area versus width
exclusion.
Figure 4: BrdU gating scheme. G0 = resting phase, G1 = Gap 1 phase, S = synthesis phase, G2 = Gap
2 phase, M= mitosis
To analyze cell cycle phase length a BrdU pulse change experiment was performed. P493-6
Myclow cells were stimulated with IL10, CpG or IL10+CpG for 12 h to allow cells to en-
ter S-phase. 5·105 cells per sample were then pulsed with 20µM BrdU for 20min. Cells
were washed once in PBS and seeded in fresh media. After indicated time points cells were
harvested and fixed with EtOH as described before. Samples were stained as described be-
fore and cell cycle distribution of S-phase gated cells was analyzed by using propidium iodide.
STAT3/NF-κB translocation assay
To analyze STAT3 and NF-κB pathway activation, nuclear staining of p-STAT3 and total
p65 was performed as previously described (Blaecke et al., 2002). P493-6 Myclow cells were
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stimulated with IL10, CpG or both and 5·105 cells were collected (400 x g, 3min, 4 ◦C) after
indicated time points. Pellet was washed one with ice cold PBS and lysed in 500µl PIPES
(Table 5) for 30min on ice. Nuclei were isolated by centrifugation (2000 x g, 3min, 4 ◦C) and
washed two times with cold washing buffer (PBS + 0.1% BSA+2mM MgCl2) to remove
cytosolic proteins. For p-STAT3 staining, nuclei were incubated in 25µl 1:5 diluted Alexa488
anti-pSTAT3 (Y705) in washing buffer for 30min at 4 ◦C. For NF-κB staining, nuclei were
incubated first in 25µl of 1:400 a-NF-κB in washing buffer (30min, 4 ◦C), washed once,
followed by a second incubation in 25µl of 1:50 FITC anti-rabbit antibody in washing buffer
(30min, 4 ◦C). After staining nuclei were washed once in washing buffer and propidium
iodide was added. Gating for single nuclei was performed using area versus width of the
propidium iodide channel.
2.3 Protein biochemistry
2.3.1 Preparation of lysates
Protein lysates were prepared separately for pathway activation analysis or knockdown effi-
ciency control after siRNA knockdown.
Lysates for pathway analysis
After stimulation 1·106 cells were sedimented (300 x g, 5min, 4 ◦C), washed once in cold PBS
and dry pellets were stored at -20 ◦C. For lysis, cells were thawed on ice and resuspended in
cold RIPA buffer (Table 5) supplemented with protease inhibitor cocktail and phosphatase
inhibitor (Roche). Cells were lysed on ice for 30min and debris was removed by centrifu-
gation (13 x 000 g, 15min, 4 ◦C). Supernatant was transferred into a new tube and protein
concentration was measured by Bradford assay (Roth) according to manufactures proto-
col. Protein concentrations of all samples were diluted to 1µg/ml with RIPA buffer and
4x loading buffer. Proteins were denaturated for 10min at 95 ◦C and directly loaded on a
SDS-PAGE or stored at -20 ◦C.
Lysates after siRNA knockdown
To check knockdown efficiency, 250 000 cells were harvested 24 h after siRNA transfection.
Cells were sedimented (300 x g, 5min, 4 ◦C) and washed once with PBS. Pellet was di-
rectly resuspended in 25µl 1x loading buffer diluted with RIPA. Cells were cooked for
10min at 95 ◦Cand DNA was shared by sonification (Bioruptor, 6 times 10 sec on/off, high
power) to facilitate lysate loading. Lysates were directly loaded on SDS-Page or stored at
-20 ◦C.
2.3.2 SDS-PAGE
For separation of proteins according to molecular weight a sodium dodecyl sulfate (SDS)
polyacrylamide gel electrophoresis (PAGE) was used (Laemmli, 1970). Modified gel buffers
listed in Table 5 were used to prepare 10% separation and 5% stacking gels. Gels were loaded
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with 15µg protein lysate per sample and electrophoresis was performed in 1x Laemmli buffer
at constant 40mA for approximately 1h.
2.3.3 Immunoblotting
Separated proteins were transferred from SDS gel onto a hydrophobic membrane using wet
tank sandwich method (Towbin et al., 1979; Renart et al., 1979). Instead of nitrocellulose
a PVDF membrane was used, which was activated in 100% MeOH (10 sec), rehydrated in
H2O (2min) and equilibrated in transfer buffer (5min, Table 5) prior to use. Membrane
and gel were stacked into a wet tank chamber and transfer was performed at 4 ◦C at 100V
for 1 h. Effective transfer of proteins was visualized by ponceau S staining and unspecific
binding sites were blocked using 5% BSA or milk powder for 1 h at RT. After blocking,
antibody solutions listed in Table 15 were added over night at 4 ◦C. Next day, blots were
washed three times 10min with 1x TBS-T and a secondary antibody against the species of
the first was added for 1 h at RT. After three additional washing steps, bound antibodies were
visualized using a self-prepared luminol/peroxide solution according to Haan & Behrmann
(2007)Table 5 and LAS-4000 Image Reader. For reblotting, membrane was stripped for
15min with 1x ReBlot buffer mild, blocked in 5% BSA or milk powder for 30min at RT and
another antibody was added over night as described before.
2.4 Molecular Biology
2.4.1 Spike-in for transcriptomic data
To account for global gene expression shifts in transcriptomic data, a new spike-in method
was developed. For this a whole cell spike-in was directly added to a constant number of
sample cells during the harvest of treated cells: Sample cells were counted and (if not other-
wise depicted) 1·106 cells were transferred into a reaction tube. Previously frozen drosophila
S2 cells (see section 2.2.1) were thawed in a 37 ◦C water bath and quickly suspended. 100µl
drosophila cell suspension (= 100 000 cells) were added to each prepared human sample. Cells
were centrifuged (300 x g, 5min, 4 ◦C), washed with cold PBS and stored as dry pellet at
-80 ◦C till RNA isolation.
2.4.2 RNA Isolation
Total RNA of cells was isolated using NucleoSpin RNA kit according to manufactures pro-
tocol and RNA was eluted in 50µl RNase free H2O. For comparison of whole cell spike-in
and commercial gold standard 2µl of 1:100 diluted ERCC Mix 1 was directly added to the
elution volume. RNA concentration was measured by NanoDrop and quality of RNA for




Messenger RNA was transcribed into cDNA using SuperScript II Reverse Transcriptase Kit.
In brief, 2µl of random hexamer primers (IBA Biotechnology) were added to 1µg of total
RNA and filled up with H2O to a total volume of 10µl. Sample was denaturated at 70 ◦C
for 10min and 8µl of master reaction mix (Table 24) were added. Reverse transcription was
performed in a thermocycler according to Table 25.
Table 24: cDNA master mix
Amount Substance
4µl 5x First strand buffer
2µl 0.1M DTT
1µl Super Script II RT
1µl dNTP mix (each 10mM)






2.4.4 qRT-PCR (quantitative Reverse-Transcriptase-Polymerase Chain Reaction)
Gene expression was analyzed by SYBR green-based real-time PCR using 7900HT Fast
Real-Time PCR System in 384 well plates (Zipper et al., 2004). Per sample 10µl reaction
solution was used, containing 10 ng DNA and 5.6µl self-made SYBR green mix (Table 5)
and 3 pmol/µl of primer pair. Primer sequences used in this study are listed in Table 16.
Amplification cycles were performed as shown in Table 26 and melting curves of amplified
products were used as quality control.
Table 26: qRT PCR cycle program
Temperature Cycle length Number of cycles
95 ◦C 15min
95 ◦C 15 sec
60 ◦C 1min 40
95 ◦C 15 sec
60 ◦C 15 sec
95 ◦C 15 sec
The number of cycles used to overcome a certain fluorescent signaling threshold (threshold
cycle CT) directly correlates with the amount of DNA used in this assay.
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To account for technical differences between samples a first normalization relative to an
internal or external (spike-in) housekeeper gene is made:
∆CT = CTgeneofinterest - CThousekeeper
To calculate relative changes between a treatment sample and an untreated control a second
quotient of ∆CT is formed:
∆∆CT = ∆CTtreatment - ∆CTcontrol
As the number of cycles exponentially correlates with amount of DNA in the sample, relative
n-fold changes can be calculated as:
Rq = 2−∆∆ CT
All ∆Ct values in this study were normalized to Act42A expression of the drosophila spike-in
using SDS Rq Manager. Relative fold changes were calculated as 2−∆∆ CT relative to the
depicted sample.
2.4.5 RNA Sequencing
RNA sequencing was performed in the Transcriptome and Genome Analysis Laboratory
(TAL) in Göttingen. Libraries were prepared from 1µg total RNA (containing the spike-in
cells and the ERCC spike-in Mix 1) using the TrueSeq RNA Sample Preparation Kit v2 (Illu-
mina). Libraries were sequenced in single end mode for 100 cycles on an Illumina HiSeq 2000
with a mean sequencing depth of approximately 40mio reads/sample.
Normalization and differential gene expression
Read mapping, normalization and calculation of differential gene expression was performed
in R in cooperation with the bioinformatistic group from the institute of functional genomics
(University of Regensburg). Analysis of the spike-in experiment and stimulation experiment
was performed by Franziska Taruttis. Analysis of the RNASeq data of IL10+CpG stimulated
P493-6 cells was performed by Paula Perez-Rubio and Julia Engelmann. In brief, RNASeq
read counts were assigned to Ensembl gene identifiers using ’featureCounts’ version 1.4.5.
For all datasets, human genes with more than 100 counts for each sample were selected for
normalization and differential gene expression analyses of the respective dataset. Global
normalization based on endogenous (human) genes was performed using library size factors
calculated by ’DESeq2’, followed by differential gene expression analysis to estimate log2
fold changes between all sample groups (Love et al., 2014). To estimate log2 fold changes
based on the drosophila spike-in cells or ERCC kit, library size factors were calculated on
the counts of the drosophila genes or synthetic gene counts by ’DESeq2’, and applied to the
human gene counts of each sample.
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Gene set enrichment and heatmap calculation
Gene set enrichments were calculated using the top 2000 genes from DESeq2 analysis (sorted
after p-value, log2FC >1) and online DAVID bioinformatics annotation tool (Huang et al.,
2009). Heatmaps of differential gene expression were calculated using the ’heatmap.2’ func-
tion in the ’gplots’ package in R.
2.4.6 Chromatin Immunoprecipitation
Sample lysis and sonification
To analyze binding of STAT3 and p65 to target genes, chromatin immunoprecipitation ac-
cording to Nowak et al. was performed (Nowak et al., 2005). In brief, P493-6 Myclow cells
were stimulated with IL10, CpG or IL10+CpG for 1h at 37◦C and washed once with PBS.
Crosslinking of proteins and chromatin was performed with 2mM DSG in PBS for 45min
at RT, followed by a second crosslinking with 1% formaldehyde for 15min RT. The reaction
was stopped by adding 0.1M glycine for 10min RT and cells were washed twice with cold
PBS (12.000 x g, 1min, 4C◦C). Cells were lysed for 15min on ice in ChIP lyses buffer (Ta-
ble 5). Isolated nuclei were sedimented (12.000 x g, 1min, 4 ◦C) and resuspended in ChIP
sonification buffer (Table 5). Chromatin was sheared in Bioruptor NextGen using four cycles
of 10min (10 sec on/off duty time) at high power. SDS was quenched by adding 1% Triton
X-100 and debris was removed by centrifugation (13 000 x g, 10min, 4 ◦C). A small sample
was taken for agarose gel analysis and remaining chromatin was quickly frozen in liquid
nitrogen and stored at -150 ◦C.
Sonification test
To check for proper chromatin shearing, DNA was precipitated from chromatin by adding
two times 100% EtOH over night at -20 ◦C. DNA was pelleted (15 000 x g, 30min, 4◦C),
washed in 70% EtOH and dried at RT. RNA was digested by adding 3.3µg/ml RNase
for 1 h at 37 ◦C. 15µl 20% Chelex solution was added, DNA resuspended and heated at
95 ◦C for 10min. After cooling, 0.5µl 20µg/ml proteinase K was added and protein was
digested by heating to 55 ◦C for 30min. Samples were centrifuged (13 000 x g, 1min) and
20µl supernatant was transferred into a new reaction tube. Orange G staining solution
was added and samples were run at a 1.5% agarose gel for 45min with 100V. For further
proceeding DNA fragments had to be at a size of about 500 bp. Smaller fragmentation could
not be achieved due to two-step crosslinking method.
Immune precipitation
For one IP 50µl of protein A coupled magnetic beads (dynabeads) were washed three times
in 0.5% BSA in PBS. Afterwards, 5µg of α-IgG, α-STAT3 or α-p65 according to Table 13
were added overnight at 4◦C. After three additional washing steps, sheared chromatin of
2·106 cells were added to the beads and incubated overnight at 4◦C. Next day, beads were
washed four times with ChIP RIPA buffer (Table 5) and once in TE buffer. 10% Chelex were
added to the washed beads, resuspended and heated for 10min 95◦C. Protein was digested by
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adding 2µl of 20µg/ml Proteinase K (30min, 65◦C) and afterwards inactivated by heating
to 95◦C for 10min again. Samples were centrifuged at 12 000 g for 1min at 4 ◦C, supernatant
transferred into a new tube and DNA was stored at -20 ◦C.
Preparation of input sample
For each stimulation a portion of the sonificated chromatin was used for generating an input
control. 100% EtOH was added twice the volume of chromatin overnight at -20 ◦C. Chro-
matin was centrifuged (12 000 x g, 4 ◦C, 20min), washed twice with 70% EtOH and dried at
RT. Afterwards DNA was extracted using Chelex method described above.
Real-time PCR
For quantification of precipitated DNA sequences, qRT-PCR described in section 2.4.4 was
used. Isolated DNA was diluted 1:10 and directly used in the described assay. Primers for
sequence detection are listed in Table 17. All data were normalized to an inactive (closed
chromatin) region called PRAME and fold changes were calculated relative to unstimulated
Myclow cells.
2.5 Metabolomics
Extraction, measurement and analysis were performed in cooperation with the NMR/mass
spectrometry group of the functional genomics department in Regensburg. NMR analysis
and mass spectrometry of unlabeled metabolites were performed by Philipp Schwarzfischer,
analysis of 13C-glutamine labeling by Paul Heinrich.
2.5.1 Sample preparation
13C-Glutamine labeling
To analyze fate of glutamine in metabolism, stable isotopic labeling was performed. P493-6
Mychigh and Myclow cells were washed once in warm PBS and seeded in cell culture medium
II supplemented with 2mM ubiquitously labeled 13C-glutamine. Myclow cells were stimu-
lated with IL10, CpG and IL10+CpG as described before and cells were incubated at 37 ◦C
5% CO2. To confirm steady state of isotopic labeling distribution, time course was performed
between 18 h and 30 h after stimulation. No significance difference in isotopic distribution in
organic acids was observed, indicating a steady state during this time frame. Therefore, all
labeling were performed for 24 h.
Harvest of cells and supernatants
After 24 h cells were counted and 5·106 cells were centrifuged (300 x g, 5min, 4◦C). Super-
natants were transferred into a new tube, while cell pellets were washed two times in cold PBS
and resuspended in ice cold 80% MeOH. In the meantime, 10 kD ultra centrifugal filters were
activated by adding 3ml of H2O and centrifuged for 30min at 4 000 g. Supernatants were
loaded onto filters and centrifuged for 30min, 4 000 g at 4 ◦C. Filtrate was transferred into
a new tube and both, supernatant and pellet, were stored at -80 ◦C.
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Metabolite extraction form cell pellets
Metabolites were extracted using methanol method as described previously (Dettmer et al.,
2011). In brief, cell pellets were vortexed in 80% MeOH and centrifuged (10 000 x g, 6min,
4 ◦C). This step was repeated two more times and all supernatants were combined, dried for
2 h in a vacuum evaporator and stored at -80 ◦C.
2.5.2 NMR spectrometry
Ultrafiltrate of supernatants was mixed with phosphate buffer and 4, and 3-trimethylsilyl-
2,2,3,3-tetradeuteropropionate (TSP) dissolved in deuterium oxide as internal standard.
NMR measurement was perfomed on a 600MHz Avance III spectrometer (BrukerBioSpin,
Rheinstetten, Germany) and 1D 1H and 2D 1H - 13C heteronuclear single-quantum corre-
lation (HSQC) spectra were acquired as published before (Gronwald et al., 2008). Ab-
solute concentrations from 1D and 2D NMR data were calculated employing individual
peak calibration factors using the NMR quantification tool MetaboQuant (Klein et al.,
2013).
2.5.3 Mass spectrometry
Measurement of amino acid, tryptophan derivates, organic acids and MTA metabolites was
performed as previously described (van der Goot et al., 2012; Zhu et al., 2011; Stevens et al.,
2010). For each metabolite an internal isotope labeled standard was used.
2.6 Statistical and bioinformatic analyses
Linear regression and survival analysis were performed in cooperation with the bioinfor-
matistic group of the institute of functional genomics (University of Regensburg). Linear
regression of stimulation combinations was performed by Thorsten Rehberg. Kaplan-Meyer
curves of GOT2 and comparisons were calculated by Paula Perez-Rubio. Comparative statis-
tics of qRT and cell number data was performed by me.
Linear regression analysis
Linear regression analysis on RNASeq and metabolome data were performed in R with
the ’glmnet’ package using Lasso regression (Friedman et al., 2010). The Lasso parameter
lambda was selected such that it minimizes the cross-validation error. Linear regression
analysis on cell cycle regulator gene expression values from RT-PCR measurements and
percentage of S-phase were performed within the statistical framework R using the ’lm’
function of the ’stats’ package. Coefficients of the main effects and the interaction term of





R-CHOP treated DLBCL patient from Lenz et al. were classified according to their GOT2
gene expression (Lenz et al., 2008). Only patients with ABC and GCB classification were
included. Patients with a GOT2 expression higher than the median expression of the group
were defined as GOT2high whereas patients with an expression level lower than the me-
dian were classified as GOT2low. For both groups Kaplan-Mayer curves were calculated
and survival curves of groups were compared using the ’survdiff’ and ’coxph’ function in
R.
Comparative statistics
Data are shown as mean ± SD. Statistical analysis of cell numbers and qRT data was
performed using Graphpad Prism 6. For all samples, standard normal distributions were as-
sumed and equal variances distributions were tested using Brown-Forsythe test. For multiple
comparisons of more than two groups One-way or Two-way ANOVA was used as depicted
in figure legends using Bonferroni’s post-hoc test for pair-wise group comparisons. P-values




The aim of the study was to identify if and how factors of the GC and more importantly their
combinations affect global gene expression in B cells with low levels of the proto-oncogene
c-Myc. Furthermore the investigation of these stimuli induced gene expression changes on
metabolism and proliferation in comparison to MYC overexpressing cells was aimed.
Therefore, a B cell model with conditionalMYC expression was stimulated with different GC
derived stimuli and random combination of those. Transcriptome, metabolome and prolifer-
ation data of these stimulations were analyzed by linear regression analysis to reveal effects
of single stimuli and their combinations on these parameters. To enable the comparison of
Myc and stimuli induced gene expression, a normalization on total cell numbers per sample
by adding an external spike-in was performed.
From these data, the combination of IL10 and CpG was selected and further analyzed in
detail. Proliferation and metabolism of Myc depleted cells after IL10+CpG stimulation was
compared to MYC overexpressing cells. The involvement of Myc, JAK/STAT and NF-κB
signalling on IL10+CpG stimulation induced gene expression and proliferation was ana-
lyzed in more detail. Therefore inhibition of selected pathways by specific small molecule
inhibitors and siRNA mediated knockdown of important pathway components were per-
formed. Influence of these pathways on gene expression were analyzed by qRT PCR and
chromatin immunoprecipitation.
Finally, similarities and differences of Myc and IL10+CpG stimulation on glutamine metabolism
were investigated. Thereby, metabolome as well as glutamine tracing analysis was performed.
Dependency of proliferation on different glutamine derived metabolites was revealed by in-
hibitor treatment, knockdown of metabolic enzymes and metabolic rescue experiments.
The last part, focuses on the validation of the found metabolic dependencies in lymphoma cell
lines with aberrant signaling pathway activation and previously published patient data.
3.1 A resting B cell model by Myc withdrawal in P493-6 cells
To compare effects of different signaling pathway and Myc activation in B cells a suitable
model cell line is needed. This cell line should show no other variables than the pathway
activation and MYC expression. For example, stimulated primary B cells cannot easily be
compared with a Myc transformed cancer cell line as the latter will have additional genetic
alterations. Same genetic differences are also expected when comparing different cancer cell
lines. As Myc was described to amplify all genes with open chromatin, the genetic and epige-
netic background of a sample greatly influences the targets that are activated by Myc and this
might also be true for other signaling pathways (Lin et al., 2012; Nie et al., 2012). To ensure
that only pathway dependent changes are observed, a model cell line was needed in which
all perturbations were performed on the same genetic background.
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3.1.1 Simulating resting B cells by Myc withdrawal in P493-6
The human P493-6 B cell line fulfilled the criteria mentioned above. This B cell line carries a
tetracycline repressible MYC expression plasmid (Polack et al., 1996). As published before,
treating these cells with doxycycline rapidly decreased Myc protein within four to eight hours
(Figure 5A) (Polack et al., 1996). While untreated P493-6 cells were highly proliferative,
addition of doxycycline greatly decreased the number of cells in S-phase 24 h after treatment
accompanied by an arrest of the cells in the G0/G1 cell cycle phase (Figure 5B). Additional
to the cell cycle effects, a loss of cell size can be observed within this time frame (Figure 5C).
Therefore, the already published data for P493-6 cells (Schuhmacher et al., 1999), (Pajic
et al., 2000) could be reproduced and this cell line was chosen as a model for resting (Myclow)
and transformed (Mychigh) B cells on the same genetic background for most experiments in
this study.
Figure 5: Validation of conditional MYC expression, proliferation and growth in P493-6 cells.
Previously published experiments were repeated to evaluate P493-6 cells as a suitable model system for
further studies (Pajic et al., 2000; Schuhmacher et al., 1999). (A) Immunoblot analysis of Myc protein levels
in untreated and doxycycline treated P493-6 cells over time. Removel of doxycycline by multiple washing
steps (wash) restored high Myc level. Tubulin and ponceau staining indicate equal loading of samples.
(B) Cell cycle analysis of P493-6 Mychigh and Myclow cells 24 h after doxycycline treatment. Cell cycle
phases were separated by BrdU and PI staining using flow cytometry. Means and SD of three independent
replicates are shown. (C) Cell size of Mychigh and Myclow cells 24 h after doxycycline treatment. Shown are
mean forward scatter (FSC) and SD from samples in B.
3.1.2 Factors of the B cell microenvironment activate P493-6 Myclow cells
Previous experiments in our lab have shown that stimulation of a B cell line with single mi-
croenvironmental factors can predict aberrantly activated signaling pathways in lymphoma
and can be used to stratefy lymphoma patients(Schrader et al., 2012a). However, the used
BL-2 cell line already overexpressed Myc and therefore was unable to model activated B cells
or lymphoma cells without Myc aberrations. In addition, P493-6 cells with conditional MYC
41
Results
Figure 6: P493-6 Myclow cells respond to stimulation with single B cell activating factors.
Myclow cells were stimulated with full concentrations of α-IgM, recombinant CD40L, CpG, recombinant IGF-
1 and recombinant IL10 as described in section 2.2.3.(A) Immunoblot analysis of stimulated Myclow and un-
stimulated Mychigh cells. Activation of STAT3, p38, Erk and Akt pathways was detected by phosphorylation
specific antibodies 1 h after stimulation. NF-κB activation was accessed by degradation of IκBα. Tubulin
and ponceau staining indicate equal loading of protein per sample. (B) Number of cells in S-phase 24 h after
stimulation measured by BrdU incorporation and flow cytometry. (C) Cell sizes of stimulated cells shown
as mean FSCs from samples described in (B). All experiments were performed in three independent repli-
cates. Mean±SD and one-way ANOVA results (Bonferroni’s posttest) are shown in B and C (?? p<0.01,
??? p<0.001).
expression were frequently used as a model for resting and Myc transformed B cells before
(Polack et al., 1996; Pajic et al., 2000). To analyze the effect of microenvironmantal factors
in Myc depleted cells, P493-6 Myclow cells were used in this study. Cells treated with α-IgM
for B cell receptor (BCR) activation, recombinant CD40 ligand (CD40L), the toll like re-
ceptor (TLR9) ligand CpG, insulin like growth factor 1 (IGF-1) and interleukin 10 (IL10)
and pathway activation was monitored by immunoblot. Activation of different pathways by
the stimuli was observed in Myclow cells by visualizing corresponding protein phosphoryla-
tion (Figure 6A). Crosslinking of the BCR by α-IgM resulted in a strong activation of the
Erk MAPK and PI3K/Akt pathway. Stimulation with CD40L and IGF-1 showed moderate
activating effects on the p38 MAPK and Akt. Furthermore, activation of the NF-κB path-
way after CpG stimulation was observed by degradation of IκBα, whereas IL10 treatment
strongly activated STAT3 signaling, specifically. To analyze the functional impact of these
pathway activations on resting P493-6 Myclow cells, cell cycle distribution and cell growth
was analyzed 24 h after stimulation by BrdU staining and flow cytometry. Interestingly,
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stimulation with either CpG or IL10 significantly increased the number of cells in S-phase
while the other factors only mildly affected S-phase entry (Figure 6B). This increase was
accompanied by a significant increase in cell size in CpG treated cells as revealed by an
increased forward scatter. Only a tendency towards greater cell size was observed after
the other stimulations (Figure 6C). These experiments show that P493-6 Myclow cells are
reactive towards B cell activating factors and that some of the stimuli can activate these
resting cells in terms of inducing cell cycle entry and cell growth. It was therefore concluded
that stimulated P493-6 cells are a useful model for to study different pathways activation by
stimuli in B cells.
3.2 Development of a cell spike-in to reveal global gene expression
changes
Myc was described to dramatically increase total RNA levels in the cell accompanied by
an increase in cell size (Lin et al., 2012; Nie et al., 2012). Comparing MYC overexpressing
with other cells on transcriptomic levels is therefore challenging as total RNA levels can
greatly differ between these groups. These differences were shown to hamper gene expres-
sion analysis in a way that can only be solved by normalizing gene expression to a constant
number of cells (Lovén et al., 2012). As shown in Figure 6 not only Myc but also stimulation
can affect the cell size, suggesting that also total RNA levels are affected by the different
stimulations. Therefore, normalization on total cell numbers was performed in all stimula-
tion experiments. This normalization can be done by using a stable external normalization
control called spike-in like synthetic nucleotides developed by the External RNA Controls
Consortium (ERCC)(consortium, 2005). However, commercial available spike-in kits are ex-
pensive, limiting their use in daily lab routine for example in qRT experiments. Therefore, a
new spike-in method was developed, which is affordable, easy to use and should be applicable
for normalization of RNASeq as well as quantitative reverse transcriptase PCR (qRT PCR)
data throughout the whole study.
3.2.1 Drosophila melanogaster is a suitable spike-in organism
Sun et al. (2012) first described whole cell spike-ins in the context of dynamic gene expression
analysis. They added a fixed number of 4-thiouridin-labeled whole cells of a different yeast
strain to the sample yeast cells and hybridized this mixture to a custom microarray. While
this method reliably controls for all technical variations and global gene expression changes
in microarray analysis of yeast strains, it is not applicable for RNASeq of human samples.
Therefore, an improvement of this methods was aimed in this study in which the addition of
whole spike-in cells of a foreign organism to a constant number of human cells controls for
technical and biological variations. To reliable normalize human gene expression to genes of
a foreign organism both genomes must be as different as possible to minimize the number
of genes that would be fitted to both organisms in RNASeq analysis. In contrast, cells
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should have equal lysis properties to reliably control for technical variances during cell lysis,
excluding bacteria or fungi cells as suitable spike-in cells. For animal cells that fulfill these
criteria, cell lines should be available and the genome must be completely annotated, like
for example mouse or drosophila melanogaster. While human and mouse genomes show a
broad overlap of conserved gene sequences, drosophila genes should be evolutionally distant
enough to distinguish most of the genes.
In cooperation with the biostatistical group from Regensburg an in situ experiment was
performed to evaluate the overlap of between human and drosophila genes. Hence RNASeq
libraries from drosophila S2 cell line (accession numbers SRR569914 and SRR424185) and
human P493-6 cell line (accession numbers SRR567561 and SRR567562) from the SRA
database were compared. Using bioinformatical tools, reads from one organism were aligned
to the genome of the organism itself or a concatenated genome consisting of all drosophila
and human genes. Mapping human or drosophila gene counts to the concatenated genome
showed that the drosophila spike-in did not significantly alter the number of genes that are
uniquely identified as human genes and vice versa.
In summary, drosophila cells might be a suitable spike-in organism, as equal lysis properties
are expected and gene sequences are distant enough from human to be reliably distinguished
in RNASeq analysis.
3.2.2 Drosophila spike-in reliably detects global gene expression changes
Next, an in vitro experiment was designed to proof the capacity of drosophila spike-in cells
to reveal global gene expression changes. Different total amounts of RNA per cell were sim-
ulated by using increasing amounts of human P493-6 B cells as follows. Fixed numbers of
P493-6 cells (0.5·106 cells, 1·106 cells and 2·106 cells) were spiked each with an equal amount
of drosophila cells. For this, aliquots of 1·106 frozen drosophila cells (from one freezing stock)
were thawed and 100µl (= 100 000 cells) were directly added to each sample (see scheme in
Figure 7A). Cells were equally harvested, lysed and total RNA was extracted in equal vol-
umes. After extraction an equal amount of commercial ERCC nucleotide spike-in was added
as gold standard. This experimental setup resulted in an increased total RNA content be-
tween the different conditions (Figure 7B) and also enabled precise fold changes predictions
between the groups (Figure 7C). The experiment was designed to predict a fold change of
two between groups B and A as well as C and B (log2 fold change = 1), while between
sample C and A a fold change of four (log2 fold change = 2) was predicted.
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Figure 7: Experimental design of drosophila spike-in experiment.
(A) Scheme of dilution experiment. 100 000 drosophila cells were directly added to sample tubes containing
0.5 ·106, 1 ·106 and 2 ·106 cells. Cells were centrifuged together, washed and lysed. RNA was isolated in equal
amounts of water and ERCC spike-in mix was added to total RNA solution. Samples were then sequenced
or analyzed by qRT PCR. (B) Total RNA concentration of samples described in A after elution. (C) Scheme
of sample composition and predicted fold changes of the experiment in A.
Isolated RNA of all samples were sequenced and gene expression was normalized on cell
number by factors calculated from drosophila gene count or ERCC spike-in. As reference,
gene expression was normalized without spike-in assuming a constant RNA amount between
all samples. Both cell count based normalization models correctly revealed fold changes of
total RNA leading to a distance of log2 fold change to the expected fold chage about zero
(Figure 8A). However, drosophila spike-in even outperformed ERCC spike-in with a median
directly at zero. In contrast, calibration assuming a constant RNA amount failed to predict
any fold changes leading to a difference between one and two. In addition to prediction of
global fold changes, normalization on drosophila spike-in revealed true fold changes on single
gene expression levels as shown for the gene ABL (Figure 8B). These fold changes were not
only observed in RNASeq data, but could be confirmed in qRT PCR on the same samples as
well (Figure 8C). For this a primerset against the drosophila actin gene (ACT42A) was de-
signed, which showed high enough expression levels to be precisely detected in the added 100
000 drosophila cells. Calculation of ∆Ct between the human ABL and drosophila ACT42A
revealed two fold changes between the groups B and A and C and B (log2 fold change = 1).
A fold change about four (log2 fold change =2) was observed between C and A. Importantly,




Figure 8: Gene expression normalization on drosophila spike-in reveals true fold changes in
dilution experiment.
(A) Distance of RNASeq log2 fold changes relative to predicted log2 fold changes of samples described in
Figure 7. Fold changes between samples were normalized either to drosophila cell spike-in, ERCC mix or con-
stant RNA amount (without spike-in). Correct fold changes scatter around zero (dashed line). (B) RNASeq
log2 fold change of ABL expression of samples in A calculated with or without drosophila spike-in nor-
malization. Means±SD are shown. (C) qRT analysis of ABL gene expression from same RNA samples as
used for A and B. Fold changes were calculated relative to drosophila ACT42 (spike-in) or human GAPDH
(housekeeper). Shown are mean expression values ±SD of three replicates. Dashed lines represent predicated
fold changes.
Therefore it was concluded that normalization on drosophila spike-in cells is able to expose
global gene expression amplification in RNASeq as well as qRT PCR data.
3.2.3 Proof of principle: Spike-in cells reveal Myc induced global amplification
Next, the already published differences in total RNA levels between P493-6 Mychigh and
Myclow cells were used to proof the capacity of drosophila cells to reveal global gene ex-
pression amplification. Thus, a constant number of Mychigh and Myclow cells were spiked
with drosophila cells, harvested and RNA was isolated. Measurement of total RNA proofed
that Mychigh cells contained two times more total RNA per cell as Myclow cells consistent
with the previously published data (Figure 9A). Gene expression of both samples was then
analyzed by RNASeq and qRT PCR. The published amplification of gene expression was
not detected in RNASeq data when both samples were normalized on equal RNA amounts
(Figure 9B). However, when genes were normalized on drosophila gene expression a global
shift of human gene expression about two to four times was observed in Mychigh compared to
Myclow cells(log2 fold change between one and two). As shown in the dilution experiment de-
scribed before, this amplification could be confirmed on single gene expression level by qRT
PCR (Figure 9C). While normalization to the human GAPDH housekeeper predicted equal
up and down regulation in the selected gene set (IL10R, SOCS1, ID3, CDKN1A, PARP,
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Figure 9: Normalization on drosophila spike-in reveals global gene up-regulation in
Mychigh cells.
(A) Total RNA concentrations of one million Myclow and Mychigh cells (n=10). (B) Log2 fold changes
of RNASeq data between Mychigh and Myclow cells. Data was normalized either on drosophila gene counts
(spike-in) or left without spike-in calibration (endogenous) (n=10). (C) qRT analysis of a panel of differential
regulated genes. Gene expression changes between Mychigh and Myclow cells were either normalized to hu-
man GAPDH (housekeeper) or drosophila ACT42A (spike-in). Mean expressions ±SD of three independent
replicates are shown.
CDK4, LDHA, MYC ), normalization to drosophila genes shifted expression of these genes
upwards. Thereby, only expression of IL10R and SOCS1 were repressed by Myc upregula-
tion, while other genes were variably up regulated. Therefore, the global RNA amplification
due to Myc and its impact on gene expression normalization could be also confirmed in
qRT PCR data. As drosophila cells are a reliable tool to detect global gene expression
amplification in B cells, this spike-in method was used in all following gene expression anal-




3.3 Analysis of combinatorial stimulation effects in Myclow cells
Physiological activation of B cells is not mediated by a single factor, but by a mixture of
different stimuli and pathway activations (Galibert et al., 1996; Rousset et al., 1992). To
achieve highest variability in signaling pathway activation, Myclow and Mychigh cells were each
stimulated with 40 different combinations of α-IgM, CD40L, IGF-1, CpG and IL10, each
in two different concentrations (see Table 19, p. 28). Due to the high number of samples
experiments were performed in 10 batches each consisting of an unstimulated Myclow and
Mychigh sample, one single simulations and three combinatorial stimulations per Myc status
leading to 100 samples in total. Thereby, stimulations were distributed randomly to min-
imize batch effects. From all stimulations, samples were taken for RNASeq, intracellular
metabolome analysis and BrdU staining 24 h after stimulation. In cooperation with the
Biostatistical Institute of the University of Regensburg, effects of one single stimulus or the
combination of two stimuli on gene expression, metabolism and proliferation of Myclow cells
were calculated by linear regression. Notably, higher combinations of stimuli (for example
combination of three stimuli) were not considered as they would have led to overfitting of
the data. Stimulations of Mychigh were needed to increase the statistical power and minimize
cross validation errors. MYC expression levels were considered as independent factors and ef-
fects of stimuli on Myclow cells were predicted by setting the Myc coefficient and Myc/stimuli
interaction terms to zero in the linear regression model. Therefore, only effects of the stim-
uli on Myclow cells on global gene expression, metabolism and proliferation are presented
below.
3.3.1 Stimuli combinations induce cooperative changes in global gene expression and
metabolome in Myclow cells
Linear regression analyis of the spike-in normalized RNASeq data of the stimulated P493-6
cells revealed that all stimuli used in this study increased the expression of the majority of
genes, while nearly no genes were downregulated (Figure 10A). Values of gene expression up-
regulation greatly differed between single stimuli. While IGF-1 and CD40L mildly increased
global gene expression, α-IgM, CpG and IL10 stimulted cells showed an even increased ex-
pression of the same genes. Investigating stimuli combinations, strong positive synergistic
effects on global gene expression could be observed after CD40L+IGF-1 and IL10+CpG
stimulation. In this cases the combinations of stimuli resulted in a stronger increase in gene
expression than the simple addition of the single stimulation effects. As IGF-1 and CD40L
showed only minor effects on gene expression in single stimulations, their combination just
increased gene expression to a level comparable to α-IgM or CpG alone. In contrast, IL10
and CpG already showed strong positive effects on gene expression leading in combination to
the highest changes in expression levels of all calculated stimuli combinations. In contrast to
these two combinations, the majority of stimuli combinations showed additive or synergistic
negative effects on gene expression. In the last case, a lesser increase in gene expression than
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Figure 10: Linear regression analysis reveals cooperative effects of stimuli on global gene
expression and metabolite abundancy.
(A) Heatmap of regression coefficients of single stimuli and the interaction terms of two stimuli on gene
expression in Myclow cells. Myclow and Mychigh cells were stimulated with α-IgM, CD40L, IGF-1, CpG and
IL10 according to Table 19 (p. 28), RNASeq was performed and data was normalized on drosophila cell spike-
in. Coefficients and interaction terms of stimuli and Myc were calculated by linear regression analysis and
coefficients of Myc and Myc interactions terms were set to zero. Red color indicates increased gene expression
for single stimulations. For combinations of stimuli the following color code is used: blue = synergistic
negative effects, white = additive effects, red = synergistic positive effects. (B) Heatmap of regression
coefficients of intracellular metabolite abundancy (pmol/1· 106 cells) measured by mass spectrometry of
samples in A. Analysis was performed analog to A. Same color code is used. Scaled regression coefficients
of A and B are provided as digital data (Supplemental Table 1+2, Appendix, p. 119).
the theoretical addition of the single stimuli was observed. This negative interactions on
gene expression are a hint for negative influences between the different signaling pathways
or a saturation of a common used pathway.
Interestingly, a comparable pattern of effects could be observed in changes of intracellu-
lar metabolite abundancy measured by mass spectrometry (Figure 10B). Strongest changes
were mediated by CpG stimulation alone, followed by IL10 and α-IgM. Again, CpG and
IL10 combination showed largest changes in intracellular metabolite abundancy based on a
positive synergistic effect.
In summary, a quantitative but not qualitative difference induced by the different stimuli
was observed on global gene expression. This quantitative response was further modified
by costimulation with a second stimulus, mostly resulting in additive or less than additive
effects. Importantly, IL10 and CpG combination showed clear synergistic effects on gene
expression as well as metabolite abundancy leading to the strongest overall changes in gene
expression and metabolites observed in this study.
49
Results
3.3.2 Stimulation induced cell cycle entry correlates with metabolic changes
Due to the qualitative equal patterns of global gene expression and metabolism changes
and the increase in S-phase shown for single stimuli (Figure 6), a strong correlation of both
factors to cell proliferation was considered. To test if metabolic changes correlated with
cell cycle changes in Myclow cells, supernatant metabolite turnover and intracellular metabo-
lite abundancy were plotted against the number of cells in S-phase 24 h after stimulation.
Combination of stimuli resulted in a variety of S-phase values and as expected, most of the
measured metabolites correlated with these (data provided at the ). Most of all, glutamine
and glucose uptake and lactate secretion fitted the number of cells that entered S-phase
(Figure 11).
Thereby, an increase of replication and metabolism comparable to unstimulated Mychigh cells
was achieved by a definded set of stimuli combinations. This positive correlation was also
reflected in the abundancy of TCA intermediates represented by intracellular citrate levels
(Figure 12A). In contrast, a negative correlation between intracellular aspartate levels and
cell cycle entry was observed (Figure 12B). Interestingly, while nearly all measured metabo-
lites correlated with the number of cells in S-phase, alanine levels were only increased in
Mychigh cells but not in any of the stimulations in Myclow cells (Figure 12C). This difference
indicates specific metabolic reprogramming in Mychigh cells.
Figure 11: Extracellular turnover of metabolites correlates with cellular replication.
Correlation of daily metabolite turnover from cell culture media and corresponding number of cells in S-phase
of unstimulated Myclow , Mychigh and stimulated Myclow cells 24 h after stimulation. Shown are consump-
tion of glucose (A), glutamine (B) and secreation of lactate (C) from ten replicates of Myclow (dark blue),
nine replicates of Mychigh (red) and 40 different stimulations of Myclow cells (light blue) according to Ta-
ble 19 (p. 28). Pearson correlation coefficients (r-values) are shown in the lower right. Further S-phase and
metabolotite measurements are provided as digital data (Supplemental Table 3, Appendix, p. 119).
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Figure 12: Intracellular metabolites differentially correlate to cellular replication rates.
Correlation of intracellular metabolites and corresponding number of cells in S-phase of unstimulated Myclow ,
Mychigh and stimulated Myclow cells 24 h after stimulation. Shown are intracellular levels of citrate (A),
aspartate (B) and alanine (C) from ten replicates of Myclow (dark blue), nine replicates Mychigh (red) and
40 different stimulations of Myclow cells (light blue) according to Table 19 (p. 28). Pearson correlation
coefficients (r-values) are shown in the lower right. Further S-phase and metabolotite measurements are
provided as digital data (Supplemental Table 3, Appendix, p. 119).
3.3.3 S-phase entry of Myclow cells is mainly driven by combined IL10 and CpG
stimulation
As descibed above, IL10+CpG stimulation synergistically increases metabolite abundancy
and global gene expression in Myclow cells (Figure 10). To reveal the effect of stimuli com-
bination on proliferation in Myclow cells linear regression analysis of BrdU incorporation,
representing the number of cells in S-phase, was performed. Thereby, the regression analysis
was able to predict BrdU incorporation after single stimulation comparable to the values
observed above (Figure 6B). Additionally, linear regression analysis predicted a strong in-
crease in BrdU incorporation for IL10+CpG and CpG+a-IgM stimulation (Figure 13). In
contrast, a less than additive S-phase entry was predicted for most of the other stimulation
combinations and total incorporation was not further increased than only CpG stimulation
alone.
As described in the introduction a synergistic effect of CpG+BCR was analyzed in B cells
before (Bernasconi et al., 2003). In contrast, no synergy of IL10 and CpG on gene expression,
metabolism or proliferation was described so far. Therefore, stimulations of Myclow cells with
IL10+CpG were chosen for further detailed analysis in this thesis work.
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Figure 13: IL10+CpG stimulation synergistically induce S-phase entry in Myclow cells.
Linear regression analysis of BrdU incorporation 24 h after stimulation of P493-6 according to Table 19 (p.
28). Regression coefficients for single stimuli and combinations were calculated as described before. Intersect
of regression is shown as Myclow ctrl line. Single stimuli are shown by their coefficients, combinations by the
addition of the coefficients of the two single stimuli plus their interaction term. Expected additive effects of
two stimuli are shown as dashed line. Observed effects under the line represent negative synergistic effects,
above positive synergism. Absolute linear regression coefficients are shown in Table 30 (Appendix, p. 117)
3.4 Comparison of IL10+CpG and Myc induced gene expression
So far predictions of the stimuli on gene expression were performed by linear regression anal-
ysis and thus limited for functional analysis. To get further insight in the synergistic effect of
IL10+CpG stimulation and to compare its gene expression to Myc induced gene expression
changes, RNASeq of untreated Myclow , IL10, CpG and IL10+CpG stimulated Myclow and
Mychigh cells was performed in triplicates and fold changes relative to Myclow cells were com-
pared. Figure 14 shows log2 fold changes (log2FC) of the top 200 differentially regulated
genes in IL10+CpG stimulated Myclow cells.
As predicted by the linear regression analysis (Figure 10A), single IL10, CpG and IL10+CpG
stimulation increased the expression of the same set of genes. Furthermore, a stronger up-
regulation of these genes was observed in IL10+CpG stimulated cells, which was mostly
qualitative and qualtative comparable to Myc overexpression. However, a small set of genes
was only increased after IL10+CpG stimulation, while some genes were even stronger up-
regulated in Mychigh cells.
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Figure 14: Comparison of IL10, CpG, IL10+CpG stimulation and Myc induced gene expres-
sion.
Heatmap of gene expression changes of three replicates of IL10 and CpG single and double stimulated
Myclow and Mychigh cells 24 h after stimulation. Gene expression was normalized on drosophila spike-in and
differential expressed genes relative to unstimulated Myclow cells were calculated for each sample. The top
200 differential regulated genes of IL10+CpG stimulated cells are shown. Heatmap color code of log2 fold
changes is shown in the upper right. Original Log2FC data are provided digitally (Supplemental Table 4 ,
Appendix, p. 119)
To define which genes were differently expressed between IL10+CpG stimulted Myclow and
Mychigh cells, a more detailed comparison of IL10+CpG and Myc induced genes was per-
formed. For this the top 2000 upregulated genes in IL10+CpG stimulated Myclow and
Mychigh cells were calculated(log2FC>1, ranked by p-value). Overlap of the these gene sets
is shown in Figure 15A. Out of the top 2000 genes of each stimulation there is an overlap
of 1376 that are upregulated in each scenario. Gene set enrichment analysis of this overlap
showed, that both, IL10+CpG stimulation and MYC overexpression, highly induced the
expression of cell cycle and various metabolism associated genes (Figure 15B and Table 29,




About 600 genes were only found within the top 2000 of either IL10+CpG stimulated
Myclow or Mychigh cells (Figure 15A). Gene set enrichment analysis of theses genes showed,
that the genes induced by IL10+CpG stimulation mainly included JAK/STAT and TLR
signaling associated genes (Figure 15C and Table 27, Appendix p. 114), reflecting the ex-
tracellular pathway activation by IL10+CpG stimulation that was missing in Myc overex-
pressing cells. On the other hand, Mychigh cells showed greater induction of ribosomal and
metabolic genes including alanine metabolism (Figure 15D and Table 28, Appendix p. 114).
However, it has to be mentioned that in both cases nearly 10 000 genes were differently to
unstimulated Myclow cells expressed. Therefore some of these genes upregulated under one
condition might also be upregulated in the other condition, but to a much lesser extent.
In summary, the by linear regression analysis predicted synergistic effect of IL10+CpG stim-
ulation on gene expression was confirmed. Furthermore, gene expression changes affecting
cell cycle and most metabolic genes were mostly qualitative and quantitative comparable
to Myc induced gene expression. Nevertheless, some stimulation and Myc specific changes
seem to exist which also may affect metabolism in Mychigh cells. Therefore, in a step by step
approach similarities and differences in cell proliferation and metabolism of both Mychigh and
IL10+CpG stimulated Myclow cells were analyzed.
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Figure 15: Comparison and functional annotation of IL10+CpG stimulation and Myc induced
gene expression.
(A) Venn diagram of top 2000 differential expressed genes (log2FC>1, p-value ranked) of IL10+CpG stim-
ulated Myclow and Mychigh cells compared to Myclow cells. (B-D) KEGG pathway enrichment of genes
grouped in A calculated by DAVID online annotation tool (Huang et al., 2009). Gene set enrichment of
the overlap in A is shown in Figure B. Pathways of only IL10+CpG stimulation induced genes are shown
in C, only Myc induced genes in D. Pathways with adjusted p-values smaller than 0.05 were assumed to be
significant enriched of the differential expressed genes. List of genes included in each gene set is shown in
Table 29 to Table 28 in the Appendix (p. 115). Log2FC of the genes are provided digitally as Supplemental
Table 4 (Appendix, p. 119.)
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3.5 Investigation of IL10R and TLR9 activation in B cell proliferation
The previous results suggest a synergy of IL10 and CpG stimulation on proliferation. This
assumption was based on the linear regression analysis of cells entering S-phase after stim-
uli combination and an increase of cell cycle associated genes after combined IL10+CpG
stimulation (Figure 13 and Figure 15). To get further inside into the synergy of IL10+CpG
stimulation on proliferation, cell cycle phases and cell doubling after stimulation were ana-
lyzed in detail.
3.5.1 Combined IL10 and CpG stimulation induces cell doubling in Myclow cells
To confirm the synergistic effect of IL10+CpG stimulation on S-phase entry, Myclow cells were
treated with single IL10 or CpG or the combination of both for 24 h and BrdU incorporation
was compared to Mychigh cells. As predicted an additional increase in BrdU incorporation
was observed after IL10+CpG stimulation which was comparable to MYC overexpression
(Figure 16A). However, the number of cells undergoing active DNA synthesis does not neces-
sarily reflect cell proliferation as cells also must be able to divide and constantly enter a new
round of cell cycle to effectively double cell numbers over time. Therefore, cells were stimu-
lated every 24 h and proliferation of cells was accessed by daily cell counting (Figure 16B).
Interestingly, only IL10+CpG but not IL10 or CpG stimulated cells were able to exponen-
tially increase the number of cells over three days. Furthermore, a comparable proliferation
of IL10+CpG stimulated Myclow to Mychigh cells was observed.
Figure 16: IL10+CpG stimulation induces proliferation in Myclow cells comparable to MYC
overexpression.
(A) BrdU incorporation of IL10, CpG and IL10+CpG stimulated Myclow and Mychigh cells 24 h after stimuli
treatment. Results of three independent experiments are shown. Error bars represent standard variations.
One-way ANOVA results (Bonferroni’s posttest) are shown. (B) Numbers of cells counted via hemocytometer
over three days. Myclow cells were stimulated with IL10, CpG or both every 24 h. Number of unstimulated
Mychigh cells were analyzed in parallel. Means ± SD of three independent experiments are shown. Two-way
ANOVA was calculated (Bonferroni’s posttest)(? p<0.05,?? p<0.01, ??? p<0.001).
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3.5.2 IL10+CpG stimulation induces G1/S-phase entry in Myclow cells
To analyze why only IL10+CpG but no single stimulated cells doubled cell number over
time, further cell cycle analysis using BrdU pulse chase was performed. By quick pulsing
with BrdU and sequential cell cycle analysis by flow cytometry, a small fraction of cells can be
followed during its passage throughout the cell cycle (gating example shown in Figure 17A).
This setting allows the detailed analysis of single cell cycle stages of a selected set of cells.
In unstimulated Myclow and IL10 treated cells only a small fraction of cells was labeled with
BrdU (compare with Figure 16A). Therefore, the fate of these cells was difficult to follow
over time. In contrast, CpG and IL10+CpG stimulated cells incorporated high amounts of
BrdU (Figure 16A) and entered G2/M phase synchronously 8h after labeling (Figure 17B).
However, after 24 h unstimulated and single stimulated Myclow cells were arrested in the
G0/G1 phase again. Importantly, in IL10+CpG stimulated Myclow cells a fraction of pre-
viously BrdU labeled cells entered S-phase again after 24h (Figure 17C). Therefore, a high
number of cells enter a first round of cell cycle in IL10+CpG stimulated Myclow cells and
in contrast to single stimulated cells these cells are also able to undergo a second round of
cell cycle. Thereby, IL10+CpG stimulation but not the single stimulations is able to induce
exponential proliferation in Myclow cells.
Figure 17: IL10+CpG stimulation increases S-phase entry compared to single stimulations in
Myclow cells.
(A) Gating scheme of BrdU pulse chase experiment. Myclow cells were stimulated with IL10, CpG and
IL10+CpG for 12 h to induce S-phase entry and pulsed with BrdU for 20min. Afterwards samples were
harvested every two 2 h and cell cycle distribution of BrdU labeled cells was analyzed by propidium iodide
(PI) staining. (B) Cell cycle distribution of BrdU labeled cells 8 h after labeling. (C) Cell cycle distribution
of labeled cells 24 h after labeling. Representative experiment out of two is shown. Further analysis time
points are shown in Table 31 (Appendix, p. 117).
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3.5.3 Synergistic upregulation of G1/S cell cycle regulators in IL10+CpG stimulated
cells
To analyze which cell cycle regulators are differently regulated in single and double treated
Myclow cells, the expression of differentially expressed cell cycle genes from the previously
shown RNASeq data (Figure 14) was compared. Gene clustering revealed that some genes
were already upregulated by CpG alone and not further increased by IL10+CpG stimula-
Figure 18: IL10+CpG stimulation synergistically increases G1/S regulator gene expression.
(A) Heatmap of log2 gene expression changes of IL10, CpG, IL10+CpG stimulated Myclow and Mychigh cells
relative to unstimulated Myclow . Genes annotated as cell cycle regulators calculated in gene set enrichment
from the overlap in Figure 15 are shown. Log2FC values of the genes are provided digitally in Supple-
mental Table 4 (Appendix, p. 119). (B-D) Relative expression of a selected set of G1/S cell cycle regula-
tors measured by qRT PCR 24h after stimulation of Myclow cells. Expression of CDK4, CDK6, CCND2,
CCND3, CDKN1A(p21) and CDKN1B(p27) was calculated relative to drosophila ACT42A and unstimu-
lated Myclow cells. Mean± SD of three independent experiments are shown. Significant changes relative to




tion or MYC overexpression. These included the S-phase transition regulator cyclin A2
(CCNA2 ) and the mitotic regulators like cyclin B (CCNB1/2 ), BUB1 (BUB1, BUB1B) or
CDC20 (Figure 18A). Instead, G1/S regulators were stronger activated in IL10+CpG stim-
ulated Myclow and Mychigh cells than after single stimulations including CDK4, CDK6 and
CCND2, which was validated by qRT PCR (Figure 18B-D).
Using a qRT PCR expression based linear regression analysis, significant effects of the inter-
action of IL10 and CpG were calculated to analyze if the additional effect of both stimuli was
only additive or synergistic (Table 32, Appendix p. 117). The interaction term for CDK4/6
expression by IL10 and CpG stimulation was significant in this analysis, including main
effects for IL10 and CpG besides the interaction term (CDK4, p=0.003; CDK6, p=0.026)
suggesting a synergistic effect of the two stimuli. By the same means an additive increase
in CCND2 (p=0.09) and synergistic activation of CCND3 (p=0.015) was observed. How-
ever, no significant change in CDKN1A (p21) or CDKN1B (p27) expression was revealed.
Therefore, it is reasonable to suggest that IL10+CpG stimulation enables Myclow cells to
increase gene expression of positive cell cycle regulators, including CDK4, to overcome the
G1 restriction point and to enter a new cell cycle.
To further validate the importance of G1/S cell cycle regulators in IL10+CpG stimulation
mediated proliferation, an inhibitor against CDK4 and CDK6 complexes, called PD0332991,
was used. Myclow cells were simultaneously stimulated with IL10, CpG or IL10+CpG as
well as the inhibitor and cell number was determined after 48 h. The CDK4/6 inhibitor
completely blocked cell doubling of CpG, IL10+CpG stimulated Myclow and Mychigh cells,
while the slight increase in cell number after IL10 stimulation was not affected by this
Figure 19: IL10+CpG stimulation and Myc mediated proliferation is dependent on CDK4/6
activity.
Relative cell number of stimulated Myclow and Mychigh cells after CDK4/6 inhibition by 0.5µM PD0332991.
Cells were treated with inhibitor or DMSO 3h prior to IL10, CpG and IL10+CpG stimulation. Cell number
was accessed 48 h after stimulation. Experiment was performed in triplicates and cell numbers±SD relative
to unstimulated DMSO treated Myclow cells are shown. Significant differences were calculated by one-way
ANOVA (Bonferroni’s posttest)(? p<0.05,?? p<0.01, ??? p<0.001).
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inhibitor (Figure 19). It was concluded, that CDK4 and CDK6 complexes play an important
role in IL10+CpG stimulation and Myc mediated proliferation.
3.5.4 Synergistic effect of IL10+CpG stimulation on proliferation is Myc independent
Myc is a well known regulator of cell cycle genes and CDK4 is a direct target of Myc (Pajic
et al., 2000; Hermeking et al., 2000). Therefore, the involvement of endogenous Myc induc-
tion in IL10+CpG stimulation mediated proliferation was accessed. Immunoblotting 2 h after
IL10+CpG stimulation revealed a more than 2-fold increase of Myc protein levels compared
to unstimulated Myclow cells (Figure 20A). To estimate the effect of this Myc increase on pro-
liferation and CDK4 expression, a transient knockdown of MYC by siRNA was performed
Figure 20: Endogenous Myc induction is dispensable for IL10+CpG stimulation induced pro-
liferation.
(A) Immunoblot of Myclow and Mychigh cells after MYC siRNA transfection. 24 h after transfection cells
were stimulated with IL10+CpG for 2 h. Knockdown efficiency (Myc/tubulin) relative to non-target (scrb)
control cells was calculated using Image J. (B) Relative cell numbers of IL10, CpG and IL10+CpG stim-
ulated Myclow and untreated Mychigh cells 72 h after MYC knockdown and 48 h after stimulation. Stimuli
were added every 24 h. Mean±SD of three independent experiments is shown. (C+D) Relative cell numbers
48 h after Myc inhibition by 60µM 10058-F4 in stimulated Myclow cells (C) and unstimulated Mychigh cells
(D). Mean± SD of three experiments is shown. (E) qRT analysis of relative CDK4 expression 24 h after
10058-F4 treatement of simultanous stimulated Myclow and unstimulated Mychigh cells. Gene expression was
normalized on drosophila ACT42A and DMSO treated unstimulated Myclow cells. One representative out of
three experiments is shown.(? p<0.05,?? p<0.01, ??? p<0.001).
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in Myclow and Mychigh cells. This knockdown reduced Myc levels of IL10+CpG stimulated
cells back to the bases of unstimulated Myclow cells (Figure 20A). The reduced MYC expres-
sion only affected IL10+CpG stimulation induced cell proliferation about 10 to 20% after
48 h and more importantly did not block the synergistic effect of IL10+CpG stimulation
(Figure 20B). However, a reduction of cell proliferation was observed in Mychigh cells at a
knockdown about 40%. These results were confirmed by inhibition of Myc-Max dimerization
by the small molecule inhibitor 10058-F4 (Follis et al., 2008). Incubation with 10058-F4 of
Myclow cells 3 h prior to stimulation, reduced IL10+CpG stimulation mediated cell doubling,
but was not able to block the additional effect of IL10+CpG stimulation on cell doubling com-
pared to CpG stimulation alone (Figure 20C). In contrast, a complete block of Myc induced
proliferation was observed after 10058-F4 treatment (Figure 20D). This proliferation block
was accompanied by a decreased CDK4 expression in Mychigh cells, while the IL10+CpG
stimulation mediated CDK4 expression increase was largely unaffected (Figure 20E).
Considering both, Myc knockdown and inhibition experiments, it can be concluded that Myc
is only partially involved in IL10+CpG stimulation induced proliferation. Therefore it is pro-
posed that the synergistic effect of IL10 and CpG on CDK4 expression and proliferation is
mainly driven by other factors than Myc.
3.5.5 IL10+CpG stimulation induced proliferation is NF-κB and STAT3 dependent
IL10 and CpG have been shown to activate STAT3 and NF-κB in P493-6 Myclow cells,
respectively (Figure 6). Combined stimulation with both factors activated the same pathways
in Myclow cells (Figure 21). Within one hour CpG and IL10+CpG stimulation induced
Figure 21: IL10+CpG stimulation synchronously activates STAT3 and NF-κB signaling in
Myclow cells.
Immunoblot analysis of NF-κB (A) and STAT3 (B) signaling in single IL10 and CpG and double stimulated
Myclow and unstimulated Mychigh cells. Myclow cells (Doxy +) were treated with either IL10, CpG or both
for 1 h. NF-κB activation is shown by p65 phosphorylation and IκBα degradation, STAT3 activation by
Tyr705 phosphorylation. Equal loading is indicated by tubulin and ponceau staining. One representative
blot out of three is shown.
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p65 phosphorylation accompanied by a decrease in IκBα, while both, IL10 and IL10+CpG
stimulation, induce STAT3 phosphorylation. In contrast none of these pathways was active in
Mychigh cells. Since NF-κB and STAT3 are important mediators of normal and transformed
B cell proliferation (Ding et al., 2007; McCarthy et al., 2012) their involvement in IL10+CpG
stimulation mediated proliferation was further analyzed.
First, cell doubling after NF-κB or STAT3 pathway inhibition was accessed (Figure 22A).
To inhibit NF-κB signaling two inhibitors against IKK, called ACHP and MLN120B, were
used. Incubation with ACHP completely blocked cell proliferation, while the synergistic
effect of IL10+CpG stimulation vanished after MLN120B treatment. Same reduction of
cell doubling of IL10+CpG to only CpG stimulated levels could be observed after JAK
inhibition by using the small molecule inhibitors Ruxolitinib and Pyridone 6. Importantly,
Mychigh cell proliferation was only slightly effected by ACHP and Pyridone 6 treatment and
not by MLN120B or Ruxolitinib. As an increase of CDK4 expression was thought to be
involved in IL10+CpG stimulation induced proliferation, its expression was analyzed after
ACHP and Ruxolitinib treatment (Figure 22B). Like observed for cell doubling experiments,
ACHP treatment completely blocked CDK4 expression in stimulated Myclow cells, but not in
Mychigh cells, while Ruxolitinib reduced IL10+CpG stimulation induced expression to CpG
stimulation alone.
Figure 22: IL10+CpG stimulation mediated proliferation is NF-κB and JAK/STAT depen-
dent.
(A) Relative cell numbers of stimulated Myclow and unstimulated Mychigh cells after IKK or JAK inhibi-
tion. Cells were preincubated for 3 h with IKK inhibitors (7µM ACHP, 5µM MLN120b) or JAK inhibitors
(1µM Ruxolitinib, 1µM Pyridone 6), stimulated twice with IL10 and/or CpG as described before and
total cell number was counted after 48 h. Data represent mean±SD of three independent experiments.
Two-way ANOVA (Bonferroni’s posttest) results are shown. (B) Relative CDK4 expression of stimu-
lated Myclow and unstimulated Mychigh cells measured by qRT PCR 24 h after IKK and JAK inhibitor
treatment. Expression was normalized on drosophila ACT42A expression and unstimulated DMSO treated
Myclow cells. Mean expression values and SD of three independent experiments and One-way ANOVA results
are shown.(? p<0.05,?? p<0.01, ??? p<0.001).
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Figure 23: CDK4 expression is STAT3 and p65/RELA dependent.
(A) Immunoblot analysis of STAT3 and p65 after STAT3, RELA or STAT3 and RELA knockdown. GAPDH
staining indicates equal protein loading. Figure is taken from MD thesis of Judith Kemper (Kemper, unpub-
lished). (B) qRT analysis of CDK4 mRNA expression of stimulated Myclow cells after knockdowns shown in
A. Analysis was performed 48 h after knockdown and 24 h after stimulation with IL10 and/or CpG. Results
are shown relative to drosophila ACT42A and scrb transfected unstimulated Myclow cells. Data represent
mean±SD of three independent experiments. Two-way ANOVA (Bonferroni’s posttest) results are shown.
To further support these observations, the involvement of NF-κB/p65 and STAT3 in IL10+
CpG stimulation induced proliferation was analyzed with support from Judith Kemper
(Kemper, unpublished). She performed siRNA mediated knockdown of STAT3 and p65
(Figure 23A) and observed significantly reduced cell doubling in IL10+ CpG stimulated
cells. To confirm the STAT3 and NF-κB dependent regulation of CDK4, its gene expression
was analyzed after STAT3 and/or p65 knockdown by qRT PCR (Figure 23B).
In line with the above described inhibitor experiments, CDK4 mRNA expression was sig-
nificantly reduced after STAT3 or NF-κB knockdown, but double knockdown of both tran-
scription factors showed strongest reduction of CDK4 expression in IL10+CpG stimulated
cells. In conclusion, synchronous STAT3 and p65 activation synergistically increases the
expression of cell cycle regulators, for example CDK4, and thereby facilitates cell cycle entry
and cell doubling in IL10+CpG stimulated Myclow cells.
3.5.6 IL10 and CpG do not influence each other’s STAT3 and p65 activation
While an important role of STAT3 and NF-κB in IL10+CpG stimulated cells was confirmed,
the mechanism underlying the synergistic effect of both pathways was still unknown. As
described in the introduction, STAT3 and NF-κB signaling can interact by modifying each
other’s signaling activity or duration (Liu et al., 2013; Lee et al., 2009). Therefore, pathway
activation of NF-κB and STAT3 signaling was monitored over time by immunoblotting and a
flow cytometry based nuclear translocation assay. Immunoblot analysis with phosphospezific
antibodies revealed no significant difference in STAT3 and p65 phosphorylation or IκBα
degradation over 2hrs (Figure 24A-C) or up to 24 h (data not shown) between double or
single stimulated Myclow cells. In both cases STAT3 signaling was activated within 15min,
63
Results
Figure 24: Comparable time course of STAT3 and NF-κB activation after single and combined
stimulation in Myclow cells.
(A-C) Comparison of IκBα degradation and STAT3 activation after single IL10 and CpG and double stim-
ulation of Myclow cells. Cells were stimulated with either IL10, CpG or both for indicated time points,
followed by immunoblot analysis (A). Equal loading is shown by tubulin and ponceau staining. One rep-
resentative blot out of three is shown. Activation of pSTAT3 (Tyr705, B) and degradation of IκBα (C) of
immunoblot shown in A were quantified using Image J. (D+E) Nuclear translocation time of p65 (D) and
pSTAT3 (Tyr705, E) after IL10, CpG and IL10+CpG stimulation analysed by flow cytometry. Mean±SD
of three independent experiments are shown.
followed by slow decrease of the signal. In contrast, IκBα was degraded after 30min and 1 h
but again increased after 2 h in single as well as IL10+CpG stimulated cells. This time course
was confirmed by nuclear staining of p65 and STAT3 by flow cytometry. No difference of
p65 (Figure 24D) or STAT3 (Figure 24E) nuclear translocation was observed between 15min
and 8 h.
Therefore, differences in signaling strength or duration as a main reason for the synergistic
effect of STAT3 and p65 on CDK4 gene expression are excluded. Instead, is suggested that
a combined binding of STAT3 and NF-κB to the CDK4 promoter or a second unknown




3.5.7 STAT3 and NF-κB directly bind to the CDK4 promoter
It was shown that STAT3 and NF-κB cooperatively induce gene expression (Kesanakurti
et al., 2013; Hagihara et al., 2005). Therefore, STAT3 and NF-κB were considered as direct
regulators of CDK4 expression in stimulated P493-6 Myclow cells. To proof this hypothe-
sis, IL10+CpG stimulation induced gene expression was analysed after 6 hrs of stimulation.
An increase in the expression of the STAT3 target gene SOCS3 and the NF-κB target
NFKBIA, coding for IκBα, could be observed within this time frame(Figure 25A+B). Im-
portantly, within 6 h also an increase in CDK4 expression could be observed indicating a
direct regulation by STAT3 and NF-κB (Figure 25C).
To proof this hypothesis, chromatin immunoprecipitation of STAT3 and p65 after IL10
and/or CpG stimulation was performed. For this purpose, Myclow cells were stimulated with
single IL10 or CpG or both for 1 h. Proteins bound to the chromatin were fixed by double
crosslinking and pulldown of STAT3 and p65 bound chromatin was performed by immuno-
precipitation. After protein removal, the gene promoters fractions of SOCS3, NFKBIA and
CDK4 were identified in the isolated DNA by qPCR. A strong increase in STAT3 bind-
ing was observed on the SOCS3 promoter after IL10 stimulation, while CpG treatment
increased binding of p65 to the NFKBIA promoter (Figure 25D+E). Different primers am-
plifying regions between the transcription start side (TSS) and -1000bp of CDK4 were used
to screen for proximal binding site of STAT3 and p65 at CDK4. About 100bp from the
TSS of CDK4 a binding of STAT3 was detected after IL10 treatment accompanied by a
weak p65 binding (Figure 25F). In contrast, after CpG treatment a strong p65 and a weak
STAT3 binding was shown. Importantly, after IL10+CpG stimulation a strong binding of
both STAT3 and p65 to the same promoter region was found. Interestingly, this dual bind-
ing of STAT3 and p65 was observed in the classical STAT3 and NF-κB targets, SOCS3 and
NFKBIA. Both genes are synergistically upregulated after IL10+CpG stimulation. These
data imply that strong dual binding of STAT3 and p65 to the same promoter region of a
gene is involved in the synergistic increase in gene expression, including CDK4. Further-




Figure 25: STAT3 and p65 bind to the proximal promoter of CDK4.
(A-C) Gene expression of SOCS3 (A), NFKBIA (B) and CDK4 (C) 6 h after IL10, CpG and IL10+CpG
stimulation in Myclow cells analyzed by qRT PCR. Expression was normalized on drosophila ACT42A and
unstimulated Myclow cells. Means±SD of three independent experiments are shown. (D-F) Chromatin
Immunoprecipitaion of STAT3 and p65 1 h after stimulation of Myclow cells with IL10, CpG or IL10+CpG.
qPCR analysis of proximal promoter regions of SOCS3 (D), NFKBIA (E) or CDK4 (F) of the pull down are
shown. Fold changes were calculated relative to an inactive, closed intron region (PRAME) and unstimulated




3.6 Effects of IL10R and TLR9 signaling on cell metabolism
So far, a synergism of IL10R and TLR9 signaling on B cell proliferation and gene expression
of cell cycle regulator was shown. However, beside the activation of specific cell cycle regula-
tors, increasing evidence exist that changes in metabolism of the cell are important to provide
energy and biomolecules for DNA replication and cell division (Vander Heiden et al., 2011).
First hints for these changes were shown above by a correlation of extracellular and intracel-
lular metabolites and the number of cells in S-phase (Figure 12). More interestingly, these
changes in proliferation and metabolism are often mediated by the same oncogenic pathways
in cancer cells (Fritz & Fajas, 2010), indicating a possible role for STAT3 and NF-κB in cell
metabolism. However, metabolic and transcriptomic data obtained from the linear regres-
sion analysis have shown first possible differences between IL10+CpG stimulation and Myc
induced proliferation (Figure 15). Therefore, the metabolic changes mediated by IL10+CpG
stimulation or MYC overexpression and the molecular pathways underlying these changes
were further analyzed in this study.
3.6.1 IL10+CpG stimulation synergistically induces expression of metabolic genes
Within the genes upregulated by IL10+CpG stimulation or MYC overexpression an enrich-
ment of metabolism associated genes was observed (Figure 15D). Further gene set enrichment
analysis revealed that these sets included genes associated with glycolysis or involved in glu-
taminolysis. Figure 26 shows log2FC of important glycolysis and glutaminolysis genes in
IL10+CpG stimulated Myclow and Mychigh cells from the dataset shown in Figure 14. As
shown above for genes involved in cell cycle regulation most glycolysis or glutaminolysis
associated genes were significantly higher expressed in IL10+CpG stimulated Myclow cells
than single stimulated. This increase resulted in a comparable expression of genes after
IL10+CpG stimulation as MYC overexpression. For example, Hexokinase 2 (HK2 ), the
key enzyme of glycolysis, and the lactate dehydrogenase A (LDHA) are highly expressed
in IL10+CpG stimulated Myclow and Mychigh cells. This suggests a greater usage of glucose
via anaerobic glycolysis. Key enzymes of glutaminolysis (including TCA cycle enzymes) are
higher expressed in both proliferating cells under both conditions compared to unstimulated
Myclow cells. Importantly, expression of the glutaminase (GLS) and aspartate transaminases
(GOTs) are increased in IL10+CpG stimulated Myclow and Mychigh cells.
Therefore, an increase in glycolysis and glutaminolysis dependent genes in IL10+CpG stim-
ulated Myclow and Mychigh cells was observed that should facilitate the usage of glucose or glu-
tamine as energy and biosynthetic sources in these cells. Notably, an increased usage of glu-
cose and glutamine is resonable after IL10+CpG stimulation as depicted from the linear re-
gression analysis (Figure 10, Supplemental Table 3, Appendix p. 119)
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Figure 26: Synergistic upregulation of metabolic genes in IL10+CpG stimulated Myclow cells.
Heatmaps of log2 gene expression changes induced by IL10, CpG, IL10+CpG stimulation and MYC ex-
pression relative to unstimulated Myclow cells. Shown are genes of the IL10+CpG stimulation and MYC
overexpression overlap presented in Figure 15, which are enriched for glycolysis (A) and glutaminonlysis
(B). Color codes used are shown above the figures. Log2FC of the genes are provided digitally (Supplemen-
tal Table 4, Appendix p. 119).
3.6.2 Proliferation of IL10+CpG stimulated Myclow and Mychigh cells is strictly
glutamine dependent
The suggested increase in glucose and glutamine usage should be visible as a higher con-
sumption rate of these metabolites from the media. Therefore, measurements of cell culture
supernatants 24h after stimulation were performed by NMR spectrometry. A significant
increase in the uptake of glucose and glutamine from the cell culture media in IL10+CpG
stimulated Myclow and Mychigh cells compared to untreated or single treated Myclow cells was
revealed (Figure 27A+B). Comparing IL10+CpG stimulation and MYC overexpression, a
higher usage of glucose and glutamine was observed in Mychigh cells, consistent with the
higher expression of TCA associated metabolic genes. Next it was analyzed, which of the
metabolites, glucose or glutamine, was most important for IL10+CpG stimulation or Myc in-
duced cell proliferation. Therefore, cells were grown in media depleted from either glucose or
glutamine and cell numbers of IL10+CpG stimulated Myclow and unstimulated Mychigh cells
were defined. Depletion of glutamine from the media completely blocked IL10+CpG stimu-
lation and Myc induced proliferation (Figure 27C). Glucose withdrawal resulted in a reduced
proliferation rate under both conditions (Figure 27D).
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Figure 27: Increased glutamine consumption is important for proliferation of IL10+CpG stim-
ulated Myclow and Mychigh cells.
(A+B) Consumption of glucose (A) and glutamine (B) from cell culture media of IL10, CpG and IL10+CpG
stimulated Myclow and unstimulated Mychigh cells measured by NMR spectrometry. (C+D) Relative cell
number of IL10+CpG stimulated Myclow (C) and unstimulated Mychigh cells (D) grown in media depleted
from glucose (-Glc) or glutamine (-Gln). Total cell number was counted every 24 h. Mean and SD of three
independent experiments are shown.
To further support this observation the GLS inhibitor CB-839 was used. This inhibitor
blocks the conversion of glutamine to glutamate (Figure 28A). Inhibiting the GLS blocked
IL10+CpG stimulation and Myc mediated proliferation comparable to glutamine withdrawal,
while untreated and single treated Myclow cells were unaffected by this inhibitor (Figure 28B).
Notably, the total cell number and viability of unstimulated or single stimulated Myclow cells
was not affected by either glutamine withdrawal or CB-839 treatment. Therefore, prolifera-




Figure 28: IL10+CpG stimulation and Myc induced proliferation is dependent on GLS.
(A) Scheme of selected pathway knots of glutaminolysis. Conversion of glutamine to glutamate by glutam-
inase (GLS) is blocked by the small molecule inhibitor CB-389. (B) Relative cell numbers of 1µM CB-839
treated Myclow and Mychigh cells 48 h after treatment. Myclow cells were simultaneously stimulated with
IL10, CpG and IL10+CpG. Cells grown in media with glutamine (+Gln) and without glutamine (-Gln) were
used as controls. Mean and SD of three independent experiments are shown.
3.6.3 Glutamine is incorporated into TCA intermediates and amino acids
To evaluate how glutamine is further metabolized, stable isotopic labeled glutamine was
used. Myclow and Mychigh cells were grown in media containing ubiquitous 13C-labeled glu-
tamine and Myclow cells were left unstimulated or stimulated with IL10+CpG and incubated
at 37 ◦C for 18 h, 22 h, 24 h, 26 h, 30 h. Mass spectrometry of the cell lysate revealed no
significant differences of 13C-enrichment in TCA metabolites or amino acids within these
time points (data not shown). This indicates a steady state of metabolite labeling within
this time frame. Therefore, an incubation time of 24 h was chosen for glutamine tracing
of IL10+CpG stimulated Myclow and Mychigh cells. Unstimulated Myclow cells incorporated
glutamine in about 20 to 30% of each TCA metabolite within these 24 h (Figure 29A). In
IL10+CpG stimulated cells a stronger enrichment of isotopic labeling of about 50% was
detected, while in Mychigh cells 60 to 65% of each metabolite was derived from glutamine.
In both, IL10+CpG stimulated Myclow and Mychigh cells a small fraction (2 - 4%) of lactate
was glutamine derived, while nearly no glutamine was metabolized to lactate in unstimu-
lated Myclow cells (Figure 29B). In addition to TCA metabolites and lactate, a significant
incorporation of glutamine into the amino acids aspartate, glutamate, proline and ornithine
was observed (Figure 29C). Thereby, an equal distribution as TCA intermediates was ob-
served for aspartate, glutamate and proline, while ornithine labeling was not increased by
IL10+CpG stimulation or Myc induction compared to unstimulated Myclow cells. Interest-
ingly, only in Mychigh cells a small fraction about 2 - 3% of alanine was glutamine derived.
These results show, that both IL10+CpG stimulated Myclow and Mychigh cells increase the
incorporation of glutamine in metabolites involved in biosynthesis and energy production
compared to unstimulated Myclow cells. Nevertheless, Mychigh cells use more glutamine for
this purpose consistent with a higher consumption rate of glutamine from the media ob-
served in this (Figure 27) and published studies (Murphy et al., 2013).
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Figure 29: IL10+CpG stimulation and MYC overexpression are associated with an increase
of glutamine incorporation into TCA intermediates and amino acids. (A-C) Isotopic enrich-
ment of metabolites of unstimulated Myclow , IL10+CpG stimulated Myclow and Mychigh cells treated with
ubiquitously labeled 13C-glutamine for 24 h. TCA intermediates (A), intracellular lactate (B) and amino
acids (C) were measured by mass spectrometry. In all plots mean ± SD of three independent experiments
are shown.2-KG=α-ketoglutarate, Suc=succinate, Fum=fumarate, Mal=malate, Cit=citrate, Ala=alanine,
Asp=aspartate, Glu=glutamate, Gly=glycine,Pro=proline, Ser=serine.
Glutamine derived metabolites can be metabolized via two different mechanisms in the
TCA, oxidative decarboxylation or reductive carboxylation. These mechanisms can be dis-
tinguished by mass spectrometry due to different masses of the end products. These mass
distributions were compared to answer the question if IL10+CpG stimulated Myclow and
Mychigh cells metabolize glutamine by equal mechanisms. In Figure 30 A an example of mass
distribution for the synthesis of citrate is shown. First glutamine is converted to aKG via
transaminases or deamination, which leads to labeling of all five carbons (m+5). During the
oxidative carboxylation, which is part of the a respiration, one carbon is lost by the release
of CO2 leading to m+4 labeling of the following TCA intermediates. To generate citrate,
glucose derived acetyl - CoA is added to the four carbons of OAA. Thus citrate is still m+4
labeling under this conditions. Lower levels of 13C-labeling indicate multiple rounds of oxida-
tive TCA function as in each round an additional glutamine derived carbon will be removed
as CO2. In case of reductive carboxylation, one unlabeled CO2 derived carbon is added
to the five labeled carbons of aKG to build up citrate (m+5). Thus, the precise isotopic
fractions (m+0 till m+6) of citrate were calculated for unstimulated Myclow , IL10+CpG
stimulated Myclow and Mychigh cells. M+0 fraction was highest in unstimulated Myclow cells,
whereas IL10+CpG stimulated Myclow and Mychigh cells a strong decrease in unlabeled cit-
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Figure 30: More citrate is oxidatively derived from glutamine in Mychigh cells.
(A) Oxidative decarboxylation (blue) and reductive carboxylation (red) can be distinguished by isotopic
labeling and mass spectrometry. While oxidation of glutamine leads to m+4 labeled citrate, reductive
generation of citrate is shown by m+5 labeling. aKG = α-ketoglutarate, Suc = succinate, Fum = fumarate,
mal = malate, OAA = oxaloacetate. Glutamine derived carbons are shown in grey. (B) Isotopic fractions
of citrate in IL10+CpG stimulated Myclow and Mychigh cells. Mass spectra described in Figure 29 were
analyzed according to the different masses of citrate. Mean±SD of three independent experiments and
one-way ANOVA results are shown.
rate was observed. Furthermore, m+2, m+3 and m+5 fractions of IL10+CpG stimulated
and Mychigh cells were equally increased compared to unstimulated Myclow cells. However,
the oxidative derived m+4 fraction was significantly increased in Mychigh cells compared to
IL10+CpG stimulated Myclow cells. Thus it is proposed, that both, IL10+CpG stimulated
and MYC overexpressing cells, increase glutamine incorporation into TCA intermediates,
but that Mychigh cells use more glutamine for aerobic respiration.
3.6.4 Mychigh but not IL10+CpG stimulated cells use glutamine for aerobic
respiration
To further support that glutamine is used for aerobic respiration in Mychigh cells, the res-
piratory and glycolytic capacity of unstimulated Myclow , IL10+CpG stimulated Myclow and
Mychigh cells was analyzed. Oxygen consumption rates (OCR) and extracellular acidification
rates (ECAR) were simultaneously measured in the presence of glucose, glutamine or both.
Figure Figure 31A shown an example of OCR measurement in the presents of both glucose
and glutamine. Adding oligomycin inhibits ATP synthase (complex V) and OCR decreases.
This decrease correlates to the mitochondrial respiration associated with cellular ATP pro-
duction. By adding Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) the
membrane potential of the mitochondrium is uncoupled from the proton gradient. Thereby,
the electron flow through the ETC is uninhibited and maximally oxygen consumption is mea-
sured. Here, highest increase in CpG and IL10+CpG stimulated Myclow and Mychigh cells is
visible. At last rotenone, a complex I inhibitor, and antimycin A, a complex III inhibitor, are
added. These inhibitors completely block mitochondrial respiration. From these inhibitor




Figure 31: Respiration and acidification of Mychigh but not IL10+CpG stimulated Myclow cells
is glutamine dependent.
(A) Measurement of oxygen consumption rates (OCR) of 24 h IL10, CpG and IL10+CpG stimulated
Myclow and unstimulated Mychigh cells. Mean± SD of technical replicates of one representative experiment
are shown. Respiratory parameters were calculated by inhibitor addition (O = 1.5µM Oligomycin, F =
0.5µM FCCP, A = 2µM antimycin A, R = 1µM rotenone) as described in section 2.2.2 (B) Basal OCR of
IL10+CpG stimulated Myclow and Mychigh cells under different media conditions. Cells were seeded in media
with glucose and glutamine, without glucose and without glutamine and 24 h after seeding OCR was ana-
lyzed as shown in A. Basal respiration rates calculated from three independent biological replicates. (C+D)
Extracellular acidification rates (ECAR) of samples described in A and B. Mean± SD of three independent
experiments and one-way ANOVA (Bonferroni’s posttest) results are shown (??? p<0.001).
Calculation of these parameters are described in method section (page 29). Simultaneous
to OCR the ECAR was measured at all time points (Figure Figure 31C). Notably, highest
ECAR was observed in IL10+CpG stimulated Myclow cells and Mychigh . Oligomycin treat-
ment further increased the ECAR, due to a switch from aerobic respiration to anaerobic
glycolysis and an increase in lactate production. Figure 31B shows basal respiration rates of
triplicates of cells treated with glucose and glutamine or without glucose or glutamine. When
both were present, comparable basal respiration rates of IL10+CpG stimulated Myclow and
Mychigh cells were observed. Without glucose respiration was equally increased, compen-
sating for the loss of anaerobic glycolysis which reflected by a decrease in ECAR rates
(Figure 31C+D). When glutamine was depleted from the media, however, no change in
IL10+CpG stimulated cells was observed, while both, OCR and ECAR, significantly dropped
in Mychigh cells (Figure 31B+D). Same effects were detected on ATP dependent and maximal
respiration (data not shown). To further confirm the dependency of respiration on glutamine
in Mychigh cells, OCR measurements were modified the following was. Cells were seeded in
media without glucose and glutamine and instead adding respiratory inhibitors, glutamine
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and glutaminolysis inhibitors (CB-839 and transaminase inhibitor aminooxyacetic acid) were
added stepwise (Figure 32A). At the last step antimycin was added to enable the calcula-
tion of basal respiration. IL10+CpG stimulated cells showed higher respiration rates than
Mychigh cells when glutamine was absent (Figure 32B). Adding glutamine increased OCR of
Mychigh cells to levels comparable to IL10+CpG stimulated in Myclow cells. This increase
was reversed in Mychigh by addition of the transaminase inhibitor AOA, while IL10+CpG
stimulation mediated respiration was unchanged. Treatment with the GLS inhibitor CB-839
did not further decrease respiration of Mychigh cells. In contrast a tendency towards even
greater basal respiration rates was observed in IL10+CpG stimulated Myclow cells.
Considering both respiration experiments, only the respiration of Mychigh cells was depen-
dent on glutamine, while IL10+CpG stimulated Myclow cells seemed to use other fuels, most
likely fatty acids, to increase respiration rates.
Figure 32: Respiration of Mychigh cells is dependent on glutaminolysis.
(A) OCR of IL10, CpG, IL10+CpG stimulated Myclow and Mychigh cells seeded in media without glutamine
and glucose. Glutamine and glutaminolysis inhibitors (500µM AOA= aminooxyacetic acid, 1µM CB=CB-
839) were added stepwise. One representative analysis out of three is shown. Error bars indicate technical
variations. (B) Basal respiration rates were calculated from three replicates of A as described before.
Mean±SD of three independent experiments and one-way ANOVA (Bonferroni’s posttest) reults are shown
(? p<0.05, ?? p<0.01).
3.6.5 Glutamine derived aKG is important for proliferation of Mychigh cells
While the oxidation of glutamine via respiration is shown above for Mychigh cells and reported
previously (Gao et al., 2009), the importance of increased oxidative derived TCA interme-
diates and aerobic respiration for proliferation was still unknown. To analyze this, rescue
experiments of cell proliferation were performed. Cells were grown in media without glu-
tamine and TCA intermediates (Pyr, aKG, Mal, OAA) were added (Figure 33). Afterwards
total cell numbers were counted 48 h after treatment. Proliferation of IL10+CpG stimulated
Myclow cells could only partially be rescued by the addition of oxaloacetate (OAA) to the
media (Figure 33A) whereas Pyr, aKG or Mal showed no significant effects. In contrast,
proliferation of Mychigh cells was partially restored by pyruvate and completely restored af-
ter aKG addition (Figure 33B), but neither Mal or OAA significantly increased cell doubling
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Figure 33: Proliferation of Mychigh cells but not IL10+CpG stimulated cells is aKG dependent.
Cell numbers of glutamine deprived and metabolite treated IL10+CpG stimulated Myclow and Mychigh cells
relative to cells seeded in glutamine containing media. TCA intermediates were added as indicated to the
glutamine deprived media (Pyr=pyruvate, aKG=α-ketoglutarate, Mal=malate, OAA= oxaloacetate) and
cells were stimulated as described before. Cell number of IL10+CpG stimulated cells (A) and unstimulated
Mychigh cells (B) was counted 48 h after treatment. Mean±SD of three independent experiments and one-
way ANOVA results are shown (??? p<0.001).
of Mychigh cells over time. Importantly, proliferation of unstimulated Myclow cells was not
increased by any of the metabolites (data not shown).
The fact that only aKG, but not Mal or OAA, is able to rescue Mychigh cells from glu-
tamine dependent proliferation block, supports that the oxidation of glutamine derived TCA
metabolites and therefore energy and reduction equivalent production is most important
for proliferation in Mychigh cells. However, although proliferation of IL10+CpG stimulated
Myclow cells was equally glutamine dependent, other glutamine dependent pathways than res-
piration must play an important role for proliferation in these cells.
3.6.6 Proliferation of IL10+CpG stimulated Myclow cells depends on aspartate and
nucleotides synthesis
Only OAA, but not other TCA intermediates, was able to rescue IL10+CpG stimulation
induced proliferation from glutamine deprivation and OAA is an important precursor for as-
partate. Therefore the role for glutamine derived aminoacids, observed by glutamine tracing
(Figure 29), was further analyzed in IL10+CpG stimulated Myclow and Mychigh cells. Glu-
tamine is not only incorporated in the carbon backbone of amino acids, but is also an impor-
tant donor for amino groups, a process which is catalyzed by aminotransferases. To block
enzyme activity of aminotransferase, cells were treated with aminooxyacetic acid (AOA)
and cell doubling was analyzed. Treatment with AOA blocked proliferation of IL10+CpG
stimulated andMYC overexpressing cells comparable to glutamine withdrawal (Figure 34A).
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Figure 34: IL10+CpG stimulation induced proliferation is dependent on glutamine derived
aspartate.
(A) Relative cell numbers of IL10+CpG stimulated Myclow and unstimulated Mychigh cells after transam-
inase inhibition with 500µM AOA. IL10+CpG stimulation was performed as described before and cells
were counted 48 h after treatment. (B+C) Intracellular amino acid abundancy of IL10+CpG stimulated
Myclow (B) and Mychigh cells(C) 24 h after AOA treatment and stimulation measured by mass spectrom-
etry. Percentage of DMSO treated cells are shown for each amino acid. (D+E) Relative cell numbers of
IL10+CpG stimulated Myclow (D) and unstimulated Mychigh cells (E) after glutamine withdrawal or 500µM
AOA treatment and simultaneous 10mM aspartate addition. Cells were stimulated as described before and
numbers were counted 48 h after treatment. All experiments in this figure were performed in triplicates.
Numbers were calculated relative to glutamine containing sample. Mean± SD and one-way ANOVA (Bon-
ferroni’s posttest) results are shown (? p<0.05, ?? p<0.01, ??? p<0.001)).
This supports the view that aminotransferases are important for proliferation of IL10+CpG
stimulated Myclow and Mychigh cells.
To answer the question which glutamine derived amino acid was most important for IL10+CpG
stimulation or Myc induced proliferation, intracellular amino acid abundancy after AOA
treatment was measured by mass spectrometry (Figure 34B). In IL10+CpG stimulated
Myclow cells a 30% reduction of alanine levels was observed, while aspartate levels were
nearly vanished. In contrast, in Mychigh cells a strong reduction of both alanine and aspar-
tate was detected accompanied by a significant reduction of proline levels (Figure 34C). Since
both, IL10+CpG stimulated Myclow and Mychigh cells, showed strong decrease in aspartate
levels, the role of aspartate for IL10+CpG stimulation and Myc mediated proliferation was
analyzed. Cells were grown in glutamine deprived media or treated with AOA. To test the
ability of aspartate to rescue cell proliferation, aspartate was added to the cells prior to stim-
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ulation. Supplementing glutamine deprived media with aspartate significantly increased the
total cell number after IL10+CpG stimulation (Figure 34D). The same rescue of proliferation
was observed after aspartate addition to AOA treated IL10+CpG stimulated Myclow cells.
In contrast, no significant rescue of Myc induced proliferation was observed after aspartate
treatment of glutamine deprived Mychigh cells and only a partial rescue of proliferation after
AOA treatment could be achieved by aspartate addition (Figure 34E).
Aspartate is an important precursor for nucleotide synthesis (Lane & Fan, 2015). Thereby,
carbon and nitrogen atoms of the aspartate are incorporated into the backbone of pyrim-
idines, while aspartate derived nitrogen is important for purine synthesis (Figure 35A).
Importantly, also glutamine is a nitrogen donor for both nucleotides. To test if nucleotide
synthesis is the main function of glutamine and glutamine derived aspartate in IL10+CpG
stimulated cells, the nucleotide bases thymine (T) and adenine (A) were added to glutamine
deprived and AOA treated cells (Figure 35B). Only in IL10+CpG stimulated Myclow cells a
complete rescue of proliferation was achieved by nucleotide base addition, while no significant
increase in cell numbers was observed in Mychigh cells neither after glutamine deprivation nor
AOA treatment (Figure 35C).
Figure 35: IL10+CpG stimulation induced proliferation depends on glutamine derived nu-
cleotides.
(A) Aspartate and glutamine are important precursors for pyrimidine and purine base synthesis. Glutamine
derived nitrogen are shown in blue, aspartate derived carbons and nitrogen in red. (B+C) Relative cell
numbers of glutamine deprived (-Gln) and 500µM AOA treated IL10+CpG stimulated Myclow (B) and
Mychigh cells (C) after 100µM thymine (T) and 100µM adenine (A) addition. Percent of glutamine treated
positive control are shown. Experiment was performed in triplicates. Mean±SD and one-way ANOVA
(Bonferroni’s posttest) are shown.
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Therefore a model is proposed in which glutamine derived aspartate is important for nu-
cleotide synthesis and thus cell proliferation in IL10+CpG stimulated Myclow cells. In con-
trast, aspartate and nucleotides are not sufficient to rescue Mychigh cells proliferation block
mediated by glutamine deprivation. Furthermore, not only aspartate but also alanine is
glutamine derived in Mychigh cells. Therefore, different dependencies of cell proliferation on
glutamine is proposed for IL10+CpG stimulated and Mychigh cells.
3.6.7 GOT2 is important for aspartate and nucleotide synthesis in IL10+CpG
stimulated Myclow cells
Both, aspartate and aKG, are end products of the transamination from glutamine to ox-
aloacetate. This reaction is catalyzed by the aspartate aminotransferases, also known as
glutamic-oxaloacetic transaminase (GOT). There are two isoforms of GOT, the cytosolic
form GOT1 and the mitochondrial form GOT2 (Panteghini, 1990). To investigate their role
in IL10+CpG stimulation and Myc induced proliferation, siRNA mediated knockdown of
both was performed (Figure 36A) and cell doubling after two days was analyzed. Knock-
down of GOT1 reduced proliferation of Mychigh cells about 25%, but did not affect cell
doubling of IL10+CpG stimulated Myclow cells. In contrast, knockdown of GOT2 affected
proliferation of both, IL10+CpG stimulated and Mychigh cells. Thereby, proliferation of
IL10+CpG stimualted cells was reduced about 30% (Figure 36B).
Next, it was tested whether GOT2 derived aKG or aspartate and nucleotide synthesis was
important for cellular proliferation. After GOT2 knockdown cells were treated with aKG,
aspartate, adenine or thymine and cell numbers were counted after 48 h. In IL10+CpG stim-
ulated cells a partial rescue by aspartate and a complete rescue of proliferation by nucleotide
supplementation was observed (Figure 36C). Importantly, these metabolites were not able to
rescue GOT2 knockdown in Mychigh cells (Figure 36D). Instead, supplementation with aKG
was needed to completely restore proliferation in Mychigh cells as already observed after glu-
tamine deprivation. Therefore, glutamine is needed for aspartate and following nucleotide
synthesis in IL10+CpG stimulated cells to support proliferation, while Mychigh primarily
seems to rely on glutamine dependent aKG production, but in both cases generation of
these metabolites is GOT2 dependent.
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Figure 36: IL10+CpG stimulation induced proliferation is dependent on GOT2 mediated as-
partate and following nucleotide synthesis.
(A+B) Transient knockdown of GOT1 and GOT2 in P493-6 cells performed by siRNA transfection. Knock-
down efficiency was checked 24 h after knockdown by immunoblot (A). Knockdown efficiency (GOT/tubulin
ratio) relative to scrb sample is shown below the images. 24 h after knockdown cells were seeded in fresh
media and Myclow cells were stimulated daily with IL10+CpG. After 48 h cells were counted and relative
cell number was normalized on non-target (scrb) control (B). (C+D) Relative cell number after GOT2
knockdown and indicated 1mM aKG, 10mM aspartate (Asp), 100µM adenine (A) or 100µM thymine (T)
addition in IL10+CpG stimulated Myclow (C) and Mychigh cells (D). All experiments were performed in
triplicates. Mean and SD are shown.
3.6.8 GOT2 is a target of Myc and STAT3/NF-κB
GOT2 was shown above to be important for cell proliferation of IL10+CpG stimulated
Myclow and Mychigh cells. Furthermore, RNASeq data revealed an increase in GOT2 expres-
sion after IL10+CpG stimulation and MYC overexpression (Figure 26B). Since STAT3 and
NF-κB were main mediators of CDK4 expression after IL10+CpG stimulation (Figure 23),
an additional role for these transcription factors in GOT2 gene expression regulation was
supposed. Therefore, cells were treated with ACHP and Ruxolitnib and GOT2 gene expres-
sion of unstimulated, single stimulated, IL10+CpG stimulated Myclow and Mychigh cells were
compared by qRT PCR. Aftr DMSO treatment a strong upregulation of GOT2 expression
in Mychigh cells was observed (Figure 37A). In addition, a synergistic upregulation of GOT2
was observed in IL10+CpG stimulated Myclow cells and this expression was, as CDK4 before,
dependent on IKK and JAK/STAT signaling. Importantly, none of these inhibitors affected
Myc mediated GOT2 expression. The dependency of GOT2 expression on STAT3 and p65
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in IL10+CpG stimulated Myclow cells was further confirmed by Judith Kemper (Kemper,
unpublished).
Furthermore a binding of STAT3 and p65 to the proximal promoter of GOT2 was shown
by chromatin immunoprecipitation (Figure 37B). It is supposed, that a combined binding of
STAT3 and p65 is not only involved in CDK4 regulation, but plays a role in the regulation
of GOT2. However, the detailed mechanism that leads to an synergistic increase in gene
expression needs to be analyzed in future experiments.
Figure 37: GOT2 expression is directly regulated by STAT3 and NF-κB.
(A) qRT analysis of GOT2 expression of samples described in Figure 22 (p.62). Expression was normalized
on drosophila ACT42A and unstimulated Myclow cells. Mean± SD of three independent experiments are
shown. (B) ChIP analysis of the GOT2 promoter of samples described in Figure 25 (p.66). Pull down
of chromatin fragments was quantified by qPCR. Enrichment was calculated relative to an inactive, closed
intron region (PRAME) and unstimulated Myclow cells. One representative precipitation out of three is
shown. Error bars represent technical variance
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3.7 Comparison of glutamine metabolism in lymphoma cell lines
A GOT2 dependent differential usage of glutamine in Myc and STAT3/NF-κB dependent
B cell proliferation was shown in P493-6 cells. Importantly, MYC overexpression, aberrant
STAT3 and NF-kB activation are known to be main drivers of lymphomagenesis. While
Myc deregulation is a hallmark of Burkitt lymphoma (Dave et al., 2006), a subtype of Dif-
fuse Large B cell Lymphoma (DLBCL) was shown to be dependent on cooperative STAT3
and NF-kB signaling (Lam et al., 2008). Furthermore Hodgkin lymphoma cells were also
shown to be dependent on NF-kB signaling and additional STAT3 or STAT5 activation
(Wood et al., 1998; Küppers, 2009). By using cell lines representing these types of lym-
phoma, the pathway dependent usage of glutamine observed in P493-6 cells was investi-
gated.
3.7.1 B cell lymphoma cell lines dependent on different signaling pathways
CA-46, OCI-Ly3 and L-428 cells were chosen to represent Burkitt, DLBCL and Hodgkin
lymphoma, respectively. First, MYC expression and activation of STAT3 and NF-κB sig-
naling was confirmed in these cell lines by immunoblot (Figure 38A). While neither STAT3
nor p65 were active in CA-46 cells, OCI-Ly3 cells showed strong STAT3 and p65 phosphory-
lation. In L-428 cells a weak STAT3 and p65 phosphorylation was detected, but a complete
deletion of the NF-κB inhibitor IκBα, which was mediated by non-sense mutation in IκBα
in this cell line (Wood et al., 1998). Myc levels were strongest in CA-46 cells, followed by a
moderate protein level in the other two cell lines. To analyze the dependency of OCI-Ly3
and L-428 cells on active STAT3 and NF-κB signaling, the previous described small molecule
inhibitors ACHP and Ruxolitinib were used. In CA-46 cells no effect of these inhibitors on
any of the investigated pathways was detected in immunoblot analysis and proliferation of
this cells was not significantly affected by STAT3 or NF-κB inhibition (Figure 38B). A strong
reduction of p65 phosphorylation accompanied by an increase in IκBα by ACHP and a de-
crease in STAT3 phosphorylation by Ruxolitinib were observed in OCI-Ly3. Importantly,
these inhibitions correlated with a complete loss of cell doubling over two days in this cell
line (Figure 38B). In contrast, L-428 cells only mildly responded to both inhibitors, which
was reflected in lower STAT3 and p65 signaling pathway activations, that were only slightly
effected by ACHP or Ruxolitinib treatment. This might be due to the published mutations
in this cell line.
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Figure 38: Proliferation of B cell lymphoma cell lines relies on different pathway activations.
(A) Immunoblot of signaling pathway activations in CA-46 Burkitt, OCI-LY3 DLBCL and L-428 Hodgkin
cell lines. STAT3 activity is shown by Tyr705 phosphorylation, NF-κB signaling by p65 phosphorylation
and IκBα degradation. Signaling was blocked by inhibitors against IKK (7µM ACHP) or JAK (1µM
Ruxolitinib). Equal protein loading is indicated by GAPDH staining. (B) Cell number of 1µM Ruxolitinib
und 7µM ACHP treated cell lines in A relative to initial cell number 48 h after seeding. Mean and SD of
three independent experiments are shown.
3.7.2 Differential usage of GOT2 derived metabolites in B cell lymphoma cell lines
As above shown P493-6 cells can proliferate either when overexpressing exogeneous MYC
or when Jak/STAT and NF-κB signaling is activated in a way were global gene epression is
affecting both cell cycle regulators but also metabolic enzymes. Therefore, one question was,
whether in lymphoma cell lines a comparable dependency between Myc or Jak/STAT and
NF-kB , glutamine and proliferation can be observed. CA-46 BL cells, OCI-LY3 DLBCL and
L428 HL cells were used.Cells were grown for 48 h in glutamine free media and cell doubling
was defined. As shown in Figure 39 the cell doubling (and thus proliferation) in all three
cell lines was reduced by 50% after glutamine withdrawal, confirming the importance of glu-
tamine metabolism in B cell proliferation. In previous chapters clear evidence was provided
that the inhibitor AOA affecting aminotransferase reduces both, Myc or IL10+CpG stimu-
82
Results
Figure 39: Proliferation of B cell lymphoma cell lines is glutamine dependent.
Cell number of CA-46, OCI-Ly3 and L-428 cells 48 h after seeding in glutamine media relative to glutamine
containing media (+Gln). Mean and SD of three independent experiments are shown.
lation, driven proliferation through interrupting metabolic support of cell cycle progression.
Therefore, CA46, OCI-LY3 and L-428 cells were treaed with AOA (Figure 40). A strong
reduction in cell doubling as for Glu deprivation was observed and was also comparable to
the reduction of proliferation by AOA treatment in P493-6 cells (Figure 40A). Importantly,
when adding aspartate or adenine to AOA treated CA-46 cells a twofold increase in the
relative cell number was detected. In contrast in OCI-Ly3 and L-428 cells aspartate and to
some extend also adenine was rescuing proliferation of AOA treated cells (Figure 40). 90%
of OCI-Ly3 proliferation could be rescued by aspartate and over 60% by adenine addition
(Figure 40B). L-428 cells could nearly be rescued from AOA induced proliferation block by
aspartate or adenine addition (both > 80%, Figure 40C).
As GOT2 was important for aspartate synthesis and proliferation in P493-6 cells (Figure 34,
Figure 36), its role in the other cell lines was further analyzed. The GOT2 knockdown of
about 40% resulted in a reduced proliferaiton in all three lymphoma cells lines at about 20-
35%(Figure 41B). Importantly, in CA-46 cells the GOT2 mediated proliferation was rescued
by aKG, while the reduced cell proliferation under lower GOT2 gene expression in L-428
and OCI-LY3 cells was reverted by adding aspartate or adenine.
Figure 40: Proliferation of lymphoma cells is amino transaminase dependent.
Cell numbers of 500µM AOA treated CA-46 (A), OCI-Ly3 (B) and L-428 cells (C) relative to DMSO
control. For rescue 10mM aspartate (Asp) or 100µM adenine (A) was added simultaneously to the cells.
Cell numbers were counted 48 h after treatment. Mean and SD of three independent experiments are shown.
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Figure 41: Pathway dependent usage of GOT2 derived metabolites in lymphoma cells.
(A) Immunoblot of GOT2 in CA-46, OCI-Ly3 and L-428 cells 24 h after siRNA mediated knockdown.
Knockdown efficiencies (GOT2/tubulin) relative to scrb control are shown under the images. (B) Relative
cell number of CA-46, OCI-LY3 and L-428 cells after GOT2 knockdown and metabolite treatment. 24 h
after transfection cells were seeded in fresh media as indicated 1mM α-ketogluterate (aKG), 10mM aspartate
(asp) or 100µM nucleotide bases adenine (A) and thymine (T) were added to the media and cell number
was calculated after 48 h. Mean and SD of cell numbers relative to non-target siRNA (scrb) are shown. All
experiments were performed in triplicates.
Summing these data, a comparable dependency on glutamine for aKG synthesis for pro-
liferation could be shown for CA-46 cells as well as P493-6 Mychigh cells. Also OCI-Ly3
cells showed a comparable dependency on glutamine for aspartate and nucleotide synthe-
sis as IL10+CpG stimulated P493-6 Myclow cells. However, L-428 cells showed an equal
dependency on aspartate and nucleotides for proliferation as OCI-Ly3. This could be ex-
plained by the well known geregulated Jak/STAT and Nf-kB pathways in both cell lines,
although mainly for HL cells a more comprehensive analysis fo involved pathways is nec-
cessary. Importantly, GOT2 was identified as a central player also in lymphoma cell lines
in vitro. Furthermore, either aKG or aspartate and nucleotides can rescue aminotransferase
deficiency in this cells depending on the signaling network active in the corresponding cell
line mediated either by Myc or NF-κB/STAT3.
3.7.3 GOT2 expression is upregulated in Burkitt and ABC DLBCL patients
To answer the question about GOT2 gene expression in primary lymphoma samples mi-
croarray based GE data from Oncomine were used (Rhodes et al., 2004)(Figure 42). In a
dataset published by Basso et al. (2005) increased expression of GOT2 in Burkitt (n=17,
p=4.9E-9) and DLBCL (n=32, p=7.6E-7) samples compared to normal B cell controls
was observed (Figure 42A). Interestingly highest expression of GOT2 in normal controls
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was detected in proliferting centroblast. A higher expression of GOT2 was also observed in
HL, however, in this dataset only data from three different cell lines were included. There-
fore, a second dataset from Brune et al. (2008) was analyzed (Figure 42B). In this dataset a
higher expression of GOT2 was observed for in BL and DLBCL in comparison to pre-GC B
cells and memory B cells but not normal circulating B cells. Thereby the latter again were
characterized by the highest expression in control cells. Notably, expression of GOT2 in
both subgroups of HL was less pronounced as in the Basso data set. Therefore, it is stated
that GOT2 seems to be highly expressed in proliferating B cells or aggressive NHL but also
in subsets of HL which needs to be further defined.
In additon to different expression between normal B cells and lymphoma, it is obvious that
the different lymphoma subtypes and most notably DLBCL are heterogenic in their GOT2
expression. Therefore it was suggested that further molecular subgroups with different GOT2
expression exist. As described in the introduction DLBCL can be disitinguished in so called
ABC-like and GCB like DLBCL. Expression analysis of primary lymphoma with ABC-like
and GCB-like DLBCL subgrouping but also clinical data for R-CHOP treated DLBCl pa-
tients are only available from Lenz et al. (2008) which was analyzed using the LYMMML
web based analysis tool (http://lymmml.ur.de/). Within this DLBLC cohort 93 ABC-like
and 117 GCB-like DLBCL cases but also 33 unclassified DLBCL were analyzed. A higher
expression of GOT2 in ABC patients compared to GCB or unclassified DLBCL was ob-
served. Importantly, GOT1 was not differential expressed in any of these datasets (data
not shown). The high expression of GOT2 in ABC-DLBCL underlines the important role
for GOT2 in OCI-Ly3 cells, as OCI-Ly3 cells are molecular classified as ABC-like DLBCL.
Figure 42: High expression of GOT2 in BL and ABC DLBCL patients.
(A+B) Microarray gene expression data of GOT2 from Basso et al. (2005) (A) and Brune et al. (2008) (B)
taken from oncomine.org. Expression of normal B cell controls (1=naive pre-germinal B cell, 2=B lympho-
cyte, 2=plasma cell, 3= centroblast, 4=memory B cell) and lymphoma samples (5=Burkitt, 6=DLBCL,
7/8= Hodgkin lymphoma (classical/nodular lymphocyte predominant) is shown. Shown are minimum and
maximum values (dots), 10% and 90% percentile (outer whiskers), 25% and 75% percentile (outer edges of
the box) and median value (middle lane). (C) Differential expression of GOT2 in molecular DLBCL sub-
types. Patient data from Lenz et al. (2008) were analyzed using the MMMLymphoma Miner (lymmml.ur.de).
Shown are minimum and maximum values (whiskers) upper and lower quantile (outer edges of the box) and
median value (middle lane).
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Importantly, it also connects ABC DLBCL to the observed STAT3/NF-κB regulation of
GOT2 in IL10+CpG stimulated P493-6 as ABC DLBCL are defined by aberrant activated
STAT3 and NF-κB signaling (see introduction).
Next it was analyzed, whether high GOT2 expression is also prognostic in DLBCL. This is
most likely as in a number of studies for ABC-like DLBCL are worse clincical outcome has
been shown (Lenz et al., 2008).
3.7.4 High GOT2 expression is a negative prognostic factor in DLBCL
To analyze if high GOT2 expression affects lymphoma aggressiveness or progression in vivo,
R-CHOP treated DLBCL patient from Lenz et al. (2008) were classified according to their
GOT2 expression. Thereby, patients with a GOT2 expression higher than the median
expression of the group were defined as GOT2high whereas patients with an expression
level lower than the median were classified as GOT2low. For both groups Kaplan-Mayer
curves were calculated in R and survival curves were compared (Figure 43). A significant
difference in the survival of GOT2high and GOT2low expressing patients was observed in a
univariat model (survdiff: p=0.00255) but also an effect of GOT2 on patient survival in a
multivariat model could be proved (Cox: p=0.03756). Thereby, a high GOT2 expression
was associated with a worse clinical outcome compared to low expression. About 80%
of GOT2low patients lived for 5 or more years after diagnose, whereas less than 50% of
patients with high GOT2 expression survived during this time frame. From this retrospective
Figure 43: High GOT2 expression is associated with decreased survival rates DLBCL patients.
Kaplan-Meyer curves of R-CHOP treated DLBCL patients from Lenz et al. (2008) (n=157). Patients were
grouped according to their GOT2 expression relative to the median of the group (high > median, low ≤
median). GOT2 low is shown as red, GOT2 high as blue line. Grey arias and dashed lines indicate 95%
confidence intervals. P value shown was calculated using the ’survdiff’ function in R.
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DLBCL cohort, although not derived from a clincial trial, first evidence is provided that
GOT2 might play an important role in subtypes of lymphoma and also in their clinical
outcome. Thus GOT2 is suggested a promissig drug target or therapeutic predictive marker
in DLBCL. However, additional in vitro analysis and data from patients cohort of different
retrospective and prospective clicial trials are neccessary to further support this assumption
in the future.
4 Discussion
The aim of the study was to investigate the impact of combinations of microenvironmental
stimuli on global gene expression, proliferation and metabolism in resting B cells. Thereby, a
new regulatory circuit of IL10R and TLR9 stimulation was found that involved interactions
of the transcription factors STAT3 and NF-κB. The proposed gene expression regulatory
mechanisms of STAT3 and NF-κB interaction, the impact of the increased gene expression on
proliferation and metabolism and its supposed role in B cell lymphomagenesis are discussed
below.
4.1 Global gene expression amplification is not limited to MYC
overexpression
A major question of this study was how signaling pathways activated by single or combina-
tions of stimuli affect B cell proliferation by global gene expression. It could be shown, that
α-IgM, CD40L, IGF-1, CpG and IL10 activate different signaling pathways in Myclow P493-6
cells and that these stimulations vary in their capacity to induce S-phase entry in these cells.
Previous publications have shown that perturbations that induce cell cycle changes can also
affect total RNA amounts (Darzynkiewicz et al., 1979). More importantly, comparison of
different samples with varying RNA amounts have been shown to result in hampered gene
expression interpretation (Lovén et al., 2012). By using cell number based normalization
and a newly developed spike-in method, a RNA amount unaffected comparison of gene ex-
pression in unstimulated Myclow , stimulated Myclow and Mychigh cells could be performed in
this study. Thereby, a global amplification of RNA expression after Myc induction could be
confirmed in the P493-6 cell line (Lin et al., 2012; Nie et al., 2012). Interestingly, stimulating
the P493-6 Myclow cells with factors derived from the microenvironment also increased global
gene expression. Thereby, the same set of genes was affected by all stimuli and differences
between the stimuli were mainly quantitative and not qualitative, indicating an important
role for gene expression amplification in normal B cell activation as well. Importantly,
stimulation of lymphocytes with the TLR agonist lipopolysaccharide (LPS) was reported
to increase global RNA levels in a Myc dependent fashion (Nie et al., 2012). In contrast,
data published during the time course of this study showed that the increase in total RNA
in LPS stimulated lymphocytes was largely independent from endogenous MYC expression
after longer time periods (24 - 48 h) (Sabò et al., 2014). The concept of a Myc independent
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amplification of global RNA is also supported from data in this thesis. CDK4 and GOT2
expression was dependent on STAT3 and NF-κB activation but largely unaffected by Myc
inhibition after IL10+CpG stimulation. In B cells more than 10.000 STAT3 and 20.000 p65
binding sites could be found by ChIP Seq and about one-third of the NF-κB binding sites
lacked the canonical binding motifs (Hardee et al., 2013; Zhao et al., 2014). Due to the large
number of binding sides, it is therefore likely that a majority of genes consists both, STAT3
and NF-κB, binding sites and that the observed global upregulation of gene expression is
also largely mediated by simultaneous STAT3 and NF-κB binding.
To confirm this Myc independent gene expression amplification after IL10+CpG stimula-
tion, RNASeq of stimulated samples could be performed after MYC knockdown. How-
ever, the present study shows that endogenous MYC expression can be reduced by RNAi
but not completely diminished. To completely knockout MYC expression the clustered
regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) sys-
tem might be applicable (Jinek et al., 2012). By these means an involvement of Myc in
the global gene expression increase after IL10+CpG stimulation could be completely ex-
cluded.
4.2 Synergy in gene expression changes by STAT3 and NF-kB pathway
activity
The most important observation in this study was that simultaneous stimulation with IL10
and CpG synergistically increased global gene expression in Myc deprived cells. Moreover, on
the example of CDK4 and GOT2 it was shown that this synergistic effect was not mediated
by an increase in MYC expression but that a simultaneous activation of STAT3 and NF-κB
was underlying this gene expression increase.
4.2.1 Simultaneous binding of STAT3 and NF-κB to target gene promoters
While there is just one publication about the role of combined STAT3 and NF-κB in B cells,
their cooperation was extensively studied in solid tumors and inflammation (Lam et al., 2008;
Grivennikov & Karin, 2010). One theory states that the interaction of STAT3 recruits the hi-
stone acetylase p300, which acetylates p65 and increases nuclear retention (Lee et al., 2009).
However, prolonged nuclear retention can be excluded based on nuclear staining of p65.
In a second study, direct interaction of STAT3 and NF-κB and combined binding at the
ICAM-1 were found (Kesanakurti et al., 2013). Using chromatin immunoprecipitation com-
bined binding of STAT3 and NF-κB to the proximal promoters of CDK4 and GOT2 were
also found this study. Based on these ChIP data, a model of STAT3 and NF-κB binding




While single stimulation of Myclow cells with IL10 or CpG results in moderate binding of ei-
ther STAT3 or p65 and only weak binding of the corresponding other, combined stimulation
with IL10+CpG leads to strong, simultaneous binding of STAT3 and p65 to the same pro-
moter region. This increased combined binding is then thought to be involved in the increased
gene expression by so far unknown regulatory mechanisms. Possible mechanisms involved in
the observed increased transcription are further discussed below.
Figure 44: Scheme of STAT3 and NF-κB bind-
ing to target gene promoters.
Arrows indicate gene expression value.
TSS = transcription start site.
There are no known canonical STAT3 or NF-
κB binding sites in the investigated promoter
regions of CDK4 and GOT2. Nevertheless, it
was shown that STAT3 and p65 directly in-
teract and together bind sequences that differ
from the canonical binding sites (Kesanakurti
et al., 2013; Hagihara et al., 2005). Further-
more, binding of STAT3 to the CDK4 and
GOT2 promoters (CDK4 -200 bp, GOT2 -
32 bp) can be concluded from DLBCL cell line
ChIP-Seq data, and a binding of NF-κB next
to these sides (CDK4 -125 bp, GOT2 -7 bp)
can be found in the ChIPbase database of the
lymphoblastoid cell line GM12878 (Hardee
et al., 2013; Yang et al., 2013). Importantly,
these data correspond with the increased
STAT3/NF-κB binding at the proximal pro-
moter regions found in this study (CDK4 -
88 bp, GOT2 -13bp), confirming the existence
of these binding sites. It has to be mentioned,
that due to a strong sequence conservation
of the proximal CDK4 and GOT2 promoter
regions no specific PCR primer could be de-
signed that exactly matched the binding sites
found in the ChIP Seq data. However, these
conserved promoter regions also imply a com-
mon sequence pattern for combined STAT3 and NF-κB binding within gene promoters. ChIP
Seq analysis of STAT3 and NF-κB binding in IL10+CpG stimulated P493-6 and OCI-Ly3
cells might be able to reveal this patterns. Although combined binding of STAT3 and p65 to
promoters could be shown, the presented experimental approach was unable to discriminate
whether STAT3 binding is a prerequisite for NF-κB binding (or vice versa) as it was also
recently shown (Lee et al., 2011). Therefore, future co-precipitation experiments and corre-




4.2.2 Supposed gene regulatory mechanisms of STAT3 and NF-KB
As descripted above, the precise mechanism of STAT3/p65 mediated transcription increase
was not investigated so far. However, combining experimental and literature based knowl-
edge possible mechansims are supposed.
The fact that the expression of the same genes is increased by IL10, CpG or IL10+CpG
stimulation resembles the gene expression observed in cells with different Myc levels (Nie
et al., 2012; Lin et al., 2012). By combintation of IL10+CpG an increase in the expression
of already single stimulation increased genes is achieved, but no additional genes is activated
compared to single stimuli alone. The same activation pattern was observed in case of Myc.
Increasing the Myc level only increased the expression of already active genes, but not of
new ones. A mechanism, called transcriptional pause release is believed to be underlying this
effect in case of varying Myc levels (Nie et al., 2012; Rahl et al., 2010). After recruitment of
the RNA polymerase II by initiation complexes, the elongation of the transcription can be
blocked by DRB-sensitivity inducing factor (DSIF) and negative elongation factor (NELF).
In case of Myc binding, the positive transcription elongation factor b (P-TEFb) is recruited,
which releases the polymerase from these blocking factors and promotes transcriptional elon-
gation and thereby increases transcription rates. As both, STAT3 and NF-κB, were shown to
be able to recruit P-TEFb, the synergistic effect of combined binding of these transcription
factors could be mediated by an increased P-TEFb recruitment and therefore increased tran-
scriptional elongation instead of initiation (Barboric et al., 2001; Hou et al., 2007). Thereby
the expression of under single stimulation already active genes is further increased by the
combinination of IL10+CpG. Future localization and phosphorylation analysis of the RNA
polymerase II are needed to prove this assumption.
Second, posttranslational modifications of STAT3 and p65 might be involved in the syn-
ergistic effect of IL10+CpG stimulation on gene expression. While a mutual modification
of tyrosine STAT3 and p65 phosphorylation could be excluded, other phosphorylation or
acetylation sites could differ between single and double stimulations. One example is an
additional serine 727 phosphorylation of STAT3, which was shown to modulate STAT3
transcriptional activity before (Andrés et al., 2013). Importantly, TLR signaling is able
to induce this serine phosphorylation via a mTOR dependent mechanism (Dreher, 2009).
Future proteomic approaches have to reveal if such mutual modifications might occur in




4.3 Effects of gene expression changes on proliferation and metabolism
A further question of this study was how global gene expression changes due to MYC over-
expression or stimulation effects proliferation and metabolism in B cells. Thereby, it was
found that most importantly gene expression of G1/S cell cycle regultors (e.g. CDK4 ) and
glutaminolysis associated enzymes (e.g. GOT2 ) were synergistically increased by combined
STAT3 and NF-κB activation and important for Myc as well as IL10+CpG stimulation
induced proliferation.
4.3.1 Overexpression of G1/S cell cycle regulator genes induces proliferation
The importance of CDK4 overexpression for B cell proliferation was confirmed by inhibition
of the CDK4/6 complex, which completely blocked cell doubling over time. Importantly,
beside posttranslational regulation of CDK4 activity, CDK4 overexpression was shown to
be sufficient to overcome cell cycle arrest of serum starved cells (Latham et al., 1996). Fur-
thermore, gene amplification of CDK4 correlates with high proliferation rates in breast
cancer (Ewen et al., 1993; An et al., 1999). As the expression of negative cell cycle regu-
lators (CDKN1A, CDKN1B) was not affected by IL10+CpG stimulation, overexpression of
CDK4 and CDK6 shifts the ratio of kinases to inhibitors, thereby leading to more activated
CDK/cyclin complexes than in unstimulated cells and increased cell cycle entry (Harper
et al., 1995; Hengst et al., 1998). The activity of CDK4/CDK6 complexes is further in-
creased by the expression of CCND2 and CCND3, while CCND1 was not detected in any of
the samples. Beside their classical role as cofactors for CDKs, cyclin D’s were shown to se-
quester the negative regulators p21 and p27, thereby leading to more active CDK complexes
(Quintanilla-Martinez et al., 2003). Therefore, cell cycle progression is not solely mediated
by posttranslational modifications, but overexpression of genes coding for activating cell
cycle regulators is sufficient to induce proliferation.
4.3.2 Increased gene expression of glutaminolysis enzymes supports transformation
processes
Beside gene expression of cell cycle regulators, the gene expression of metabolic enzymes is
increased in proliferating cells (Whitfield et al., 2006). In line with these observations, gene
expression of glucose and glutamine metabolism regulating enzymes was increased by either
IL10+CpG stimulation or MYC overexpression. However, only glutamine deprival com-
pletely blocked proliferation of IL10+CpG stimulated Myclow and unstimulated Mychigh cells.
These data correlate with previous findings showing that most cancer types are highly glu-
tamine dependent (Hensley et al., 2013). The dependency on glutamine is often reflected in
an increased expression of GLS isotypes in different cancer entities, which is also associated
with an increased invasiveness or poor clinical prognosis (van den Heuvel et al., 2012; Pan
et al., 2015; Huang et al., 2014). Nevertheless, an important role for increased GLS expres-
sion in lymphoma is so far only provided by in vitro data and mouse models (Xiang et al.,
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2015; Gao et al., 2009). The current study shows that high GOT2 expression, is equally
important for glutaminolysis and proliferation in lymphoma. Most importantly high GOT2
expression was shown to be associated with worse prognosis in DLBCL patients.
GOT2 was described to be a potential Myc target genes before (Korangath et al., 2015). In
line with these data, MYC expression was increased in Mychigh P493-6 cells as well as BL
patient samples. Additionally, a regulation by and simultaneous binding of STAT3 and NF-
κB to the promoter of GOT2 could be shown. The supposed regulation of GOT2 expression
by STAT3 and NF-κB was further confirmed by an increased expression in ABC DLBCL
patients, the subgroup of DLBCL described to rely on deregulated STAT3 and NF-κB sig-
naling (Lam et al., 2008).
Expression of transaminases, including GOT2, was shown to be increased in glutamine de-
pendent breast cancer cell lines and treatment with AOA decreased tumor growth concurrent
xenograft models (Korangath et al., 2015). Also in pancreatic tumors a role for GOT1 and
GOT2 was described. Here an increased glutamine metabolism and high GOT1 expression
were necessary to provide reducing equivalents for redox homeostasis in the cell. The impor-
tance of transaminases is further supported by a recent publication, showing that quiescent
fibroblasts metabolize glutamine via GLUD’s, while proliferating cells rely on transami-
nases to provide both aKG for energy and amino acids for biosynthetic demands (Coloff
et al., 2016). Considering these data altogether, specific transaminase inhibitors could be a
promising therapeutic target for STAT3/NF-κB and Myc dependent lymphoma while non
proliferating naive B cells should be not affected.
4.4 Different glutamine usage in B cell lymphoma
Inhibitor and knockdown experiments revealed an important role for GOT2 in proliferation of
MYC overexpressing and STAT3/NF-κB activated cells. However, rescue experiments with
different glutamine derived metabolites showed that the proliferation of these cells relied on
different GOT2 derived metabolites. While MYC overexpressing cells needed glutamine and
aKG, STAT3/NF-κB activated cells were dependent on aspartate for nucleotide biosynthesis.
These differences in glutamine usage and the supposed underlying mechanisms are discussed
below und summarized in Figure 45.
4.4.1 Using glutamine as a energetic fuel
Different energetic dependencies were observed for P493-6 Mychigh and IL10+CpG stim-
ulated Myclow cells. While MYC overexpressing cells used glutamine for respiration and
lactate production, oxygen consumption and extracellular acidification of IL10+CpG stim-
ulated Myclow cells was independent from glutamine. MYC overexpression was shown to
increase mitochondrial function and glutamine respiration before (Li et al., 2005). It was
also shown that the usage of glutamine for TCA function and respiration is independent
from glucose metabolism (Le et al., 2012). Importantly, both studies focused on increased
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Figure 45: Supposed metabolism in STAT3/NF-κB and Myc mediated proliferation.
(A) STAT3/NF-κB dependent cells do not rely on glutamine or glucose for cellular respiration, therefore a
dependency of fatty acid oxidation (blue) is supposed. In contrast, the majority of glutamine (red) is needed
for aspartate and nucleotide synthesis. (B) Myc dependent cells use more glutamine for TCA function,
respiration and lactate production possibly mediated by the additional usage of GPT2. Aspartate is most
likely derived from both GOT1 and GOT2. Note, that narrow or missing arrows do not indicate that these
pathways are not active in these cells, but only that they are not that important for the proliferation of the
depicted model. Gene names of important enzymes are shown in grey and italic letters. Gln = glutamine, Glu
= glutamate, Ala = alanine, Asp = aspartate, aKG = α-ketoglutarate, Suc = succinate, Fum = fumarate,
Mal = malate, OAA = oxaloacetate, Cit = citrate, Isocit = Isocitrate, Pyr = pyruvate.
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GLS activity as a major reason for increased usage of glutamine in respiration. However, the
expression of GLS was also increased in IL10+CpG stimulated Myclow cells in this study. In
contrast, a major difference in the expression of the alanine aminotransferase (GPT2 ) was
observed between both samples (Table 28, Appendix p. 114). Expression of GPT2 was only
increased in Mychigh cells. Furthermore high levels of alanine were found in Mychigh cells but
not in any of the stimulations performed on Myclow cells. GPT2 uses glutamate and pyruvate
to synthesize alanine and aKG. Therefore, Mychigh cells could use GPT2 in conjunction with
GOT2 to synthesize aKG from glutamate therefore fueling the TCA and respiration with glu-
tamine. As pyruvate is the acceptor of the amino group of glutamine, usage of GPT2 would
explain the high levels of alanine in Mychigh cells. This hypothesis is further supported by
a higher percentage of glutamine derived TCA metabolites and a dependency of respiration
and acidification on glutamine. Future knockdown experiments will prove the dependency
of glutamine respiration on GPT2 in Mychigh cells, which would then be a promising target
for Myc dependent cancer.
Since oxygen consumption of IL10+CpG stimulated Myclow cells was neither glutamine nor
glucose dependent, STAT3/NF-κB activated cells are supposed to use fatty acids for cellu-
lar respiration. This hypothesis is further supported by a recent publication showing that
another B cell derived malignancy, chronic lymphocytic leukemia, oxidize free fatty acids
in a STAT3 dependent manner (Rozovski et al., 2015). It was also shown, that STAT3
activation in general regulates ETC function (Wegrzyn et al., 2009). Therefore, respiration
of STAT3 and NF-κB activated cells might be independent from glutamine due to a oxi-
dation of free fatty acids. Further respiratory analysis with inhibitors affecting fatty acid
oxidation will test this hypothesis in future. If validated positively, inhibiting fatty acid
oxidation could be a promising tool for the treatment of STAT3/NF-κB dependent lym-
phoma.
4.4.2 The role of glutamine in aspartate and nucleotide synthesis
Finally an important role for aspartate in proliferation of STAT3/NF-κB dependent P493-6
and OCI-Ly3 cells was shown. Importantly, the synthesis of aspartate is highly linked to
cellular respiration. Two recent publication showed that the main function of the ETC is
to provide reduction equivalents for biosynthesis mainly including aspartate and nucleotides
synthesis (Birsoy et al., 2015; Sullivan et al., 2015). In line with these findings, knockdown
of GOT2 in STAT3/NF-κB dependent cells was completely rescued by nucleotide bases con-
firming the important role aspartate and nucleotides for proliferation.
Nevertheless, proliferation of MYC overexpressing P493-6 Mychigh and Burkitt CA-46 cells
was not rescued by aspartate and nucleotides after GOT2 knockdown. While cellular res-
piration is supposed to be mediated by a glutamine independent process in STAT3/NF-κB
dependent B cells, this thesis and other studies show that glutamine is a major source for
both, reduction equivalents and energy, in Myc dependent cells (Gao et al., 2009). Due to the
connection of ETC and biosynthesis, it is proposed that providing reduction equivalents and
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energy is a prerequisite for biosynthesis and proliferation in these cells. Therefore, without
the addition of aKG for fueling the TCA and respiration neither addition of aspartate nor
nucleotides is able to rescue Myc dependent proliferation as energy and reduction equivalents
are missing to support the further biosynthetic processes.
Nevertheless, it is still not known how soly aKG addition can be sufficient to rescue pro-
liferation of Mychigh cells under glutamine deprived conditions. Glutamine is necessary for
nucleotide synthesis and nucleotides themself are mandatory for cell proliferation. In con-
trast, aKG cannot be used for nucleotide de novo synthesis. Therefore it is still unknown
how Mychigh cells synthesize nucleotides without glutamine.
Mychigh cells show an increased glutaminolysis rate and large glutamate pools. It can be sup-
posed that the increased glutamate pool in Mychigh is able to support nucleotide synthesis
for at least one more cell doubling. Another hypothesis would be that Mychigh cells could
use the excess of intacellular alanine and the addition of aKG to synthesize glutamate in a
GPT2 dependent manner. Glutamate can then be converted to glutamine by the glutamine
synthetase also known as glutamate-ammonia ligase (GLUL). Importantly GLUL expres-
sion was only increased in Mychigh cells but not in IL10+CpG stimulated cells (Table 28,
Appendix p. 114). Thereby, Mychigh cells could use the intracellular alanine pool to generate
glutamate and glutamine for nucleotide synthesis. These assumptions are further supported
by a recent publication showing that Myc is directly regulating GLUL expression by pro-
moter demethylation (Bott et al., 2015). Future assays have to reveal, if GPT2 and GLUL
might be involved in the proliferation rescue after aKG addition in Mychigh .
In summary, new metabolic differences between Myc and STAT3/NF-κB activated B cells
were found that, when further investigated, could lead to the development of new lymphoma
subtype specific therapy.
4.5 IL10R and TLR9 signaling in B cell lymphoma development and
progression
Since IL10R and TLR9 signaling are involved in GC formation, the supposed mechanism of
IL10 and CpG stimulation and the synergy of STAT3 and NF-κB might be involved in B cell
activation. Moreover, as lymphoma cells rely on different mutations that aberrantly activate
these pathways, it can be proposed that comparable mechanisms are not only observed
in normal B cell physiology but also in transformed B cells. This hypothesis is further
supported by studies providing first evidence that also the B cell microenvironment might




4.5.1 The role of IL10 and CpG in B cell lymphoma
During the last years, multiple studies have shown an impact of either IL10 or CpG signaling
on lymphomagenesis. For example, deregulated IL10 gene expression is thought to increase
lymphoma susceptibility and risk (Cao et al., 2013; Edlefsen et al., 2014). IL10 also was
shown to be involved in lymphoma progression, as high IL10 serum levels are associated
with worse clinical outcome in DLBCL patients (Lech-Maranda et al., 2006; Gupta et al.,
2012). Furthermore, gene amplifications of IL10RA and IL10RB can be found in DLBCL
(Béguelin et al., 2015). While IL10 signaling is thought to mainly induce antiapoptotic
processes in these studies, data from this thesis imply that a prominent role for IL10 in
lymphomagenesis might be the promotion of proliferation and metabolism in B cells with
additional activated NF-κB signaling.
In contrast to IL10, less evidence exists about a direct role for CpG in lymphoma devel-
opment. Only in BL an activation of TLR9 signaling by malaria parasites is discussed
(Torgbor et al., 2014). However, in DLBCL mutations in MYD88, a key component of
TLR signaling, were frequently reported (Ngo et al., 2011; Choi et al., 2013). In this study
it is supposed that stimulation of P493-6 Myclow cells with CpG can serve as a model for
chronic TLR activation and canonical NF-κB activation in lymphoma with these gene mu-
tations.
4.5.2 STAT3 and NF-κB are important factors in B cell lymphoma pathogenesis
While IL10 is mainly activating STAT3, CpG is a strong mediator of canonical NF-κB signal-
ing. In lymphoma aberrant activation of both pathways can be found: STAT3 is frequently
activated in DLBCL or HL (Hu et al., 2013; Kube et al., 2001) and found to correlate with
higher cell proliferation and worse clinical outcome in both (Ding et al., 2007; Huang et al.,
2014). Additionally, constitutive NF-κB signaling can be found in DLBCL and HL and
phosphorylated p65 was shown to be an independent prognostic factor in DLBCL (Wood
et al., 1998; Davis et al., 2001; Zhao et al., 2015). Importantly, NF-κB and STAT3 were
shown to cooperate and promote the development and progression of glioma, colon, gastric
and liver cancers (Grivennikov & Karin, 2010). Today, also growing evidence exists about
a cooperative role of both transcription factors in lymphoma. In DLBCL with constitutive
NF-κB signaling phosphorylated STAT3 was found, activated by an interleukin dependent
feed forward loop (Davis et al., 2001). Importantly, Lam and colleagues showed that pro-
liferation and survival is maintained by cooperation of both transcription factors in this
subgroup of DLBCL (Lam et al., 2008). These findings are further supported by a study
that showed that STAT3 is important for ABC DLBCL pathogenesis, the subtype of DLBCL
with highest NF-κB activation (Scuto et al., 2011). Therefore, simultaneous activation of
the NF-κB and STAT3 pathway might be a common feature in different B cell lymphoma.
Importantly, the current thesis shows, that not solely mutations but continuous stimula-
tion with factors of the GC environment are able to induce a proliferation comparable to
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MYC overexpression in resting B cells. It also implies, that continuous activation of STAT3
and NF-κB signaling by both, stimuli (IL10/CpG) or a mutation in one pathway combined
with the stimulation of the corresponding other, might be sufficient for B cell transfor-
mation. Therefore, histologic analysis of STAT3 and NF-κB pathway activations, also in




5 Summary and conclusion
Using a cell based normalization method, it was shown that different GC derived stimuli in-
duce qualitative comparable but quantitative distinct global gene expression and metabolic
changes in P493-6 Myclow cells. Thereby, expression of the same set of genes was increased
independently from the used stimuli, implying that global gene expression amplification,
which was supposed for Myc before, might also be involved in other B cell activations.
Importantly, specific combination of stimuli resulted not only in in additive but synergistic
effects in global gene expression and metabolite abundancy. Strongest synergistic global gene
expression and metabolic reprogramming was observed by combined IL10 and CpG stimula-
tion of Myclow cells, leading to sustained cell doubling comparable to overexpression of MYC.
Further mechanistic analyses revealed that the synergism of IL10 and CpG stimulation was
mediated by NF-κB and STAT3 signaling. Therefore, a model is presented in which the
simultaneous binding of both transcription factors is involved in this synergistic increase in
target gene expression, as for example CDK4 and GOT2. While this new regulatory circuit
of IL10R and TLR9 signaling in B cells is proposed, its detailed underlying mechanisms
involved in gene expression regulation need to be elucidated in future experiments.
Importantly, IL10+CpG stimulation induced gene expression changes greatly resembled Myc
mediated global amplification of gene expression, cell cycle changes and proliferation. Al-
though proliferation of IL10+CpG stimulated Myclow and Mychigh was strictly glutamine
dependent and the aspartate aminotransferase GOT2 was identified as a common regu-
lator of glutaminolysis in both, the following differences were observed: proliferation of
IL10+CpG stimulated Myclow cells was dependent on glutamine derived aspartate and nu-
cleotides whereas Myc induced proliferation was rescued by α-ketoglutarate addition under
AOA treatment or glutamine deprivation. Equally, the STAT3/NF-κB dependent lymphoma
cells OCI-LY3 and L-428 relied on glutamine derived aspartate and nucleotides for prolif-
eration, whereas proliferation of Myc associated CA-46 cells was dependent on glutamine
derived α-ketoglutarate. Thus, first evidence for signaling pathway dependent regulation of
glutamine metabolism was provided in this study.
In addition to in vitro data, GOT2 could be shown to be strongly expressed in prolifer-
ating centroblasts but also in primary B cell lymphoma, where STAT3/NF-κB dependent
ABC-like DLBCL were characterized by higher GOT2 expression as germinal centre like
DLBCL. More importantly high GOT2 expression was shown to be associated with a worse
clinical outcome of R-CHOP treated DLBCL patients, showing that some of the found in
vitro results might also be important for in vivo lymphomagenesis.
Therefore, from previously published and herein presented data, it is now proposed that
simultaneous NF-κB and STAT3 signaling, activated either by extracellular stimulation or
already known pathway mutations as for example MYD88, SOCS1 or CARD11, plays an
important role in B cell proliferation and relies on a synergistic increase in global gene expres-
sion including key cell cycle and metabolism regulators. The presented data also highlight
98
Summary and conclusion
the importance of factors of the B cell microenvironment in transformation processes of B
cells. Additionally, for the first time evidence is provided that GOT2 plays an important role
in STAT3/NF-κB and Myc mediated transformation and that different glutamine dependent
metabolism exist in lymphoma. However, future analyses are necessary to fully understand
the mechanism behind and its functional role in lymphomagenesis but also normal home-
ostasis of mature B cells. Further investigating the mechanism underlying the synergistic
effect of IL10R and TLR9 signaling as well as metabolic differences could help to reveal new
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Table 27: Gene Set Enrichment in KEGG Pathways of only IL10+CpG stimulation regulated genes.
Term PValue Genes
hsa04060: Cytokine-cytokine receptor in-
teraction
1.59E-5 IL6, CCL3, IL2RA, IL21R, IL24, CD40,
CX3CL1, CCL4, CCL17, CXCL10,
ZFP91, TNFRSF9, CCL22, CCR7,
CXCR5, CCL3L3, CCR2, IL12A, TN-
FRSF18, TNFRSF19, IL15RA, IL12B,
IL13RA1, LTB
hsa04630: Jak-STAT signaling pathway 1.80E-4 IL6, IL2RA, SOCS2, SOCS3, GRB2,
STAT5A, IL21R, PIM1, IL24, STAT3,
ZFP91, CCND2, IL12A, IL15RA, IL12B,
IL13RA1
hsa04620: Toll-like receptor signaling
pathway
4.91E-4 CD86, CCL3, IL6, CD80, JUN, IL12A,
NFKB1, MAPK11, IL12B, CD40, CCL4,
CXCL10
hsa04062: Chemokine signaling pathway 0.0093 CCL3, BRAF, GRB2, NFKB1, CX3CL1,
CCL4, STAT3, CCL17, CXCL10, CCL22,
CCR7, CXCR5, CCL3L3, CCR2
hsa05221: Acute myeloid leukemia 0.0122 BRAF, GRB2, STAT5A, PIM1, NFKB1,
MTOR, STAT3
hsa04514: Cell adhesion molecules
(CAMs)
0.0318 ALCAM, CD86, CD80, PECAM1, CD58,
VCAN, CD40, HLA-DMB, CD226,
PDCD1LG2
Table 28: Gene Set Enrichment in KEGG Pathways of only Myc regulated genes.
Term PValue Genes
hsa03010: Ribosome 0.0061 RPS18, RPL18A, RPL6, RPL15,
RPL4P5, RPS15A, RPL38, RPS4X,
RPL13AP5
hsa00052: Galactose metabolism 0.0482 GALK1, B4GALT2, GALE, PFKM
hsa00250: Alanine, aspartate and gluta-
mate metabolism
0.0444 GLUL, ASS1, ALDH5A1, GPT2
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Table 29: Gene Set Enrichment in KEGG Pathways of IL10+CpG stimulation and Myc regulated genes.
Term PValue Genes
hsa04110: Cell cycle 3.37E-11 E2F3, DBF4, PRKDC, TTK, CHEK1,
CHEK2, RBX1, CCNE1, CDC45, MCM7,
BUB1, CCNA2, BUB3, TFDP1, CDC7,
ANAPC1, CDC6, ANAPC5, RBL1,
SKP2, CDC23, CDK6, MCM2, MCM3,
CDK4, YWHAE, MCM4, CDC25A,
CCNB1, YWHAG, YWHAH, CCNB2,
BUB1B, ANAPC7, SMC1A
hsa00240: Pyrimidine metabolism 5.79E-7 POLR3G, POLR2G, POLR1E, POLR3K,
DTYMK, POLR1A, POLA1, POLR1C,
POLR3A, CTPS2, CAD, POLR1B,
POLR2D, POLR3B, PNP, POLD3,
NME2, POLE2, POLE3, RRM2, POLD1,
DHODH, UCK1, UCK2
hsa00970: Aminoacyl-tRNA biosynthesis 1.20E-6 CARS, YARS, SARS, AARS, WARS2,
QARS, DARS2, LARS2, KARS, EARS2,
IARS, FARSB, MARS2, AARS2, MARS
hsa00230: Purine metabolism 1.36E-5 POLR2G, POLA1, POLR2D, PNP,
PFAS, PPAT, POLE2, ATIC, POLE3,
IMPDH2, POLR3G, POLR1E, POLR3K,
POLR1A, AK2, POLR3A, POLR1C,
POLR1B, AK7, GMPS, POLR3B,
GART, POLD3, NME2, RRM2, POLD1,
PAICS, PRPS2, PRPS1
hsa03040: Spliceosome 2.88E-5 DHX8, PRPF31, PPIL1, CWC15,
ZMAT2, SNRPB2, SNRPD2, PRPF4,
RBMX, HNRNPA1, SF3A3, PPIH, AQR,
TCERG1, USP39, SNRNP200, LSM5,
DHX16, SNRNP40, PHF5A, HNRNPC,
THOC3, SNRPE, HSPA8, PRPF38A
hsa00010: Glycolysis / Gluconeogenesis 3.68E-5 LDHA, PFKL, ALDOC, PGAM1, HK2,
PFKP, HK1, DLAT, TPI1P1, GPI,
AKR1A1, ALDH1B1, PGAM4, PGM1,
PDHA1, ENO1
hsa03030: DNA replication 5.61E-5 POLD3, RFC5, MCM7, POLE2, POLE3,
RFC2, POLD1, POLA1, MCM2, MCM3,
RNASEH2A, MCM4
hsa00030: Pentose phosphate pathway 6.37E-5 GPI, TALDO1, PFKL, ALDOC, PGM1,
PGD, PFKP, RPIA, PRPS2, PRPS1 115
Appendix
hsa03020: RNA polymerase 1.74E-4 POLR3G, POLR2G, POLR3K, POLR1E,
POLR1A, POLR1C, POLR3A, POLR1B,
POLR2D, POLR3B
hsa03410: Base excision repair 2.28E-4 POLD3, HMGB1, POLE2, POLE3,
UNG, NEIL3, POLD1, NEIL2, NTHL1,
APEX1, PARP2
hsa00020: Citrate cycle (TCA cycle) 4.12E-4 SDHA, SDHB, ACO2, ACO1, IDH2,
IDH3B, ACLY, PDHA1, DLAT, IDH3A
hsa00450: Selenoamino acid metabolism 5.62E-4 CTH, SEPHS1, AHCY, MAT2A, WB-
SCR22, MARS2, METTL2B, MARS,
CBS
hsa00670: One carbon pool by folate 8.76E-4 MTHFD1, SHMT1, DHFR, ATIC, MTR,
MTHFD1L, GART
hsa03430: Mismatch repair 0.0013 POLD3, RFC5, EXO1, MSH6, RFC2,
POLD1, MLH1, PMS2
hsa03420: Nucleotide excision repair 0.0016 POLD3, RFC5, GTF2H2C, POLE2,
POLE3, RFC2, POLD1, CETN2,
GTF2H3, ERCC3, RBX1, GTF2H2B
hsa00190: Oxidative phosphorylation 0.0023 NDUFA4, COX7A2, UQCRC1, ATP5B,
NDUFB9, ATP6V1B2, ATP5G1,
COX5A, NDUFA10, UQCRQ, ATP5G3,
PPA1, SDHA, NDUFV3, SDHB,
NDUFV1, ATP5C1, ATP5A1, NDUFS3,
ATP5H, NDUFS1
hsa00270: Cysteine and methionine
metabolism
0.0037 GOT2, CTH, LDHA, AHCY, GOT1,
MAT2A, MTR, ENOPH1, CBS
hsa00051: Fructose and mannose
metabolism
0.0037 GMPPB, SORD, PFKL, ALDOC,
AKR1B1, HK2, PFKP, HK1, TPI1P1
hsa00520: Amino sugar and nucleotide
sugar metabolism
0.0058 GMPPB, GPI, NANS, GNE, GNPNAT1,
PGM1, HK2, HK1, UXS1, NANP
hsa00100: Steroid biosynthesis 0.0078 EBP, CYP27B1, SQLE, LSS, FDFT1,
NSDHL
hsa00260: Glycine, serine and threonine
metabolism
0.0084 SHMT1, CTH, GCAT, PHGDH, PSAT1,
PSPH, CBS, GLDC
hsa03022: Basal transcription factors 0.0164 TAF2, TAF5L, GTF2H2C, TAF5,
GTF2F1, GTF2A2, TAF9B, GTF2H3,
GTF2H2B
hsa03010: Ribosome 0.0359 RPL7AP66, RPSAP15, RPLP0, RPL8,
RPL3, RPL26L1, RPL4P4, RPL21P119,
RPS10, RPL4, RPL10A, RPS6, RPS8,
RPS24 116
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Table 30: Linear regression coefficients of stimuli and stimuli interactions on number of cells in S-phase.



















Table 31: Distribution of cell cycle phases in BrdU labeled cells over time. Shown are percentage of total
population of BrdU positive cells.
G0/G1 S G2/M
time ctrl IL10 CpG IL10+ ctrl IL10 CpG IL10+ ctrl IL10 CpG IL10
CpG CpG CpG
0h 20.68 19.26 29.3 50.8 40.09 37.81 45.18 35.83 40.3 43.29 26.02 14.2
2h 21.13 19.11 27.22 24.21 33.54 38.4 44.53 55.18 46.25 43.23 29.44 21.57
4h 23.43 22.37 16.82 22.83 32.22 33.18 49.22 55.27 45.19 44.89 35.19 22.93
6h 38.08 33.41 20.71 12.43 26.47 33.6 50.14 48.86 36.69 34.02 30.15 39.39
8h 41.23 40.04 16.38 13.93 25.15 31.91 29.72 25.35 34.8 28.66 54.88 61.68
10h 50.45 45.36 25.21 21.91 21.11 24.69 28.49 20.2 29.6 29.95 46.99 58.63
12h 57.89 50.27 29.32 44.5 20.25 20.93 27.21 9.95 22.36 29.45 44.22 45.91
24h 79.11 75.14 74.99 52.65 10.39 12.36 14.78 30.01 11.24 13.5 10.83 18.11
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Table 32: Linear regression analysis of cell cycle regulator gene expression. Shown are the intercept,
the regression coefficients of single stimuli and the interaction term of IL10:CpG. p-Values below 0.05 are
regarded as significant effects on gene expression.
CCND2 Estimate Std.Error t-value p-value
(Intercept) 1.0833 0.499 2.171 0.0617
IL10 0.7197 0.7057 1.02 0.3377
CpG 1.8497 0.7057 2.621 0.0306
IL10:CpG 1.9213 0.998 1.925 0.0904
CCND3 Estimate Std.Error t-value Pr(>|t|)
(Intercept) 0.9003 0.2545 3.537 0.00765
IL10 0.6684 0.3599 1.857 0.10042
CpG 0.4645 0.3599 1.29 0.23296
IL10:CpG 1.5735 0.509 3.091 0.01487
CDK4 Estimate Std.Error t-value Pr(>|t|)
(Intercept) 0.9832 0.4403 2.233 0.05605
IL10 0.7905 0.6227 1.269 0.24
CpG 2.0104 0.6227 3.228 0.01209
IL10:CpG 3.6281 0.8807 4.12 0.00335
CDK6 Estimate Std.Error t-value Pr(>|t|)
(Intercept) 1.0705 0.505 2.12 0.0668
IL10 1.182 0.7141 1.655 0.1365
CpG 2.0624 0.7141 2.888 0.0203
IL10:CpG 2.7617 1.0099 2.734 0.0257
p21 Estimate Std.Error t-value Pr(>|t|)
(Intercept) 1.00342 0.25785 3.891 0.0046
IL10 0.67142 0.36466 1.841 0.1029
CpG 0.53729 0.36466 1.473 0.1789
IL10:CpG -0.08255 0.5157 -0.16 0.8768
p27 Estimate Std.Error t-value Pr(>|t|)
(Intercept) 1.0882 0.2752 3.954 0.00421
IL10 0.3634 0.3892 0.934 0.37776
CpG -0.2429 0.3892 -0.624 0.54989




To due their length, the following tables are provided as supplementary data on compact
disc (CD):
• Supplemental Table 1: Linear regression coefficients of stimulation induced gene
expression in Myclow cells.
• Supplemental Table 2: Linear regression coefficients of stimulation induced metabolic
changes in Myclow cells.
• Supplemental Table 3: S-phase and metabolites of stimulated Myclow cells and
Mychigh cells.
• Supplemental Table 4: Log2FC gene expression of IL10, CpG, IL10+CpG stimu-
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